Cycloheptapyrrolo-Fused Systems of

Pharmaceutical Interest by Giallombardo, D.
0 
 
 
 
 
Ministero dell’Istruzione,  
dell’Università e della Ricerca 
 
 
Università degli Studi di Palermo 
 
 
Facolta’ di Farmacia 
PhD in Pharmaceutical Sciences 
“Doctor Europaeus” 
A.A. 2010-2011 CYCLE XXIV SSD:CHIM/08 
 
 
 
 Cycloheptapyrrolo-Fused Systems of 
Pharmaceutical Interest 
 
 
 
Dr. Daniele Giallombardo                                                       Supervisor 
                                                                                        Prof. Paola Barraja 
 
PhD Coordinator 
Prof. Girolamo Cirrincione 
 
 
Dipartimento STEBICEF (Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche)  
 
Unione Europea 
1 
 
INDEX 
1. Introduction            p. 3 
2. Project                       p. 11  
3. Synthesis of the building blocks           p. 13 
4. Pyrrolo[3’,2’:6,7]cyclohepta[1,2-b]pyridine-9(1H)-one     p. 18 
      4.1 Synthesis              p. 18 
      4.2 Photochemoterapeutic Activity         p. 22 
5. Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole     p. 38 
5.1 Synthesis          p. 38 
5.2 Anticancer Activity         p. 42 
6. Pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidin-2-amine    p. 49 
6.1 Synthesis           p. 49 
6.2 Anticancer Activity          p. 53 
7. Pyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine     p. 56 
7.1 Synthesis            p. 56 
8. Project in collaboration with the University of Nottingham          p. 61 
8.1 Introduction                                  p. 61 
8.2 General synthesis of xanthones                          p. 63 
8.3 Synthesis of the two fragments        p. 68 
8.4 Toward the synthesis of Rubraxanthone and Toxyloxanthone B    p. 75 
8.5 Conclusions and future work        p. 77 
9. Experimental           p. 78 
9.1 Preparation of ethyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-  
      carboxylate (9a) and of 4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9c)  p. 78 
9.2 Functionalization of ethyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2- 
      carboxylate (9a) and of 4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9c)  p. 82 
9.3 Preparation of 7-((dimethylamino)methylene)-8-oxo-1,4,5,6,7,8- 
      hexahydrocyclohepta[b]pyrrole (13)       p. 86 
9.4 Preparation of ethyl 7-(hydroxymethylene)-8-oxo-1,4,5,6,7,8- 
      hexahydrocyclohepta[b]pyrrole-2-carboxylate (14)     p. 91 
9.5 Preparation of ethyl 7-((diethylamino)methylene)-8-oxo-1,4,5,6,7,8- 
      hexahydrocyclohepta[b]pyrrole-2-carboxylate (15)     p. 94 
 
2 
 
9.6 Preparation of Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridine- 
      9(1H)-ones (16,19-20)        p. 94 
9.7 Preparation of Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles (21-22)   p. 100 
9.8 Preparation of Pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidines (24-29)   p. 107 
9.9 Preparation of Pyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amines (32)  p. 113 
9.10 Total synthesis of Toxyloxanthone B (72) and toward the synthesis  
        of Rubraxanthone         p. 118 
10. References                              p. 135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
1. INTRODUCTION 
Furocoumarins are a class of planar tricyclic aromatic compounds produced by a wide variety of 
plants, whose chemical structures originate from the condensation of a coumarin nucleus with a 
furan ring. Depending on the position in which the condensation occurs, different isomers can 
originate, including linear and angular furocoumarins. Leads of these two main structures are 
respectively, psoralen and angelicin (Figure 1). 
[1] 
Such molecules have attracted great attention for their photobiological and phototherapeutic 
activity. Since ancient times, in fact, these properties have been recognized by the Turks, Hindu and 
Egyptian, and have been used for the treatment of vitiligo (skin disease of autoimmune origin). 
Nowadays, they are object of study in the treatment of skin diseases (psoriasis, mycosis fungoides, 
vitiligo), T-cell lymphoma and autoimmune diseases (lupus erythematosus). 
Figure 1 
 
Psoralen and angelicin, due to their planar and aromatic structures, can intercalate in the “dark” 
between DNA bases and can be photoactivated after irradiation by UV-A light; this molecules are 
in fact classified as photosensitizing agents, because, if activated by light of a suitable wavelength, 
give a biological photodynamic effect. The photodynamic effect induces destruction of cell 
membranes, or the block of the replication and transcription of nucleic acids, and in both cases, 
leads to cell death. 
[2]
 
The photodynamic therapy (PDT) represents an interesting therapeutic option for the treatment of 
several cancers, including carcinomas of the esophagus and lung. It requires the systemic 
administration of a photosensitizing agent (PS), followed by irradiation of the tumor with visible 
light of a wavelength compatible with the absorption spectrum of the PS. 
The interest for PDT in oncology is due to the tendency of the PS to accumulate in neoplastic 
tissues, where they are selectively activated by illuminating only the area of interest, that means an 
high therapeutic index. Furthermore, the use of PDT is not precluded by previous radio or 
chemotherapy treatments, and do not appear to be present forms of cross-resistance with these 
treatment modalities. 
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The use of psoralens in the PDT in combination with the UV-A light, was introduced by Parrish and 
collaborators in clinical practice under the name of PUVA (psoralen plus UV-A). 
[3]
 This type of 
treatment, consists in the oral administration of 8-methoxypsoralen (8-MOP) followed by 
irradiation of the patient with artificial ultraviolet light (UV-A), and has been used for the first time 
in the treatment of psoriasis, a disease characterized by hyperproliferation of skin cells. Very 
interesting results in the field of PUVA therapy, have been achieved with the introduction of a new 
clinical treatment: the extracorporeal photopheresis (ECP), a variant of the leukapheresis.  
At the end of the 80’s Edelson proposed it for the treatment of cutaneous T cell lymphoma (CTCL) 
and in 1988 it was approved by the U.S. Food and Drug Administration. 
[4]
 Currently, the ECP is 
also used in the treatment of autoimmune diseases (systemic sclerosis and rheumatoid arthritis) as 
well as in the prevention of rejection in transplantation (GVHD, Graft Versus Host Disease). 
[5]
  
The treatment is carried out in three successive stages (Figure 2): 
1. Oral administration of the photoactivatable drug, psoralen or 8-methoxypsoralen, by the 
patient. 
2. Formation of an extracorporeal blood circuit, in which the white blood cells are separated 
from the red blood cells. For both components are added heparin and saline. At this point is 
generally added other 8-methoxypsoralen, and the leukocyte portion is subjected to 
irradiation with UV-A light.  
3. After treatment, the blood, containing the photoactivated drug, is reinfused to the patient. 
Figure 2 
 
The duration of the treatment is about 4 hours and is repeated for 2 consecutive days every 3-4 
weeks. The advantages of ECP are numerous, in fact the patient is not directly exposed to UV-A 
irradiation, as in the classic PUVA therapy, and suffers fewer side effects. Patients subjected to ECP 
in fact, suffer from a mild fever in a time interval between 2-12 hours after the end of the treatment, 
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and a slight reddening of the skin associated with itching. A further advantage is that the ECP does 
not lead to suppression of the immune system of the patient, and normally doesn't harm susceptible 
organs such as liver, heart and lungs. 
The drugs currently most used in photochemotherapy are the 5-methoxypsoralen, the 8-
methoxypsoralen, and the 4,5,8-trimethylpsoralen which, however, as all linear furanocoumarins, 
showed severe side effects. Indeed UV-A inducing photoactivaction, produces covalent bonds 
between the drug and the DNA bases, through photocycloaddition reactions [2+2]. Psoralens, due to 
their planarity can form covalent bonds with two nucleotides of the two complementary strands of 
DNA (ISC inter-strand crosslinks) whereas angelicin, due to its geometry, can only form mono-
adducts. Indeed, the formation of crosslinks which bind covalently the two chains of DNA, can lead 
to long-term in mutagenesis and carcinogenesis, whereas the formation of mono-adducts, is 
associated with less severe side effects only in short-term (itching, nausea and vomiting). 
This has given importance to the study of monofunctional furanocoumarins, and has led to the 
synthesis of derivatives of angelicin. These drugs, are not phototoxic and therefore may also be 
administered topically, because they do not form inter-strand crosslink, thus the side effects in the 
long term, peculiar of the bifunctionals, are missing. For example, the trimethylangelicin (TMA) 
used in clinical trials for psoriasis, mycosis fungoides and other cutaneous diseases, has relevant 
therapeutic activity and show less mutagenicity, less risk of skin cancer, and absence of 
phototoxicity. 
[6]
 
In regard of this knowledge, in recent years, the research group in which I’m doing my PhD project, 
interested in the synthesis of new polycondensated heterocyclic systems that possessed the features 
of drugs already used as photochemotherapeutic agents, such as the presence of photoreactive sites 
in suitable position for the photo-conjugation to DNA. Based on experience gained on the chemistry 
of indoles and pyrroles, for example, new heterocyclic systems such as the pyrrolo[2,3-h]quinolin-
2-one 1, nitrogenous bioisoster of angelicin, in which both oxygens are replaced by nitrogen atoms, 
and its positional isomers, the pyrrolo[3,4-h]quinolin-2-one 2 and pyrrolo[3,2-h]quinolin-8-one 3 
were synthesized (Figure 3). 
Figure 3 
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For the first class of pyrroloquinolinones 1 (Table 1), the phototoxic activity was tested in vitro 
using three human tumor cell lines: HL-60 leukemic line, HT-1080, solid tumor from fibrosarcoma 
and LoVo intestinal adenocarcinoma. 
[7 , 8] 
Table 1 
 Cpd R R1 R2 X-X 
 
 
1a Ph SO2Ph H CH2-CH2 
1b Ph COPh H CH2-CH2 
1c Ph CN H CH2-CH2 
1d Ph COOEt H CH2-CH2 
1e Me SO2Ph H CH2-CH2 
1f Me COPh H CH2-CH2 
1g Bn SO2Ph H CH2-CH2 
1h Bn COPh H CH2-CH2 
1i H H Me CH=CH 
Table 1 Pyrrolo[2,3-h]quinolin-2-ones 1  
All derivatives have not showed cytotoxic effects "in the dark", (in the absence of irradiation), 
while after irradiation at three different UV-A doses (2.6, 3.2, 6.5 J/cm
-2
), it is evident the high anti-
proliferative activity (IC50 0.4-17.5 M), which is concentration and UV dose dependent, and it is 
comparable, and even in some cases superior, to the reference drug angelicin (Table 2). In particular 
the derivative 1a bearing the phenylsulfonyl group in position three, seems to be on all the cell 
lines, the most active derivative of the series (IC50 0.4 - 3.6 M). 
Table 2 
 HL-60 
(IC50, µM) 
HT-1080           
 (IC50, µM) 
LoVo              
 (IC50, µM) 
Dose  
UVA 
(J/cm2) 
2.5  3.75  6.5 2.5  3.75  6.5 2.5  3.75  6.5 
1a 1.20.2 0.820.02 0.450.04 3.60.5 2.30.8 0.40.04 1.20.2 0.60.1 0.410.04 
1b 8.50.3 3.90.5 0.50.08 6.61.6 4.60.9 1.70.2 4.10.6 2.80.3 1.30.2 
1c 5.41.1 4.70.5 1.30.7 >20 13.11.5 11.11.4 9.81.1 8.90.3 8.31.1 
1d 7.73.0 5.52.2 1.30.5 12.22.1 7.90.9 2.10.6 6.91.2 3.11.3 1.10.9 
1e >20 13.22.1 2.80.8 >20 >20 16.41.4 >20 17.54.7 6.61.1 
1f 8.90.1 6.20.01 0.80.06 >20 >20 >20 >20 >20 8.90.9 
1g 12.41.2 6.90.2 1.80.7 >20 15.11.2 1.70.2 >20 10.71.3 2.90.3 
1h 4.00.2 2.20.2 1.10.1 14.70.9 9.01.1 1.90.02 6.50.7 3.61.3 0.60.1 
1i >20 >20 >20 >20 >20 >20 >20 >20 >20 
8-MOP 1.4±0.1  1.2±0.1 0.7±0.1 7.8±0.7 2.1±0.3 1.5±0.2 1.1±0.4  0.7±0.1 0.4±0.1 
Ang 1.5±0.2 0.9±0.1 0.6±0.1 15.71.9 2.60.2 2.50.3 1.6±0.2 0.9±0.1 0.8±0.1 
Table 2 Photocytotoxicity of compounds 1 
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From an examination of the biological results of pyrroloquinolinones 1, in fact, it was evident the 
importance of the substituent in position three on the pyridone ring in modulating the 
antiproliferative activity, as the bond in position 3-4 together with the 8-9, is one of two 
photoreactive sites of the photoactivable drug.  
For this reason, it was proposed to synthesize the pyrrolo[3,4-h]quinolin-2ones 2 still bearing the 
phenylsulfonyl group in position three (Table 3).
[9]
 
Table 3 
 Cpd R R1 R2 
 
2a Me H H 
2b Bn H H 
2c Ph H H 
2d H COOEt Me 
2e Me COOEt Me 
2f Bn COOEt Me 
2g Me H Me 
2h Bn H Me 
2i H COOH Me 
2j Me COOH Me 
2k Bn COOH Me 
2l Me H H 
2m Bn H H 
2n Ph H H 
2o H COOEt Me 
2p Me COOEt Me 
2q Bn COOEt Me 
2r Me H H 
2s Bn H H 
Table 3 Pyrrolo[3,4-h]quinolin-2-ones 2  
Such molecules, assayed on five tumor cell lines HL-60 (leukemia line), Jurkat (lymphoblastoid 
leukemia), LoVo (intestinal carcinoma), MCF-7 (breast adenocarcinoma) and NCTC-2544 
(immortalized human keratinocytes) showed still a good photochemotherapic activity (IC50 0.2-17.5 
M) reaching submicromolar levels at 72 hours after UV-A irradiation, even in this case UV-A 
dose dependent (Table 4).  
The best results were achieved on leukemic lines rather than on solid tumors, and have been 
obtained from derivatives bearing a carboxyethyl function in adjacent position to the nitrogen of 
pyrrole ring. In some cases the results are better than angelicin, used as reference drug. 
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Table 4 
 HL-60 
(IC50, µM) 
Jurkat            
(IC50, µM) 
MCF-7           
(IC50, µM) 
LoVo              
(IC50, µM) 
NCTC-2544   
(IC50, µM) 
Dose  
UVA 
(J/cm2) 
2.5  3.75  2.5  3.75  2.5  3.75  2.5  3.75  2.5  3.75  
2a › 20 5.60.6 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2b › 20 14.51.5 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2c 12.21.0 8.01.0 › 20 7.40.7 › 20 › 20 › 20 › 20 › 20 › 20 
2d 13.71.0 9.10.8 18.02.0 10.01.0 › 20 › 20 17.51.5 13.60.5 › 20 15.01.4 
2e 3.60.5 1.80.2 2.00.2 1.40.2 10.01.0 5.10.6 7.90.8 4.00.4 10.11.0 6.20.6 
2f 1.20.2 0.80.02 2.90.3 1.90.2 3.30.4 1.40.1 4.00.4 2.30.2 4.00.5 2.50.3 
2g › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2h 4.00.4 2.50.3 13.01.5 3.00.5 › 20 7.70.8 › 20 › 20 › 20 14.40.8 
2i › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2j › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2k › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2l › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2m 4.40.4 2.80.3 3.60.4 2.50.3 6.60.7 3.70.4 3.90.4 2.80.3 8.20.9 5.80.6 
2n › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 › 20 
2o › 20 5.80.6 › 20 12.51.3 › 20 › 20 › 20 13.21.3 › 20 › 20 
2p 1.20.1 0.90.02 1.20.1 0.80.1 1.70.1 1.30.1 0.70.05 0.40.03 2.40.2 1.30.2 
2q 5.40.6 2.60.3 2.90.3 1.30.1 › 20 14.41.5 12.11.2 8.70.8 › 20 14.31.5 
2r 1.60.1 0.90.1 1.00.08 0.20.01 2.50.3 2.00.1 1.90.2 0.90.09 4.90.5 1.10.1 
2s 8.30.8 7.30.7 8.50.5 6.30.6 10.01.2 7.50.8 9.90.1 8.70.6 15.31.4 9.60.5 
Ang 1.2±0.1 0.9±0.2 1.0±0.2 0.9±0.1 4.4±0.5 1.5±0.2 4.0±0.4 1.1±0.4 4.2±0.5 0.9±0.1 
Table 4 Photocytotoxicity of compounds 2 
The class of pyrrolo[3,2-h]quinolin-8-ones 3 (Table 5), was suitably synthesized with the aim to 
evaluate the effect of different condensation of pyrrole in the tricyclic system. 
Cytotoxicity studies were undertaken "in the dark", namely in the absence of UV-A irradiation, of 
different human tumor cell lines such as a line of keratinocytes K-562 (chronic myelogenous 
leukemia), Jurkat  cells (lymphoblastoid leukemia), LoVo (intestinal carcinoma), MCF-7 (breast 
adenocarcinoma) and NCTC-2544 (immortalized human keratinocytes). 
On the same cells, tests in the presence of two different UV-A doses, 2.5 and 3.75 J/cm
-2
,were 
conducted using lamps that emit at 365 nm. These compounds showed high photocytotoxicity with 
IC50 values of 0.5-9.3 M; phototoxicity also in this case was concentration and UV-A dose 
dependent (Table 6). 
[10]
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Table 5 
 Cpd R R1 R2 
 
 
 
3a SO2Ph H SO2Ph 
3b H H SO2Ph 
3c SO2Ph H CN 
3d Me H SO2Ph 
3e Bn H SO2Ph 
3f Ph H SO2Ph 
3g BnpMe H SO2Ph 
3h BnpOMe H SO2Ph 
3i H COOEt SO2Ph 
3j Me COOEt SO2Ph 
3k Bn COOEt SO2Ph 
3l BnpMe COOEt SO2Ph 
3m BnpOMe COOEt SO2Ph 
Table 5 Pyrrolo[3,2-h]quinolin-8-ones 3 
 
 
Table 6 
 Jurkat  
(IC50, µM) 
K-562 
(IC50, µM) 
LoVo  
(IC50, µM) 
MCF-7           
(IC50, µM) 
NCTC 
 (IC50, µM) 
Dose  
UVA 
(J/cm2) 
2.5  3.75  2.5  3.75  2.5  3.75  2.5  3.75  2.5  3.75  
3a > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
3b > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
3c > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
3d > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
3e 1,3±0,2 1,1±0,1 4,8±0,5 3,3±0,5 2,6±0,2 2,2±0,2 4,0±0,6 1,7±0,7 7,5±0,8 5,5±0,6 
3f > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
3g 1,6±0,1 1,2±0,2 2,7±0,2 2,4±0,1 2,7±0,1 2,3±0,2 3,8±0,5 2,4±0,2 3,3±0,3 2,6±0,5 
3h 1,6±0,2 1,2±0,1 3,1±0,3 2,5±0,2 2,8±0,3 2,0±0,2 4,2±0,3 1,8±0,1 4,3±0,3 2,7±0,2 
3i 3,5±0,2 2,5±0,2 6,1±0,2 5,3±0,3 5,5±0,2 4,6±0,4 6,1±0,2 4,3±0,3 9,3±0,6 7,2±0,7 
3j 0,7±0,1 0,5±0,1 1,0±0,1 0,9±0,1 1,1±0,1 1,0±0,1 1,2±0,1 1,0±0,1 1,2±0,1 1,1±0,1 
3k 0,8±0,1 0,6±0,1 0,9±0,1 0,6±0,1 0,9±0,1 0,8±0,1 0,9±0,1 0,8±0,1 1,1±0,1 1,0±0,1 
3l 1,5±0,1 1,2±0,1 1,3±0,1 1,0±0,1 1,6±0,2 1,0±0,1 1,7±0,1 1,4±0,1 2,7±0,2 2,2±0,2 
3m 0,8±0,1 0,7±0,1 1,0±0,1 0,9±0,1 1,1±0,1 1,0±0,1 1,6±0,2 1,3±0,1 1,9±0,1 1,6±0,1 
Ang 1,0±0,2 0,9±0,1 1,2±0,1 1,0±0,1 3,6±0,4 1,5±0,3 4,4±0,5 1,5±0,2 4,2±0,5 0,9±0,1 
Table 6 Photocytotoxicity of compounds 3  
Studies on the mechanism of action on the best of the three classes of pyrroloquinolinones 1-3 have 
shown that: 
 Each class of compounds is able to photonduce cell death by apoptosis, demonstrated by the 
appearance of the typical peak subG1, indicating an apoptotic degradation of DNA, which 
was confirmed by the test of  “Annexin”. 
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 Easily penetrate into the cell and accumulates into subcellular organelles. Experiments using 
specific "probes" for mitochondria (JC-1) and lysosomes (Acridine orange), which have the 
property of selectively accumulate in these organelles, highlight a specific photo-induced 
damage against them, indicating them as targets for pyrroloquinolinones. 
 In addition it was studied the possible interaction of pyrroloquinolinones with the DNA, 
since this is the preferential target for psoralen and angelicin. Therefore linear dichroism 
spectra (LD) which allow to study the presence of a bond between an organic compound and 
the nucleic acid (DNA), were performed, and it was found that pyrroloquinolinones 
derivatives exclude the DNA as target. In fact, in the spectrum of LD are not observed 
absorption bands between 300 and 500 nm, which is the region where the DNA absorbs. 
Unlike the first pyrroloquinolinone classes 1 and 2, the pyrrolo[3,2-h]quinolinones 3, do not cause 
any DNA damage with formation of OC-DNA or L-DNA, indicating an absence of phototoxicity 
towards the macromolecule. This result is of great importance, in fact  this class of 
pyrroloquinolinone 3 were covered by patent, since the absence of interactions with DNA may be a 
determining factor in the modulation of the long term toxic effects related to the administration of 
psoralens, such as mutagenesis and carcinogenesis. 
[11] 
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2. PROJECT 
In light of the promising results already illustrated by the classes of pyrroloquinolinones 1-3, it was 
thought for my PhD project (Scheme 1), to study the analogous tricyclic systems always containing 
the pyridin-2-one ring, in which the six terms central ring was enlarged to seven, with the aim to 
evaluate the effect on the phototoxicity. 
Scheme 1 
 
The ideal building blocks, were cyclohepta[b]pyrrolones (A), easily functionalizable in position  
to the carbonyl with an enamine or formylic group (Scheme 2): 
Scheme 2 
 
This latter in fact appear to be versatile intermediates having two vicinal electrophilic centers: the 
carbonyl, and the exocyclic carbon bonded to  position to the carbonyl. 
In particular -N,N-disubstituted-aminomethylenketones (Figure 4), constitute a resonant system in 
which the relocation of charges, offers numerous possibilities of reactions, also thanks to the 
intervention of the nitrogen atom. 
Figure 4  
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In our case, they could lead to the formation of a variety of tricyclic systems by reaction with 
dinucleophiles as urea, guanidine, cyanomethylene compounds, hydroxylamines, thus offering the 
possibility to extend the project to the synthesis of several new ring systems.  
In particular, we thought to start from the synthesis by pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-
9-one, analogues of  pyrroloquinolinones of type 3, by planning two series of derivatives bearing 
the ethoxycarbonyl group and an hydrogen as substituents in ortho position to pyrrole nitrogen. 
Furthermore, since the lead coumpounds (Figure 5) of the series of type 3 are ethoxycarbonyl 
derivatives, bearing a methyl, benzyl, or 4-methoxy-benzyl group at the pyrrole nitrogen, we 
decided to start our own synthesis with the same type of substitution at the pyrrole. 
Figure 5 
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3. SYNTHESIS OF BUILDING BLOCKS 
The synthesis of cyclohepta[b]pyrrol-8-one ketones of type 9, suitable precursors for the new ring 
systems, was achieved with the following synthetic schemes (Schemes 3 and 4). 
By reaction of pyrrole 4 with trichloroacetyl chloride, the trichloroacetyl pyrrole 5 was obtained in 
quantitative yield, which in turn undergoes nucleophilic substitution with potassium ethylate giving 
the ethyl 1H-pyrrole-2-carboxylate 6.[12] The three position of the pyrrole was acylated by a Friedel-
Crafts acylation using AlCl3 as Lewis acid, and glutaric anhydride as acylating agent. The obtained 
derivate 7, was subsequently subjected to reduction of the carbonyl group to methylene, through the 
use of triethylsilane in trifluoroacetic acid to give 8, which in turn was cyclized by dehydration 
reaction with an excess of trifluoroacetic anhydride, with the subsequent ring closure to the seven 
members ring. Thus the ethyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate 9a 
was obtained with a high yield. 
Scheme 3 
 
In order to increase the number of derivatives, it has been synthesized a second series of products 
bearing an hydrogen as a substituent in position two. In this regard, the new scaffold, 2,3H-pyrrole, 
was obtained starting from 1-(phenylsulfonyl)-1H-pyrrole 10, which although it is commercially 
available, was prepared in quantitative yield according to the methos used in the past in our group 
(Scheme 4). 
The pyrrole 4 dissolved in anhydrous THF at -78 ° C, was deprotonated with LDA, and 
subsequently reacted with benzenesulfonyl chloride to give 10 in quantitative yield.  
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Similarly to the ethoxycarbonyl series, the second step was a Friedel Crafts acylation with glutaric 
anhydride and AlCl3. Also in this case the reaction proceeds with excellent yields. The reduction 
step with trifluoroacetic acid and triethylsilane, probably not activated due to the absence of 
ethoxycarbonyl group, has led to a secondary product of ring opening of the pyrrole ring. Also other 
attempts of reduction with NaBH4 or with H2/Pd, did not lead to the desired product too. 
The Clemmensen reduction, which involves the use of an amalgam of zinc and mercuric chloride in 
concentrated HCl and toluene at reflux condition, allowed to obtain the desired product 12 in 75% 
yield. The dehydration reaction with trifluoroacetic anhydride, led to the isolation of 9b, which in 
turn was deprotected with NaOH at reflux in ethanol to obtain the NH derivative 9c. 
Scheme 4  
 
At this point we proceeded to the subsequent functionalization of the NH of the pyrrole ring, by 
reacting the ketones of type 9a and 9c in DMF with sodium hydride as a base, and then with various 
alkyl or alkylaryl halides, in order to obtain a good number of new ketones with a good pattern of 
substitution (Scheme 5).  
In many cases the halides that we used, were prepared starting from the corresponding alcohols, in 
concentrated HCl used as solvent. 
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Scheme 5 
 
Cpd R R1 Yield Cpd R R1 Yield 
9d Me COOEt 94 % 9l Me H 88 % 
9e Bn COOEt 96 % 9m Bn H 92 % 
9f 2-OMe-Bn COOEt 78 % 9n 2-OMe-Bn H 93 % 
9g 3-OMe-Bn COOEt 81 % 9o 3-OMe-Bn H 84 % 
9h 4-OMe-Bn COOEt 79 % 9p 4-OMe-Bn H 96 % 
9i 2,5-(OMe)2-Bn COOEt 81 % 9q 2,5-(OMe)2-Bn H 90 % 
9j 3,5-(OMe)2-Bn COOEt 83 % 9r 3,5-(OMe)2-Bn H 90 % 
9k 3,4,5-(OMe)3-Bn COOEt 80 % 9s 3,4,5-(OMe)3-Bn H 89 % 
 
Having obtained a good number of derivatives, the ketones of type 9, were subjected to the next 
step (Scheme 6) in order to introduce in the molecule a second electrophilic center, to constitute 
versatile building blocks for further annelations according to the synthetic scheme anticipated in the 
presentation of the project (see scheme 2) and here proposed again. 
Scheme 6 
 
We decided to start our studies with the direct introduction of the enamine functionality according 
to previous works carried out on the analogues series of compounds in our laboratory. 
Direct introduction of the enamine functionality, generally involves the use of commercially 
available amide acetals, such as N,N-Dimethylacetamide dimethylacetal (DMADMA), N,N-
Dimethylformamide dimethylacetal (DMFDMA) and N,N-Dimethylformamide diethylacetal 
(DMFDEA). These readily react in solvents such as toluene or benzene at reflux leading to 
quantitative yields of the dialkylamino derivative. 
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In a review of Stanovnick in 2004 
[13]
 it was indicated a scale of reactivity among amide acetals 
(Figure 6), placing the DMFDMA as the less reactive and the tert-Butoxy 
bis(dimethylamino)methane (TBDMAM), as the most reactive. 
Figure 6 
 
TBDMAM, also called Bredereck’s reagent, seemed to be the most efficacious reagent; however a 
disadvantage was the high cost, and so for this reason we investigated also the use of DMFDMA 
available at low cost, but also less reactive. 
Thus the two series of products, ethoxycarbonyl and unsubstitued series, were reacted with the 
DMFDMA, but showed, different results. In fact, by reacting substrates of type 9d-k, bearing the 
ethoxycarbonyl group in position two, with an excess of DMFDMA used as solvent with 
conventional heating at reflux, we observed the introduction of the enamine functionality, but at the 
same time also a transesterification to carboxymethyl derivatives occurred.  
So we decided to carry out this reactions with the aid of microwaves apparatus. Initially, we used a 
power of 150 W for 15 minutes and temperature of 150°C, dissolving the starting material in 
anhydrous DMF and using a ratio of 10 to 1 of DMFDMA with the substrate, but also in this case, 
we isolated the transesterificated product obtaining the intermediate 13t (Table 7). 
In less drastic conditions, reducing the power of the instrument from 150 to 50 W, increasing the 
reaction time from 15 to 80 minutes, and using the amide acetal in stoichiometric ratio with the 
substrate, the 2-carboxyethyl substituted aminomethylenketones, are obtained with excellent yields 
as oily products (Scheme 7). In this case it is observed the stabilization of the temperature around 
100 ° C, which might be responsible of the undesired reaction.  
Alternatively the more reactive TBDMAM was used. In this case the desired products 13 were 
obtained as crystals with shorter reaction times and excellent yields. 
With regards to the ketones 9b,l-s of the unsubstituted series, missing the ethoxycarbonyl group as a 
substituent in the 2-position, no side reactions occurred. However they proved to be less reactive, 
and for this reason a ratio 10 to 1 of DMFDMA with the substrate was required to obtain the desired 
enaminoketones 13.  
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Scheme 7 
 
Table 7 
 
 
 
 
 
 
 R  R1  TBDMAM DMFDMA 
13d Me COOEt 99 % 
a
 ------ 
13e Bn COOEt 100 %
 a
 73 % 
b
 
13f 2-OMe-Bn COOEt 97 %
 a
 70 %
 b
 
13g 3-OMe-Bn COOEt 92 %
 a
 87 %
 b
 
13h 4-OMe-Bn COOEt 95 %
 a
 75 %
 b
 
13j 3,5-(OMe)2-Bn COOEt 94%
 a
 77 %
 b
 
13k 3,4,5-(OMe)3-Bn COOEt 99 %
 a
 ----- 
13b SO2-Ph H ----- 90 % 
c
 
13l Me H ----- 89 %
 c
 
13m Bn H ----- 95 %
 c
 
13n 2-OMe-Bn H ----- 96 %
 c
 
13o 3-OMe-Bn H ----- 91 %
 c
 
13p 4-OMe-Bn H ----- 96 %
 c
 
13q 2,5-(OMe)2-Bn H ----- 93 %
 c
 
13r 3,5-(OMe)2-Bn H ----- 90 %
 c
 
13s 3,4,5-(OMe)3-Bn H ----- 86 %
 c
 
 13t Bn COOMe ----- 65 % 
c
 
 a TBDMAM / Starting Material (1.5 eqv: 1 eqv) 50 W, 20-40min 
b DMFDMA / Starting Material (1 eqv : 1 eqv) 50W, 40-120 min 
c DMFDMA / Starting Material (10 eqv: 1 eqv) 150 W, 40-120 min 
Table 7: yield of the reactions with the use of the two different amide acetals.  
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4. PYRROLO[3',2':6,7] CYCLOHEPTA[1,2-b]PYRIDIN-9(1H)-ONE 
4.1  Synthesis 
As widely anticipated in the introduction, the pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-9(1H)-one 
system 16 was the first annelation considered. 
 
To achieve the tricyclic system 16, we could react our dimethylaminomethylenketones 13 with 
dinucleophiles having a C-C-N structure, such as cyanoacetamide, ethyl or methyl cyanoacetate, 
and phenylsulfonylacetonitrile.  
From an evaluation of results of the classes of pyrroloquinolinones 1-3, it was evident the 
importance of the substituent in position eight of the pyridone ring in the modulation of the 
antiproliferative activity. In particular, it appeared that pyrroloquinolinones 1-3 bearing a 
phenylsulfonyl group in position eight, were the most active compounds, on all the tested cell lines. 
For this reason we planned to begin our studies on the N-methyl derivative 13d, belonging to the 
ethoxycarbonyl series, using phenylsulfonylacetonitrile as dinucleophile to afford the corresponding 
tricyclic phenylsulphonyl derivative. 
The reaction was carried out in ethanol, under nitrogen atmosphere at reflux, but contrary to our 
expectations, applying the same operating conditions previously used in the pyrroloquinolinones 1-
3 series, we isolated the desired product 16d in very low yields (15%). The same behaviour was 
also observed for the N-benzyl 13e (8%) and 4-OMe-benzyl derivatives 13h (13%).  
Disappointed by the low reactivity exhibited by these derivatives, we decided to investigate the 
reactivity of diethylenaminoketones 15d,h, obtainable in two steps starting from the appropriate 
ketones 9 through hydroxymethylenketones intermediates of type 14, in order to compare their 
reactivity with the corresponding dimethylenaminoketones 13d,h (Scheme 8). 
Thus reacting ketones 9d,h in toluene with potassium tert-butoxide and ethyl formate, the 
hydroxymethylenketones 14d,h are obtained in good yields (73-80%). The subsequent reaction with 
diethylamine at 80° C, leads to the desired diethylenaminoketones derivatives 15d,h in quantitative 
yields.  
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However, reactions of this latter in the same conditions used for the compounds of type 13 
(PhSO2CH2CN, EtOH reflux), gave even more complex reaction mixtures from which it was not 
possible isolate the desired pyridone derivatives 16. 
Scheme 8 
 
In a paper by Mosti et al.
 [14]
 it was described, a study in benzofuran series, concerning the isolation 
of pyridone derivatives starting from enaminoketones. Four types of possible intermediates were 
reported, among which only E and F, gave the 
 
subsequent ring closure (Scheme 9). 
Scheme 9  
 
The proposed mechanism of cyclization, involves the initial nucleophilic attack to the enaminic 
carbon, followed by formation of an intermediate in which the nitrile was hydrolyzed to 
carboxamide, and the subsequent nucleophilic attack to the annular carbonyl by the nitrogen of the 
amide, leads to the desired cyclization (Figure 7). 
Do not allow the 
next ring closure 
Allow the next 
ring closure 
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Figure 7 
 
Thus, taking in mind these studies, we were able to isolate from two different reaction mixtures the 
intermediates of type 17 and 18 (Figure 8). 
Figure 8 
 
These intermediates confirm the direct intervention of the dimethylamine, which may act as a 
nucleophile on the carbonyl group. In particular, from reaction of benzyl substituted derivative 
enaminone 13e, we isolated the reaction product between the dimethylamine released in situ (from 
the dimethylenaminoketones) with the annular carbonyl groups, as a consequence of Michael 
addition of phenylsulfonylacetonitrile to the enamine group (intermediate of type C 17). Moreover, 
intermediate 18 was isolated from reaction of the N-Methyl substituted enaminone 13d as a 
consequence of the reaction of dimethylamine with the carbonyl group, in which the cyano group 
was hydrolyzed to carboxamide (intermediate of type F 18). 
Since that the intermediate of type 17 was supposed to fail in the ring closure, so we thought to 
extend the time of reflux in ethanol to help the hydrolysis of the cyano group. However, the reaction 
did not seem to proceed and the same behaviour was observed for the other type of intermediate 
(18) which was supposed to give the desired ring.  
21 
 
Thus we thought to encourage the ring closure by prolonging the reaction time and by favouring the 
dehydration process removing the water through the formation of an azeotropic mixture water / 
toluene using Dean-Stark apparatus.  
So at first, the mixture was reacted at reflux in ethanol for 24-48 hours, and it was possible to 
notice, by TLC monitoring, that the starting material 13 disappeared to give the intermediates 17, 
and a small amount of desired product 16. The long reflux helped the hydrolysis of the cyano 
intermediate 17 in to the carboxamide. At this point the reaction mixture was evaporated, and at the 
residue were added toluene and a catalytic amount of acetic acid, and was reacted with a Dean-
Stark apparatus. After several hours of reflux the desired pyridone was isolated from the 
corresponding reaction mixtures with discrete yields (37 – 51%).  
Once obtained the best reaction conditions, we applied the method in two steps to prepare all the 
other pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-9(1H)-one derivatives 16d-p.  
A better reactivity was observed for compounds belonging to the pyrrolo unsubstitued series. In fact 
the desired compounds, precipitated from the reaction mixture upon cooling and were recrystallized 
from ethanol. Moreover after evaporation of the ethanolic solution, the residue was reacted in the 
second step, improving the total yield of the desired tricyclic derivatives. Unfortunately, when we 
used cyanoacetamide, which already bears the carboxyamide function readily available for the 
cyclization, the yield still remains modest. 
In addition, by exploiting the tautomeric keto-enol equilibria, the N-methyl and the 4-OMe-benzyl 
substituted derivatives of the two series, 16d,h,l,p obtained in best yield, were further 
functionalizated by methylation (Scheme 10). But from the reaction mixture, only in the case of N-
methyl derivatives 16d,l it was possible to obtain both products 19d,l and 20d,l, whereas for the 4-
OMe-benzyl substituted derivatives 16h,p, it was possible to obtain, only the 9-methoxy derivatives 
20h,p. 
Scheme 10 
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A final series of sixteen compounds was completed and submitted to biological laboratory of 
“Dipartimento di Scienze Farmaceutiche” University of Padova in collaboration with professor 
Dall’Acqua with the aim of evaluating the photo-antiproliferative activity. 
Table 8 
  R1 R2 R3 Yield 
 
16d Me COOEt SO2Ph 51% 
16e Bn COOEt SO2Ph 40% 
16f 2-OMe-Bn COOEt SO2Ph 46% 
16g 3-OMe-Bn COOEt SO2Ph 39% 
16h 4-OMe-Bn COOEt SO2Ph 48% 
16l Me H SO2Ph 49% 
16m Bn H SO2Ph 40% 
16n 2-OMe-Bn H SO2Ph 43% 
16o 3-OMe-Bn H SO2Ph 37% 
16p 4-OMe-Bn H SO2Ph 48% 
19d Me COOEt SO2Ph 30% 
19l Me H SO2Ph 20% 
20d Me COOEt SO2Ph 59% 
20h 4-OMe-Bn COOEt SO2Ph 73% 
20l Me H SO2Ph 74% 
20p 4-OMe-Bn H SO2Ph 68% 
Table 8: 4,5,6,10-tetrahydropyrrolo[3',2':6,7] cyclohepta[1,2-b]pyridin-9(1H)-ones 16, 19-20 
 
 
4.2  Pyrrolo[3’,2’:6,7]cyclohepta[1,2-b]pyridine-9(1H)-one 
Photochemoterapeutic Activity 
4.2.1 METHODS 
1) SPECTROPHOTOMETRIC DETERMINATIONS 
All spectrophotometric measures were performed using UV-Vis Perkin Elmer instrument 
(Lambda12, double beam). For all the compounds, absorption spectra, molar extinction coefficients 
(ε) and determination of maxima peaks (λmax) were carried out in DMSO. 
2) IRRADIATION PROCEDURES 
HPW 125 Philips lamps, mainly emitting at 365 nm, were used for irradiation experiments. The 
spectral irradiance of the source was 4.0 mW cm
-2
 as measured, at the sample level, by a Cole-
Parmer Instrument Company radiometer (Niles, IL), equipped with a 365-CX sensor. 
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3) CELL CULTURES 
For experiments of cellular viability, 3 human cell lines were used: Jurkat, K-562 and A431. 
Jurkat were human lymphoblastoid cells taken from 14 years old boy in 1976. They were grown in 
complete RPMI 1640 medium. Cells were kept at 37°C in 5% CO2 humidified atmosphere and re-
seeded into fresh medium three times a week. 
K-562 were obtained from a 53 years old woman with chronic myelogenous leukemia in terminal 
blast crisis. Cells were kept at 37°C in 5% CO2 humidified atmosphere and re-seeded into fresh 
medium (complete RPMI) three times a week. 
A431 derived from a EGFR-overexpressing carcinoma. They were grown in complete DMEM 
medium. Cells were kept at 37°C in 5% CO2 humidified atmosphere, trypsinized and re-seeded into 
fresh medium twice a week. 
4) CELLULAR CYTOTOXICITY AND PHOTOTOXICITY 
Individual wells of a 96-well tissue culture microtiter plate were inoculated with 100 l of complete 
medium containing 5x10
3
 cells. Plates were harvested at 37 °C in a humidified 5% CO2 incubator 
for 24 hours prior to the cell viability experiments. Drugs were dissolved in DMSO and then were 
diluted with Hank’s Balanced Salt Solution (HBSS pH=7,2) for phototoxicity experiments or in the 
appropriated complete medium for the cytotoxicity ones.  
In cytotoxicity tests after medium removal, 100 l of the drug solution at different concentration 
were added to each well and incubated at 37 °C for 72 hours. 
In phototoxicity experiments after medium removal, 100 l of the drug solution were put into each 
well and incubated at 37 °C for 30 minutes and then irradiated (2.5 and 3.75 J/cm
2
). After 
irradiation, drug solution was replaced by cellular medium and plates were incubated for 72 hours. 
After the period of incubation, in both cases cell viability was assayed by the MTT [(3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide)] test. In each well, 10 l of MTT (5 mg/ml 
in PBS) (PBS = phosphate buffer 10 mM, NaCl 9g/L, pH=7,2) were added and plates were put in 
incubator for 3 or 4 hours. MTT is a yellow dye that can be absorbed by viable cell and reduced by 
mitochondrial dehydrogenases, producing insoluble blue crystals. After incubation, crystals were 
solubilized by adding 100 l of HCl 0.08 N in isopropanol and plates were detected through 
microplate Biorad reader at 570 nm. The absorbance of each sample was corrected by instrument 
which subtracted the mean value of blanks, i.e. wells in which there were all the reactives except 
cells. 
The absorbance is proportional to cellular viability, so the cellular survival was calculated by this 
equation: 
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A100% = mean of controls, i.e. cells without drug nor irradiation exposure, which represents 100% of survival. 
Asample = absorbance of various samples in which cells were in contact with drug or irradiated in presence of drug. 
For every cellular line, GI50 (GI50 is the drug concentration at which 50% of treated cells are dead) 
was measured through SigmaPlot software. In phototoxicity experiments, the protective effect of 
some scavengers was also evaluated: reduced glutathione (GSH, 1mM in PBS), vitamin E (vit E, 60 
μM in ethanol), N,N’-dimethyl thiourea (DMTU, 1 mM in ethanol), mannitol (MAN, 10 mM in 
PBS), sodium azide (NaN3, 1 mM in PBS). Each experiment was repeated at least three times. 
5) REACTIVE OXYGEN SPECIES DETERMINATION 
Samples containing the compounds under examination (10 μM), p-nitrosodimethylaniline (40 μM) 
and imidazole (40 μM) in phosphate buffer (0.02 M, pH 7.3) were irradiated with increasing UVA 
doses, and their absorbance at 440 nm was then measured for singlet oxygen production. 
Superoxide anion was determined following Pathak and Joshi:
[15]
 samples containing the 
compounds under examination (10 μM) and nitroblue tetrazolium (160 μM) in carbonate buffer (pH 
10) were irradiated with increasing UVA doses, and their absorbance at 560 nm was measured. 
6) DNA PHOTOCLEAVAGE 
To evaluate the capability of provoking DNA photodamage, we used supercoiled pBR322 plasmid, 
dissolved in phosphate buffer 10 mM. Plasmid solutions were irradiated (7.5 J/cm
2
) in the presence 
of the most active compounds in a 96-wells microplate. We used growing [compound]/[DNA] rates. 
Irradiation with a photosensitizer can induce cleavage of one or both DNA strands and so the 
formation of a open circular plasmid (OC, II form) or of a linear one (L, III form), respectively. 
Figure 9 
 
Figure 9: The 3 possible plasmidic DNA forms: supercoiled (SC, form I), open circular (OC, form II) and linear (L, form III). 
% cell survival =  
A100% - Asample
A100%
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It is possible to separate the three different forms with horizontal electrophoresis thanks to their 
different hydrodynamic properties.  
In addition to frank strand break, we also evaluated if purine and/or pyrimidine bases were involved 
in the oxidative damage to DNA using base excision repair enzymes Formamido pyrimidin 
glycosilase (Fpg) and Endonuclease III (Endo III), respectively. 
Each pBR322 DNA sample (100 ng) dissolved in TAE buffer (40 mM Tris-acetate, 1 mM EDTA, 
pH = 8.0) was irradiated with UV in the presence of the compounds.  
After irradiation, two aliquots of sample were incubated at 37 °C with Fpg (Formamydo pyrimidin 
glycosilase) and Endo III (Endonuclease III) respectively.  
Prior to the run, samples were added of loading buffer (0.25% bromophenol blue, 0.25% xilene 
cianol, 30% glycerol in water). Samples were loaded on 1% agarose gel and the run was carried out 
in TAE buffer at 80 V for 2 hrs.  
After staining with ethidium bromide solution, gel was washed with water and the DNA bands were 
detected under UV radiation with a UV transilluminator. Photographs were taken by a digital 
photocamera Kodak DC256 and the quantification of the bands was achieved by image analyzer 
software Quantity One.  
The fractions of supercoiled DNA (Form I) were calculated: 
 
Where Areasc is the area of supercoiled DNA and Arearel is the area of relaxed DNA (form II and 
III) obtained by the densitometric analysis of gels. The presence of the coefficient 1.66 in the 
formula is due to the fact that ethidium bromide bound to the supercolied pBR322 is 1.66 times less 
than that bound to the relaxed form. 
7) EVALUATION OF LIPIDIC PEROXIDATION 
Lipidic peroxidation was monitored by Morlière method or TBARS assay, which checks the 
formation of malondialdehyde, one of the final product of this oxidation process, as it reacts with 
thiobarbituric acid. 
500.000 jurkat cells were irradiated (2.5 J/cm
2
) in the presence of the most active compounds, 
dissolved in HBSS. Then, the drug solution was replaced by RPMI medium and cells were 
incubated for 24 hours.  
sc-DNA = 
Areasc
Areasc + Arearel/1.66
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To verify lipidic peroxidation, after cell centrifugation, 900 μl of surnatant were collected and put at 
253 K after having added 90 μl of 2,6-di-tert-butyl-p-cresol (BHT, 2% in absolute ethanol). Cells 
were washed, resuspended in 500 μl of water.400 μl of cells were lysed with 400 μl of SDS (1% in 
water) and vortexed.  
This suspension was divided into two aliquots: in 500 μl were added 50 μl of BHT; 300 μl were 
used for protein quantification with Peterson method. Lipid peroxidation was measured using a 
thiobarbituric acid assay as described by Morliere et al.
[16]
 
A standard curve of 1,1,3,3 tetraethoxypropane was used to quantify the amount of produced 
malondialdehyde. Data were expressed in terms of nanomoles of TBARS normalized to the total 
protein content in an aliquot of the cell extract. 
8) PROTEIN OXIDATION 
Solutions of Bovine serum albumin (BSA) (0.5 mg/ml) in phosphate buffer 10 mM were irradiated 
in the presence of 20 μM compounds for various times in a quartz cuvette.  
At each time, the tryptophan (Trp) content was followed by monitoring the characteristic Trp 
fluorescence as described by Balasubramanian and Ziegler (1990). 
9) PROTEIN EXTRACTION AND WESTERN BLOTTING. 
10
6
 Jurkat cells were seeded in 24 well-plates; after 24h, they were irradiated in the presence of the 
most active compounds. After 24h from irradiation, cell extracts were prepared, resuspending cells 
in lysis buffer. After the cells were lysed on ice for 20 min, lysates were centrifuged at 10000g at 4 
°C for 20 min. The protein concentration in the supernatant was determined.  
Equal amounts of protein (20 μg) were resolved using 8-16 % gradient polyacrylamide precast gels 
(Thermo Scientific) and transferred on a nitrocellulose Hybond-p membrane (GE Healthcare). 
Membranes were blocked with 5% skim milk powder in Tween-PBS for at least 2 h. Membranes 
were incubated with primary antibodies against caspase-3, Bid and β-actin (all rabbit, 1:1000, Cell 
Signaling,), for 2 h.  
Membranes were next incubated with peroxidase-labeled goat antirabbit IgG (1:3000, Cell 
Signaling) for 60 min.  
All membranes were visualized using ECL Advance (GE Healthcare) and exposed to Hyperfilm 
MP (GE Healthcare). 
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4.2.2 RESULTS 
1) SPECTROSCOPIC PROPERTIES 
The absorption and spectra were collected in DMSO or in phosphate buffer (10 mM, pH = 7,2) and 
ε were calculated (Table 9). 
Table 9 
 λMAX εMAX ε365 nm 
16d 390 15877 14965 
16e 359 6504 6415 
16f 388 12600 12365 
16g 359 8616 8329 
16h 362 15758 15578 
16l 404 16353 9851 
16m 403 17758 13063 
16n 403 23583 13308 
16o 403 17514 13243 
16p 403 18827 13356 
19d 384 14678 12547 
19l 399 25446 13522 
20d 354 35140 29643 
20h 351 22871 17872 
20l 365 27666 27666 
20p 364 23987 23973 
 
All compounds absorbed solar radiation spectrum and presented bands in UV-A region and this fact 
is fundamental for a photosensitizer. All compounds demonstrated quite high values of molar 
extinction coefficients in their λMAX but also at 365 nm. 
2) PHOTOSTABILITY 
When irradiated in solution, furocoumarins are subjected to photolysis. Thus, absorption spectra of 
20 μM DP in DMSO were recorded after increasing the UV-A doses.  
These spectra (Figure 10) gave information about the photostability of compounds and about the 
formation of other species as a consequence of irradiation. All photobleaching spectra were reported 
in the figure  10 below: 16h and 20h spectra were reported as representative.  
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Figure 10 
 
16h spectra was deeply modified after increasing UV-A doses, with the reduction of maxima 
absorption and the onset of a new peak at 340 nm. On the contrary, 20h was photostable. 
3) CYTOTOXICITY AND PHOTOCYTOTOXICITY 
The antiproliferative activity of the test compounds was evaluated on a panel of cultured human cell 
lines: A431 (EGFR-overexpressing carcinoma), Jurkat (T-cell leukemia) and K-562 (chronic 
myelogenous leukemia) cells.  
No cytotoxic activity was found in leukemia cell lines by MTT test after 72 hours from the 
incubation with these compounds (Table 10). However, some molecules presented an 
antiproliferative activity on the carcinoma line. 
 
 
 
16h 
20h 
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Table 10 
GI50 (μM) 
 A431 Jurkat K-562 
16d 2.31 ± 0.56 > 20 > 20 
16e > 20 > 20 > 20 
16f > 20 > 20 > 20 
16g > 20 > 20 > 20 
16h > 20 > 20 > 20 
16l 8.29 ± 0.72 > 20 > 20 
16m > 20 > 20 > 20 
16n > 20 > 20 > 20 
16o 5.22 ± 0.76 > 20 > 20 
16p > 20 > 20 > 20 
19d > 20 > 20 > 20 
19l > 20 > 20 > 20 
20d 12.96 ± 1.50 > 20 > 20 
20h > 20 > 20 > 20 
20l > 20 > 20 > 20 
20p > 20 > 20 > 20 
 
The phototoxicity tests were conducted in the same human tumour cell lines. These experiments 
were conducted as described in Materials and methods section. Briefly, we incubated cells with the 
test compounds for 30 min prior to the irradiation. We used two UV-A doses: 2.5 and 3.75 J/cm
2
 for 
the carcinoma cell line and 1.25 and 2.5 J/cm
2
 for the leukemia cell lines (Table 11). Then, the 
irradiated solution was replaced by cellular medium.  
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Table 11 
GI50 (μM) 
 A431 Jurkat K-562 
 2.5 J/cm
2
 3.75 J/cm
2
 1.25 J/cm
2
 2.5 J/cm
2
 1.25 J/cm
2
 2.5 J/cm
2
 
16d 2.25 ± 0.28 1.78 ± 0.20 3.30 ± 0.44 1.00 ± 0.14 10.70 ± 1.87 3.90 ± 0.45 
16e 0.47 ± 0.06 0.12 ± 0.02 0.30 ± 0.03 0.09 ± 0.01 0.40 ± 0.03 0.22 ± 0.01 
16f 0.26 ± 0.01 0.09 ± 0.01 0.19 ± 0.02 0.09 ± 0.01 0.27 ± 0.02 0.19 ± 0.03 
16g 0.28 ± 0.01 0.12 ± 0.02 0.24 ± 0.01 0.11 ± 0.03 0.47 ± 0.05 0.22 ± 0.03 
16h 0.30 ± 0.06 0.07 ± 0.01 0.21 ± 0.03 0.05 ± 0.02 0.28 ± 0.03 0.16 ± 0.04 
16l 8.75 ± 1.05 6.50 ± 0.50 > 20 > 20 > 20 > 20 
16m 2.56 ± 0.25 0.84 ± 0.06 3.59 ± 0.21 0.43 ± 0.13 8.50 ± 0.83 1.85 ± 0.25 
16n 4.00 ± 0.90 0.88 ± 0.03 1.90 ± 0.26 0.53 ± 0.04 7.68 ± 0.98 1.80 ± 0.20 
16o > 20 5.90 ± 0.94 > 20 > 20 > 20 > 20 
16p 2.74 ± 0.23 0.85 ± 0.05 0.93 ± 0.07 0.47 ± 0.06 2.54 ± 0.35 0.53 ± 0.02 
19d 1.95 ± 0.10 0.91 ± 0.08 1.15 ± 0.22 0.51 ± 0.06 3.53 ± 0.45 1.41 ± 0.25 
19l > 20 15.52 ± 0.89 > 20 7.08 ± 0.78 > 20 > 20 
20d 1.22 ± 0.10 0.14 ± 0.02 0.25 ± 0.08 0.09 ± 0.02 0.63 ± 0.05 0.37 ± 0.04 
20h 0.23 ± 0.02 0.09 ± 0.02 0.25 ± 0.04 0.08 ± 0.02 0.95 ± 0.23 0.19 ± 0.02 
20l 2.63 ± 0.22 1.49 ± 0.04 1.96 ± 0.28 0.68 ± 0.07 5.76 ± 0.59 2.61 ± 0.29 
20p 3.93 ± 0.78 0.87 ± 0.13 1.25 ± 0.15 0.46 ± 0.15 5.67 ± 0.52 1.64 ± 0.07 
Angelicin 5.09 ± 0.65 2.15 ± 0.35 n.a. 1.0±0,2 n.a. 1.2±0.1 
 
Almost all the compounds inhibited the proliferation of cells at submicromolar/micromolar 
concentrations. Some of them were really very phototoxic and presented GI50 in the nanomolar 
range. The most active compounds brought very lipophilic groups in position 1 and 2. The 
substitution of the carbonyl group in position 9 with a methoxyl group did not increase or reduce 
the phototoxic activity. For the following experiments the two most active compounds were chosen: 
16h and 20h. 
Phototoxicity experiments in the presence of some scanvengers can be very useful to identify which 
reactive species are involved in photosensitization. These tests were performed with the most active 
compounds using Jurkat cells. The radical scavengers reduced glutathione (GSH) and vitamin E (vit 
E); the hydroxyl radical scavengers dimethylthiourea (DMTU) and mannitol (MAN), and the 
singlet oxygen scavenger sodium azide (NaN3) were employed. Jurkat were irradiated (2,5 J/cm
2
) in 
the presence of 0.075 µM 16h or 0.1 µM 20h: we chose drug concentrations closed to GI50 values 
(Figure 11). 
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Figure 11 
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For 16h and 20h, the protective effect of scavengers was evident and non-specific. In particular, all 
scavengers seemed to demonstrate a significant protective effect in 16h experiments but 80% of cell 
viability was assessed when the irradiation was conducted in the presence of vit E and DMTU, 
indicating alkyl and hydroxyl radicals may be involved in its phototoxicity. Irradiating Jurkat cells 
in the presence of vit E and 20h, the percentage of cell survival reached the one of control. 
Significant protection was demonstrated when irradiation was carried out in the presence of sodium 
azide, glutathione and DMTU. However, from these data, an univocal mechanism of 
photosensitization was not distinguished but the complexity of the phototoxicity of these 
compounds was clear. 
16h 
20h 
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4) EVALUATION OF CELLULAR DEATH 
The activation of caspase 3 is considered as a hallmark of apoptotic process. The levels of cleaved 
active subunits of executioner caspase-3 were evaluated by immunoblotting Jurkat cell lysates after 
24 h from irradiation. No cleaved caspase 3 was detected in control cells, while the apoptotic 
process is clearly activated after 24 h from irradiation with 16h at both concentrations and the 
highest concentration of 20h. In particular, when irradiation was carried out in the presence of 0.5 
μM 16h the level of active caspase was lower than the one in the presence of 0.25 μM: this fact 
could be explained by the elevated damage with the highest concentration that could also induce 
cellular death by necrosis. Moreover, the activation of another important apoptotic protein such as 
BID, was evaluated. Following TNFα or Fas treatment, BID, a BH3-domain-only molecule is 
cleaved at its amino terminus. Cleavage of cytosolic p22 BID by caspase-8 generates a p15 
carboxy-terminal fragment that translocates to the mitochondria. Truncated p15 BID (tBID) inserts 
into the membrane and is required for cytochrome c release from the mitochondria.  
The presence of t-BID was found in the samples irradiated in the presence of 16h (Figure 12). This 
can supports the possibility of a involvement of mitochondria in cellular death. 
Figure 12 
 
 
5) DETERMINATION OF REACTIVE OXYGEN SPECIES 
Production of reactive oxygen species is one of the mechanisms underlying drug induced 
photosensitization damage. Both compounds generated the superoxide anion efficiently under UVA 
irradiation. Singlet oxygen production was very low and was increased in comparison to control 
only when irradiation was carried out in the presence of 16h (Figure 13).  
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Figure 13 
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6) DNA PHOTOCLEAVAGE 
Some experiments were carried out in order to determine whether the new derivatives were able to 
photosensitize DNA strand break activity. Their ability to photodamage DNA was evaluated using 
supercoiled circular DNA because it allowed the detection of structural alterations such as strand 
breaks. Double-stranded supercoiled (SC or I form) plasmid is sensitive to damage by a variety of 
photosensitizers. Cleavage of one strand produces a relaxed, but still double-stranded, open circular 
(OC or II form) DNA. Further cleavage of the other strand within a short distance of the first site of 
cleavage generates a linear (L or III form) DNA. 
The irradiation of supercoiled plasmid pBR322 was carried out in the presence of various rate 
[DNA]/[DP]. DNA samples were resolved by an electrophoretic run in agarose 1% gel thanks to the 
different hydrodynamic properties of the plasmidic forms (Figure 14). 
Figure 14 
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The results pointed out that the new compounds did not provoke any formation of open circular or 
linear bands, indicating that they did not sensitize single strand breaks. 
In addition to frank strand breaks, the oxidative damage of purine and/or pyrimidine bases was also 
evaluated using the base excision repair enzymes Formamido pyrimidin glycosilase (Fpg) and 
Endonuclease III (Endo III), respectively. DNA strand breaks can be induced either directly (frank 
strand breaks) or indirectly using DNA repair enzymes. Fpg demonstrated to recognize 8-hydroxy 
guanine, purines whose imidazole ring was open (Fapy residues) and sites of base loss (apurinic 
sites). Endonuclease III recognized 5,6-dihydropyrimidine derivatives, in addition to apurinic sites. 
Damaged base recognition was followed by an elimination step, resulting in DNA breakage. 
Thus, after the irradiation in the presence of 40 μM 16h and 20h, pBR322 was incubated with Fpg 
or Endo III at 37°C for 30 min. Then, DNA samples were resolved by electrophoretic run as 
described in Material and Methods section (Figure 15). 
Figure 15 
 
The treatment with the two base excision enzymes revealed that they were able to photooxidize 
DNA bases in a great amount. The percentages of OC form were calculated as suggested by Ciulla 
et al.
[17]
 and were summarized in the following figure 16: 
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Figure 16 
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All compounds were able to photoinduce base oxidation but 16h resulted the most active especially 
in the presence of Fpg, indicating purinic bases were its preferential targets. 
7) LIPID PEROXIDATION 
Like nucleic acids and proteins, unsaturated lipids, glycolipids and cholesterol are important targets 
of 
1
O2 or free radical attack in cells subjected to photooxidative stress. That photodamage develops 
as lipid peroxidation. This phenomenon is initiated by the attack of any chemical species that has 
sufficient reactivity to abstract a hydrogen atom from a methylene carbon in the side chain. The 
hydrogen atom is a free radical and its removal leaves behind an unpaired electron on the carbon to 
which it was originally attached. That new radical can give a peroxyl radical after the reaction with 
oxygen. Peroxyl radicals can combine each other or they can attack membrane proteins, but also are 
capable of abstracting hydrogen from adjacent fatty acid side chains in a membrane and so 
propagating the chain reaction of lipid peroxidation (Figure 17). 
Figure 17 
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Schematic representation of lipidic peroxidation 
16h  20h  
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Membrane lipids may be a central site of photodamage if sensitizing agents localize in the 
membrane bilayer. Being hydrophobic, these compounds may be expected to be localized mainly in 
plasmatic and/or in subcellular membranes, making these structures particularly sensitive to 
photodamage. 
The thiobarbituric assay (TBA test) was used in order to determine a potential lipid peroxidation 
after irradiation of jurkat cells in the presence of test compounds. The TBA test was performed as 
described in the experimental section. In brief, this assay used the reaction of one molecule of 
malondialdehyde (MDA), which is a secondary product of lipid peroxidation, with two molecules 
of TBA, forming a pink chromogen. Thus, the resulting chromogen was monitored by fluorescence 
at 553 nm (Figure 18). 
Figure 18 
 
Thiobarbituric reactive substances (TBARS) were significantly produced in a concentration-
dependent manner when the cells were exposed to the compounds and UV-A. Thus, lipid 
peroxidation could be important in the mechanism of phototoxicity. 
8) PROTEIN PHOTOREACTION 
In order to investigate more deeply photosensitizing properties of the title compounds towards 
proteins, solutions containing bovine serum albumin (BSA) as model and the compounds in 
phosphate buffer were irradiated several times. The amount of the aromatic aminoacid tryptophan 
(Trp) was directly analysed by monitoring the characteristic fluorescence of Trp residues. No 
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significant Trp photoreaction was assessed by fluorescence in comparison to control (data not 
shown): thus, proteins were likely marginally involved in their phototoxicity. 
9) CONCLUSION 
All the molecules showed high photocytotoxicity at the tested concentrations. In particular, 16e-h 
and 20h show the best values of photoactivity, that reach in some cases the nanomolar range, being 
far more active than Angelicin used as reference drug, and also more active than the lead 
compounds 3 (compare Table 6 with Table 11). Phototoxicity was find to be UV-A dose and 
concentration dependent.  
SAR studies indicates that all the compounds belonging to the ethoxycarbonyl series are more  
active than the unsubstituted series (compare 16d-h with 16l-p). Moreover, within the two series, 
the presence of a big lipophilic group like the benzyl or a methoxy benzylgroup, increases the value 
of activity. Furthermore the further functionalization of carboxamide of 2-pyridone ring, gave a 
little increase in the value of activity (compare 16d with 19d and 20d and compare 16l with 20l). 
Unfortunaly, biological tests show also that this class of compounds, were able to photoinduce 
DNA bases oxidation, especially the purinic bases, at difference of the class of compounds 3
[10,11]
 
(also psoralens and angelicin cause photodamage).
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5. PYRROLO[2',3':3,4]CYCLOHEPTA[1,2-d][1,2]OXAZOLE 
5.1 Synthesis 
An extension of the project, concerns the synthesis of pyrrolo[2’,3’:3,4]cyclohepta[1,2-
d][1,2]oxazoles 21-22.  
 
In the literature, there are many example of compounds bearing the oxazole core that showed 
interesting biological activity (Figure 19). Combretastatin CA-4 is an inhibitor of the polimerization 
of tubulin studied as antitumor drug. Combretastatin and its analogues with a diaryl oxazole 
structure, are significant examples of oxazole active compounds. These were synthesized in order to 
block the -C=C- bond in the cis geometry that is the most active one; some of them showed 
inhibition activity with IC50 in the nanomolar range against different tumor cell lines. The 
mechanism involved G2/M phase arrest of the cell cycle.
[18,19]
 Furthermore some pteridinic 
compounds bonded to an oxazole ring, showed inhibition of cellular growth when tested on MCF-7, 
NCI-H460 and SN-268.
[20]
     
Figure 19 
 
In the light of this results, in our research group in the past years, was thought to cyclize the oxazole 
ring on the isoindole core, obtaining the new heterocyclic system oxazole[5,4-e]isoindole (Figure 
20). The new derivatives tested by NCI of Bethesda in order to evaluate the antiproliferative activity 
on a panel of 60 human cell lines divided into 9 subpanels (breast, ovaries, lung, colon, CNS, 
melanoma, leukemia, kidney, prostate), showed antiproliferative activity from micro to nanomolar 
range. In particular, the oxazoles SIX2 (GI50 0.2-17 µM) and SIX13 (GI50 0.04-48 µM) were the 
most interesting of the first series of derivatives, active on all the tumor cell lines tested with GI50 
values from submicro to nanomolar (0.04 - 48 M) with a Mean Graph Mid-Point (pMG_MID) of 
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6.68 and 5.80 (Figure 20). Moreover a further extension of this series, led to derivatives with 
comparable activity such as SIX 2D (pMG_MID = 6.62) SIX 13O (pMG_MID = 6.61), and SIX 
13S (pMG_MID = 6.41), or even more active such as SIX 13U (pMG_MID = 7.19). 
Figure 20 
 
On derivatives SIX 2 and SIX 13 the NCI performed the Hollow Fiber Assay (HFA) a in vivo 
assay in which was evaluated the maximum tolerated dose (MTD), and on the derivate SIX 13 was 
performed a COMPARE analysis in which the compound was compared with a "standard agent 
database" giving an indication of a possible mechanism of action. The results of this analysis, 
showed a good correlation index with the antimitotic agent taxol. Studies to evaluate the mechanism 
of action are in fact underway to confirm the possible molecular target. 
Given the high efficacy shown by these compounds, the new class of [1,2]oxazolo[4,5-g]indole was 
studied, in which the isoindole scaffold has been replaced by an indole (Figure 21). 
Figure 21 
 
Also in this case the new derivatives tested by NCI of Bethesda, gave positive GI50 values against 
almost all the tested human cell lines, showing GI50 values in the micromolar - nanomolar range. 
[21]
 
An evaluation of the results, indicated that the presence of a 3,5-dimethoxy-substituted benzyl 
moiety at the indole nitrogen appeared crucial in conferring good activity to the [1,2]oxazolo[4,5-
g]indole derivatives. In fact, the most active compounds showed mean graph mid-points 
(pMG_MID) of 6.60 and 6.33. From here the idea to try the synthesis of new oxazole derivatives on 
our scaffold, using as lead compounds the 3,5-dimethoxybenzyl[1,2]oxazolo[4,5-g]indole with the 
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aim of obtaining more potent antiproliferative agents. Depending on the substitution pattern of the 
pyrrole ring, the new tricyclic derivatives pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole 21-22, 
were obtained starting from our enaminoketones 13 or hydroxymethylketones 14 by reaction with 
hydroxylamine as dinucleofile. In fact, ketones of type 9b,l-s belonging to unsubstituted series, 
were first converted into enaminoketones 13, and then subjected to ring closure with hydroxylamine 
hydrochloride to give the desired oxazole 21b, l-s. Regarding the ethoxycarbonyl series, it was 
more convenient to start from hydroxymethylenketones 14 obtained by reaction of the appropriate 
ketones of type 9d-k, in toluene, using tert-butoxide as a base and then ethyl formate (Scheme 11). 
The formyl-derivatives 14d-k, proved to be quite difficult to handle, in fact even small variations in 
the work up procedure, or in the reaction itself, led to big decrease in yield. Anyway they were 
obtained with good yields (60-90%). Also in this case the subsequent cyclization was achieved with 
hydroxylamine in refluxing ethanol to give the desired compounds 21d-k. Also the derivate 21t was 
obtained, using the intermediate 13t obtained from the reaction of transesterification of 9e with an 
excess of DMFDMA under microwave conditions.  
Scheme 11 
 
In order to complete the substitution pattern to pyrrole, and to verify the effect on biological 
activity, the oxazoles 21 were subjected to smooth chlorination with N-chlorosuccinimide in 
anhydrous DMF for one night at room temperature. Mixed results were obtained from the two series 
of compounds (Scheme 12). 
Scheme 12 
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In fact, while in the case of products 21d-k belonging to the ethoxycarbonyl series, only the 
position 7 was available for the reaction of addition of chlorine, in the case of the products of type 
21b, l-s, both the two pyrrole positions were available, and from the reaction mixture the 7-chloro 
and 8-chloro derivatives were obtained, showing identical Rf values. Unfortunately also by using 
high pressure chromatography apparatus (Biotage), we were able to isolate only in the case of the 
N-Methyl derivative 21l, the compound bearing the chlorine in position 8 (22l), as pure compound 
and in lower yield. 
Table 12 
  R R1 R2 Yield 
 
 
 
21b SO2Ph  H H 60 % 
21d Me COOEt H 90 %  
21e Bn COOEt H 60 %  
21f 2-OMe-Bn COOEt H 60 %  
21g 3-OMe-Bn COOEt H 82 %  
21h 4-OMe-Bn COOEt H 81 %  
21i 2,5-(OMe)2-Bn COOEt H 74 % 
21j 3,5-(OMe)2-Bn COOEt H 82 %  
21k 3,4,5-(OMe)3-Bn COOEt H 72 % 
21l  Me H H 75 % 
21m Bn H H 83 % 
21n 2-OMe-Bn H H 70 % 
 21o 3-OMe-Bn H H 83 % 
 21p 4-OMe-Bn H H 68 % 
 21q 2,5-(OMe)2-Bn H H 78 % 
 21r 3,5-(OMe)2-Bn H H 76 % 
 21s 3,4,5-(OMe)3-Bn H H 74 % 
 21t Bn COOMe H 72% 
 22d Me COOEt Cl 50 % 
 22e Bn COOEt Cl 57 % 
 22f 2-OMe-Bn COOEt Cl 74 % 
 22g 3-OMe-Bn COOEt Cl 65 % 
 22h 4-OMe-Bn COOEt Cl 70 % 
 22i 2,5-(OMe)2-Bn COOEt Cl 68 % 
 22j 3,5-(OMe)2-Bn COOEt Cl 70 % 
 22l Me Cl H 49 % 
Table 12: Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole 21-22. 
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5.2 Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole 
Anticancer activity  
The final series of 26 compounds (Table 12) was submitted to the US National Cancer Institute 
(NCI) in Bethesda for cell-based antiproliferative screens. Among this, 18 compounds, (with the 
exception of 21i,n,o,q,r, and 22f,g,i), were selected for the one-dose (10
-5
M) prescreening on the 
full panel of 60 human tumor cell lines divided into nine subpanels (leukemia, non-small-cell lung, 
colon, central nervous system, melanoma, ovarian, renal, prostate, and breast cancers). 
Six compounds (21f,g,j,k, and 22e,j) were then further selected for evaluation on the full panel at 
five doses (10
-4–10-8M). Three of the selected compounds (21g,k and 22j) gave positive GI50 values 
against all tested human cell lines, while 21f, 21j and 22e, were not responsive only against one or 
few cell lines (Table 13). 
Table 13 
Cpd N. of cell 
investigate 
N. of cell with  
positive GI50 
Range 
[μM] 
pMG_MID 
21f 56 50 0.30 – 46.2 5.35 
21g 56 56 0.15 – 18.7 5.84 
21j 56 55 0.01 – 13.4 7.10 
21k 55 55 0.01 – 64.9 6.70 
22e 55 46 1.29 – 5.89 5.15 
22j 57 57 0.03 – 27.0 6.39 
Table 13 Overview of the antitumor screenings of 21f,g,j,k, and 22e,j. 
An evaluation of the data listed in Table 14 indicates a good potential of this class of compounds 
showing growth inhibitory activity reaching the nanomolar range. In particular, the presence of a 
3,5-dimethoxy-substituted benzyl moiety at the indole nitrogen (position 9) appears crucial for 
conferring good activity to the pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole derivatives. In fact, 
the most active compounds were 21j, 21k and 22j, having mean graph mid-points (pMG_MID) of 
7.10, 6.70 and 6.39 respectively. All this compounds belong to the ethoxycarbonyl series. From a 
structure–activity point of view, the addition of a methoxy group (21k) in position 4, led to a slight 
decrease in activity, while the removal of one methoxy group (21f, 21g) produce a bigger decrease 
in the activity (compare 21j, pMG_MID = 7,10, 21k, pMG_MID = 6.70, 21f, pMG_MID = 5.35, 
and 21g, pMG_MID = 5.84). Moreover the presence of chlorine in 7 position, slightly reduce the 
activity with respect of corresponding non halogenated derivatives (compare 21j, pMG_MID = 
7,10, with 22j, pMG_MID = 6.39).  
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Table 14 
Cell lines  21f  21g  21j  21k  22e  22j  Cell lines 21f  21g  21j  21k  22e  22j  
Leukemia  M14  3.67  0.54  0.05  0.15  3.78  0.26  
CCRF-CEM   2.87  2.17  0.05  0.30  2.21  0.25  MDA-MB-435  0.35  0.15  0.01  0.02  1.40  0.03  
HL-60(TB)                                           3.04  0.53 0.03 0.19  3.32  0.31  SK-MEL-2  -  0.56  0.04  -  -  0.22  
K-562                                                                                           1.59 0.39  0.04 0.13  3.68 0.29 SK-MEL-28  >100  5.12  0.09  0.30  -  0.66  
MOLT-4  5.68  2.30  0.26  0.39  3.58  0.58  SK-MEL-5  2.61  0.75  0.04  0.17  3.53  0.49  
RPMI-8226  4.11  1.89  0.05  0.38  3.27  0.39  UACC-257  -  7.61  -  -  -  -  
SR  0.43  0.28  0.03  0.04  1.80  0.07  UACC-62  3.37  0.51  0.07  0.05  4.01  0.11  
Non-Small Cell Lung Cancer  Ovarian Cancer 
A549/ATCC  -  0.76  0.06  -  -  -  IGROV1  1.99  1.16  0.06  0.06  4.39  0.34  
EKVX  -  -  -  -  -  -  OVCAR-3  0.87  0.30  0.02  0.03  3.13  0.19  
HOP-62  1.89  4.34  -  0.17  4.35  0.29  OVCAR-4  9.35  18.7  13.4  0.72  -  0.85  
HOP-92  0.30  4.21  -  -  - 0.46  OVCAR-5  >100  5.94  0.18  0.53  >100  -  
NCI-H226  >100  21.0  7.98  1.21  >100  9.71  OVCAR-8  3.85  3.13  0.08  0.24  -  0.41  
NCI-H23  8.52  -  -  0.37  -  0.68  NCI/ADR-RES  1.36  0.43  0.03  0.06  2.83  0.20  
NCI-H322M  5.23  -  -  0.32  >100  0.51  SK-OV-3  2.70  2.83  0.05  0.13  >100  0.24  
NCI-H460  3.88  3.53  0.04  0.23  3.62  0.35  Renal Cancer  
NCI-H522  0.35  0.23  0.02  0.01  1.29  0.03  786-0  >100  6.74  0.05  0.97  -  4.24  
Colon Cancer  A498  3.46  0.44  0.02  0.11  4.38  0.17  
COLO 205  0.87  0.58  0.03  0.04  3.53  0.17  ACHN  16.6  3.40  0.06  0.29  5.89  0.94  
HCC-2998  >100  4.18  0.23  0.30  -  -  CAKI-1  3.51  2.31  0.05  0.07  3.51  0.28  
HCT-116  3.79  0.47  0.04  0.19  4.02  0.43  RXF 393  2.08  0.67  0.02  0.12  -  0.25  
HCT-15  2.24  0.45  0.04  0.16  3.39  0.37  SN12C  >100  3.51  0.07  0.76  -  0.83  
HT29  0.91  0.36  0.03  0.07  2.95  0.27  TK-10  67.8  11.2  >100  64.9  >100  10.3  
KM12  2.10  0.46  0.03  0.05  3.70  0.32  UO-31  6.53  3.37  0.05  0.08  -  0.78  
SW-620  2.02  0.48  0.04  0.14  3.81  0.32  Prostate Cancer  
CNS cancer  PC-3  2.48  2.35  0.04  0.17  3.16  0.29  
SF-268  46.2  6.71  0.05  0.52  >100  1.91  DU-145  5.27  2.18  0.04  0.28  >100  0.35  
SF-295  1.38  0.62  0.03  0.44  >100  0.06  Breast Cancer  
SF-539  2.48  1.14  0.03  0.12  -  0.24  MCF7  0.71  0.37  0.03  0.04  3.21  0.10  
SNB-19  64.7  8.23  0.15  0.56  >100  0.52  
MDA-MB-231/ 
ATCC  
9.12  1.84  0.24  0.48  3.51  0.84  
SNB-75  1.97  1.60  0.03  0.07  -  0.22  HS 578T  3.38  1.60  0.04  0.34  -  0.45  
U251  3.78  -  -  0.14  -  0.31  BT-549  7.73  0.98  1.72  0.29  -  27.0  
Melanoma  T-47D  2.46  2.00  -  0.10  2.69  0.44  
LOX IMVI  7.64  1.75  0.05  0.41  5.26  0.88  MDA-MB-468  2.95  0.34  0.03  0.74  -  0.73  
MALME-3M  3.08  0.89  -  0.05  3.68  0.20  The values of GI50 are expressed in micromolar. 
Table 14: Inhibition in vitro of tumor cell growth by 21f,g,j,k, and 22e,j.  
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Figure 22  
 
Figure 22 Dose Response Curves of 21j 
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Figure 23  
 
Figure 23 Mean Graphs of 21j 
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Figure 24  
 
 
Figure 24 Dose Response Curves of 21k 
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Figure 25  
 
 
Figure 25 Mean Graphs of 21k 
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Analysis of the GI50 values listed in Table 14 indicates that the most active compound, 21j, was 
particularly effective against the colon cancer, CNS cancer, melanoma, prostate and renal cancer 
subpanels (Figures 22 and 23). In fact, the calculated pMG_MID value for the single subpanels was 
in some cases higher than the overall cell lines pMG_MID value (for example prostate 7.33, colon 
7.16, CNS 7.21, melanoma7.25).  
The most sensitive cell lines were MDA-MB-435 of melanoma subpanel and A498 of renal cancer 
subpanel, having GI50 values in the nanomolar range, 19 and 20 nM, respectively. Compound 21k 
was also highly selective against the leukemia, colon cancer, CNS cancer, melanoma, ovarian 
cancer and breast subpanels, having subpanel GI50 values at sub-micromolar levels, 0.04 – 0.39 μM, 
0.04 – 0.59 μM, 0.07 – 0.56 μM, 0.02 – 0.41 μM, 0.03 – 0.72 μM, 0.04 – 0.74 μM respectively 
(Figures 24 and 25). The same compounds, however, got responses in the nanomolar range also in 
other cell lines belonging to different subpanels: just for example the cell line NCI-H522 of the non-
small cell lung cancer subpanel (20 nM for 21j and 19 nM for 21k), OVCAR 3 of the ovarian 
cancer subpanel (25 nM for 21j), MCF7 of breast cancer subpanel (24 nM for 21j) and CAKI-1 of 
renal cancer subpanel (78 nM for 21k) and moreover.  
In conclusion, was reported a method for the synthesis of derivatives of the new ring system 
pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole. The antiproliferative activity exhibited by 
derivatives 21f,g,j,k, and 22e,j against the totality of the NCI full panel of human tumor cell lines 
makes this class of compounds interesting for further studies. In particular, the potent activity of 
compounds 21j, 21k and 22j encourages the synthesis of new derivatives and makes them lead 
compounds for new classes of compounds with the aim of obtaining more potent antiproliferative 
agents. The mechanism of action is under investigation by the “Istituto Tumori di Milano” on a big 
panel of kinases.  
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6. PYRROLO[3',2':6,7]CYCLOHEPTA[1,2-d]PYRIMIDIN-2-AMINE 
6.1 Synthesis 
Continuing our studies on tricyclic systems, we set the synthesis of pyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidin-2-amine 24-29. 
 
The pyrimidine nucleus is of great interest, being the scaffold of many antitumor drugs, and 
compounds that incorporate such moiety have recently emerged as inhibitors of cyclin dependent 
kinases (CDKs) and Polo-like kinase 1 (Plk1). It is well known that compounds targeting the 
complexes between cyclin-dependent kinases (CDKs) and cyclins (Cy) and inhibiting their activity, 
are regarded as promising antitumor agents to complement the existing therapies. 
CDKs are a family of serine/threonine kinases that specifically form heterodimeric complexes with 
regulatory subunits named cyclins (Cy), and in concert with cyclins (positive regulators) and natural 
inhibitors (CDKI), play a crucial role in the cell cycle progression. Deregulation of the activity of 
CDKs, (due to alterations of expression and/or genetic mutations of cyclins, CDKs, CDKIs, and 
other components of the retinoblastoma protein (pRB) pathway), has been reported in more than 90 
% of human neoplasms. For example, cyclins E and A have been found overexpressed in 50 % of 
breast and lung cancer whereas decreased levels of the inhibitor p27 indicate a poor prognosis in 
breast, prostate, colon, gastric, lung and esophageal cancer. The high frequency of alterations found 
in the core members of this pathway in human tumors led to the suggestion that its deregulation, 
leading to increased activity of CDK/cyclin complexes, is an obligatory event for the development 
of all human cancers. 
Overexpression of these kinases mediated by disruption of the mechanisms that keep the cell cycle 
under control is a hallmark of virtually all cancer cells. In fact CDKs not only are recognized to be 
key components in the control of the cycle cell progression, but they play also very important roles 
on the mitotic entry, centrosome duplication, bipolar mitotic spindle formation, transition from 
metaphase to anaphase, cytokinesis and maintenance of genomic stability.  
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Tricyclic quinazoline system reported in the literature 
[22]
 with similar structure to our scaffold, have 
been reported as potent selective inhibitors of the complex CDK2/CyA (Figure 22). Moreover, 
recently in our research laboratory, a series of products bearing the pyrimidine core condensed to 
the indole moiety were synthesized. This class of compounds pyrrolo[3,2-h]quinazoline (Table 19) 
showed significant activity after irradiation with UV light against a panel of different human tumor 
cell lines 
[23]
, demonstrating a very promising class of photosensitizing agents with IC50 values of 
0.21-15.21 M. 
Figure 22 
 
Two of these compounds (Figure 23) showed IC50 values lower than angelicin used as reference 
drug. It was also studied the possible mechanism of action, and it seems that they induce apoptosis 
mediated by mitochondria and lysosomes. The DNA does not seem to be involved in the process of 
induction of phototoxicity. This aspect is of great importance in modulating the side effects since 
that the drugs currently on the market, can cause genotoxicity, mutagenicity and skin cancer. 
Figure 23 
 
From the phototoxicity data listed in the table 20, we can note that the substituent in position two 
plays an important role in inducing phototoxicity. In fact, the antiproliferative activity was maximal 
when in position two there was an amino group (23i and 23j), and decreased if there were an aniline 
group (23l and 23m), a carbonyl group (23d) or a hydrogen (23q). In general the presence of a 
ethoxycarbonyl group in position eight increases phototoxicity. It passes from inactive compounds 
such as 23a,b,e and analogous phototoxic 23c,d,h. 
51 
 
Table 19 
 Cpd R R1 R2 Cpd R R1 R2 
 
 
23a Me H C=O 23j 4-OMe-Bn COOEt NH2 
23b Bn H C=O 23k Me H NHPh 
23c Me COOEt C=O 23l  Bn H NHPh 
23d Bn COOEt C=O 23m 4-OMe-Bn H NHPh 
23e Me H NH2 23n Me COOEt NHPh 
23f  Bn H NH2 23o 4-OMe-Bn COOEt NHPh 
23g 4-OMe-Bn H NH2 23p Bn H H 
23h Me COOEt NH2 23q Ph H H 
23i Bn COOEt NH2     
Table 19: List of pyrrolo[3-2h]quinazolines 23 
Table 20  
 Jurkat  
(IC50, µM) 
K-562 
(IC50, µM) 
LoVo  
(IC50, µM) 
A-431 
(IC50, µM) 
Dose  
UVA 
(J/cm2) 
2.5  3.75  2.5  3.75  2.5  3.75  2.5  3.75  
23a > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
23b > 20 > 20 > 20 13,69±1,09 > 20 > 20 > 20 > 20 
23c 4.85±0.53 3.47±0.11 5.70±0.76 4.38±0.44 9.72±1.32 6.76±0.57 > 20 8.05±1,69 
23d 2.05±0.62 1.08±0.25 7.96±1.46 2.92±0.42 3.07±0.35 2.30±0.24 3.91±0.15 2.45±0.38 
23e > 20 8.42±1.49 > 20 > 20 > 20 > 20 > 20 > 20 
23f 0.65±0.13 0.39±0.05 1.44±0.12 0.72±0.28 0.85±0.19 0.54±0.09 1.19±0.03 0.96±0.05 
23g 0.43±0.08 0.28±0.08 1.71±0.17 0.53±0.09 1.12±0.23 0.59±0.18 1.31±0.17 0.60±0.16 
23h 0.83±0.16 0.46±0.09 2.38±0.70 1.16±0.20 1.57±0.12 1.02±0.09 1.90±0.11 1.34±0.25 
23i 0.43±0.08 0.21±0.06 0.74±0.13 048±0.08 0.56±0.07 0.44±0.04 0.74±0.07 0.39±0.10 
23j 0.29±0.02 0.23±0.01 0.75±0.18 0.41±0.05 0.47±0.07 0.34±0.03 0.44±0.05 0.26±0.06 
23k 0.83±0.08 0.55±0.09 3.51±0.80 1.82±0.39 0.82±0.14 0.55±0.08 2.28±0.18 1.44±0.15 
23l 0.81±0.07 0.52±0.11 3.90±0.70 2.85±0.20 2.31±0.17 0.95±0.09 1.77±0.27 1.16±0.12 
23m 2.05±0.12 0.68±0.09 4.06±0.60 2.16±0.28 2.80±0.29 1.43±0.15 3.79±0.43 2.53±0.53 
23n > 20 8.53±1.53 > 20 > 20 15.21±1.97 9.61±1.32 > 20 5.69±1.32 
23o 0.70±0.11 0.50±0.05 2.63±0.36 1.88±0.35 0.88±0.11 0.48±0.11 1.57±0.11 1.09±0.21 
23p > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
23q > 20 > 20 > 20 > 20 > 20 > 20 > 20 > 20 
Ang 1.00±0.20 0.90±0.10 1.21±0.11 1.09±0.10 4.08±0.41 1.12±0.44 5.09±0.65 2.15±0.35 
Table 20: Phototoxicity of Pyrrolo[3,2-h]quinazolines 23 
Given these results of considerable importance, it was planned the synthesis of this new class of 
derivatives pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidin-2-amine 24-29. Since the lead coumpounds 
(Figure 23) of the previous series 23 are ethoxycarbonyl derivatives, bearing a benzyl or 4-
methoxy-benzyl group at the pyrrole nitrogen, we decided to start our own synthesis with the same 
type of substitution at the pyrrole.  
Starting from our intermediates of type 13, in only one step, the pyrimidine ring was anellated to  
our scaffold bearing the proper decoration. With the aim of obtaining the best interactions with the 
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above mentioned kinases, a further functionalization, was achieved by converting the ester 
functionality in position nine to carboxamide in two steps. Indeed by using KOH in ethanol at 
reflux, the ester functionality was hydrolyzed to corresponding acid, and then by using ammonium 
carbonate in presence of benzotriazole and N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
hydrochloride, as activating agents of acid function, the carboxamide derivatives 27 - 29 were 
obtained with good yields (Scheme 13). 
Scheme 13 
 
Table 21 
 Cpd R1 R1 R2 Yield 
 
 
 
 
 
24d Me COOEt H 59% 
24e Bn COOEt H 40% 
24h 4-OMe-Bn COOEt H 50% 
25d Me COOEt Ph 62% 
25e Bn COOEt Ph 60% 
25h 4-OMe-Bn COOEt Ph 43% 
26d Me COOEt Cyclohexyl 76% 
26e Bn COOEt Cyclohexyl 81% 
26h 4-OMe-Bn COOEt Cyclohexyl 49% 
27d Me CONH2 H 66% 
27e Bn CONH2 H 25% 
27h 4-OMe-Bn CONH2 H 94% 
28d Me CONH2 Ph 74% 
28e Bn CONH2 Ph 64% 
28h 4-OMe-Bn CONH2 Ph 54% 
29d Me CONH2 Cyclohexyl 82% 
29e Bn CONH2 Cyclohexyl 85% 
29h 4-OMe-Bn CONH2 Cyclohexyl 93% 
Table 21:  List of pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidin-2-amine 24-29 
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6.2 Pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidin-2-amine 
Anticancer activity 
The obtained compounds (Table 21), were submitted for the antitumor evaluation at NCI of 
Bethesda (USA). The compounds also were sent to University of Padova to evaluate their photo 
antiproliferative activity. Subsequently it will be evaluated the mechanism of action.  
Figure 24 
          
Figure 24 Dose Response Curves of 28d 
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Figure 25 
 
Figure 25 Mean Graph of 28d 
Moreover, only nine of the compounds submitted bearing the caboxamide functionality, were 
selected by NCI. After the first prescreening, only the compound 28d was selected for the one-dose 
(10
-5
M) screening on the full panel of 60 human tumor cell lines divided into nine subpanels 
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(leukemia, non-small-cell lung, colon, central nervous system, melanoma, ovarian, renal, prostate, 
and breast cancers).  
In detail (Figures 24 and 25) it can be observed that compound 28d showed the best selectivity 
against the renal and the non-small cell lung cancer subpanels. In fact the calculated pMG_MID 
values for the single subpanels (5.56 and 5.48 respectively) was higher than the overall cell lines 
pMG_MID value (5.38). 
The most sensitive cell lines were A498 of the renal subpanel and NCI-H226 of the non-small cell 
lung cancer subpanel, having GI50 values in the submicromolar range, 0.2 and 0.9 M respectively. 
These results in “the dark” could indicate a possible inhibitory effect induced only after 
photoactivation, in agreement with the previous class of pyrrolo[3-2h]quinazolines 23. 
The evaluation of their photoantiproliferative activity is still in progress at the University of Padova. 
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7. PYRROLO[3',2':6,7]CYCLOHEPTA[1,2-d][1,3]THIAZOL-2-AMINE 
7.1 Synthesis 
Starting from our scaffold, another class of tricyclic compounds was planned. In this case we set the 
synthesis of the new ring system pyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine 32. 
    
Inositol trisphosphate or inositol 1,4,5-trisphosphate (abbreviated InsP3 or Ins3P or IP3), together 
with diacylglycerol (DAG), are a secondary messenger molecules used in signal transduction in 
biological cells. While DAG stays inside the membrane, IP3 is soluble and diffuses through the cell. 
It originates from hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), a phospholipid that is 
located in the plasma membrane, by phospholipase C (PLC).  
The IP3, binds and activates the inositol triphosphate receptor, a large channel protein that is found 
on the surface of the endoplasmic reticulum. His bonding with this protein, allows its opening and 
the release of calcium flowing into the cytoplasm. There are multiple molecular actions resulting 
therefrom. Just think that through its link with the calmodulin protein, the calcium ion is able to 
affect more than thirty intracellular enzymes linked to metabolism, signal transduction or 
production of energy. 
The phosphatidylinositide 3-kinases (PI 3-kinases, PI3Ks, PI(3)Ks, or PI-3Ks) are a family of 
intracellular signal transducer enzymes involved in complex cellular functions such as cell growth, 
proliferation, differentiation, motility, survival and intracellular trafficking; mechanisms that in turn 
are also involved in cancer. PI3Ks are capable of phosphorylating the hydroxyl group in position 
three of the inositol ring of phosphatidylinositol. Alterations in the activity of PI3 kinase are present 
in a broad spectrum of tumors, so this has stimulated the research and the development of inhibitors 
of these kinases. 
The interest on this class of compounds rised from the similarity of the trycliclic scaffold with 
compounds of the pyrazole series, such as thiazolyl-dyhydro-indazoles derivatives, 
[24]
 which 
proved potent inhibitory activity of PI3K. On the basis of these data, we had already synthetized the 
tricyclic 2-amine-[1,3]thiazolo[4,5-e]isoindoles derivatives 30 (Figure 26) with the aim of studying 
their inhibitory activity toward kinases, and the effect of the replacement of the pyrazole with a 
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pyrrole ring on the biological activity. Among the new derivatives 6 out of 32 reacted the 5-doses 
NCI in vitro screening, forth evaluation of the growth inhibitory effect against a panel of about 60 
tumor cell lines. 
Figure 26 
 
Table 22 
Cpd R1 R2 R3 R4 pMG_MID 
30-a 4-OMe-Bn Br 3,4,5-(OMe)3-Ph H 6.08 
30-b SO2-Ph H 3,4,5-(OMe)3-Ph H 5.99 
30-c 4-OMe-Bn Br Br H 5.43 
30-d 4-OMe-Bn Br 3,4,5-(OMe)3-Ph Acetyl 5.36 
30-e Bn Br Br Benzoyl 5.29 
30-f Bn Br Br H 5.09 
An evaluation of the data listed in Table 22 indicates a good potential of this class of compounds 
showing growth inhibitory activity in the micromolar range with a pMG_MID value between 6 and 
5. The most active compounds of the series were 30a and 30b, having mean graph mid-points 
(pMG_MID) of 6.08 and 5.99 respectively. From a structure–activity point of view, it seems that 
the presence of a 3,4,5-trimethoxyphenyl moiety at position 6, is essential for the activity. Among 
the 3 derivatives bearing a 3,4,5-(OMe)3-Ph moiety, the addition of a bromine atom in position 8, 
seems to be important in the modulation of activity, whereas the presence of acetyl groups as 
substituent on the amine in position 2, produces a slight decrease in the activity (compare 30a 
pMG_MID = 6.08 and 30d pMG_MID = 5.99). Moreover for the N-benzyl derivatives, the 
presence of the free amine produces a small reduction of activity, with respect to the corresponding 
benzoyl substituted derivatives (compare 30e, pMG_MID = 5.29 and 30f pMG_MID = 5.09).  
In this contest we decided to extend the synthesis to new thiazole derivatives bearing the seven 
member ring in the tryciclyc scaffold, obtaining the new class of compound 
pyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine 32, aiming to an improvement of the 
activity. To achieve the new ring system 32, we reacted ketones 9, with copper(II) bromide (CuBr2) 
obtaining brominated intermediates of type 31, that upon subsequent reaction with thiourea, gave 
the desired compounds (Scheme 14). 
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In our firs attempt of obtaining compounds 32 in one pot reaction using ethyl acetate as solvent and 
CuBr2 as brominated agent, we noted that ketones 9 reacted giving the brominated intermediates 31. 
The following addition of potassium carbonate and thiourea to the reaction mixture, yielded the 
desired thiazole derivatives in modeste yields (30 - 40 %). We tried also the reaction in two steps, 
using the same reagents and solvent. Thus, when the brominated intermediates were formed, the 
reaction mixtures were filtered to remove the copper(I) bromide. Mixtures were concentrated and 
reacted in DMF with potassium carbonate and thiourea obtaining an improvement of the yields up 
to 50 - 60%. (Table 23) 
Scheme 14 
 
 
From the reaction of ketone 9j with copper(II) bromide, beside the main component 31j, which was 
successfully cyclized to 32j, from the reaction mixture a secondary product 31u was isolated, 
bearing a second bromine atom to position 2 of the 3,5-(OMe)2-Bn moiety (Scheme 15). This 
product was also annellated with thiourea to obtain another derivate 32u to submit for biological 
screening.  
Scheme 15 
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When the ketone 9c bearing the free NH, was reacted with copper(II) bromide, the bromine atom 
was introduced preferentially at the position 2 of the pyrrole ring rather than the  position of the 
carbonyl (Scheme 16) furnishing 31v. Thus, in order to obtain the thiazole derivative 32c bearing 
the free NH, we tried directly the deprotection of the SO2Ph group with NaOH starting either from 
thiazole 32b and from the brominated intermediate 31b. However it was not possible obtain the 
desired product because decomposition of the starting material was observed upon heating.  
Scheme 16 
 
So we decided to insert a different protecting group to the pyrrole nitrogen in order to direct the 
bromination to the desired position, but which could be more easily removed. Thus by reaction with 
NaH and benzoylchloride, a benzoyl group was introduced to furnishing ketone 9w, which was 
subjected to bromination giving 31w. 
The reaction of bromination made with Pyridine hydrobromide perbromide in THF at room 
temperature, instead the copper(II) bromide in ethyl acetate at reflux, gave 31w with better yield 
(65% versus 18%). The deprotection step, also in this case made with NaOH solution, but at room 
temperature, gave 31c with good yield, and finally the ring closure with thiourea gave the desired 
tryciclic derivative 32c. 
Considering that in the pyrazole series, thiazoles bearing an acetylamino group gave interesting 
results of biological activity, a further functionalization was achieved by acylation of amine group, 
by reaction of derivates 32 with DIPEA and acetyl chloride at room temperature in DCM as solvent 
(Scheme 17).  
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A final series of 14 derivatives has been prepared (Table 23), but further functionalization of the 
ring system at the pyrrole and/or at the thiazole moiety are still in progress. All the compounds will 
be submitted to NCI of Bethesda (USA) to evaluate their antiproliferative activity.  
Scheme 17 
 
Table 23 
 
 
 
 
 
Cpd R1 R2 R3 Yield 
32a H COOEt H 52 % 
32b SO2Ph H H 44 % 
32c H H H 64 % 
32d Me COOEt H 50 % 
32h 4-OMe-Bn COOEt H 59 % 
32j 3,5-(OMe)2-Bn COOEt H 38 % 
32k 3,4,5-(OMe)3-Bn COOEt H 92 % 
32u 2-Br-3,5-(OMe)2-Bn COOEt H 23% 
33b SO2Ph COOEt Acetyl 73 % 
33d Me COOEt Acetyl 51 % 
33h 4-OMe-Bn COOEt Acetyl 65 % 
33j 3,5-(OMe)2-Bn COOEt Acetyl 72 % 
33k 3,4,5-(OMe)3-Bn COOEt Acetyl 39 % 
33v 2-Br-3,5-(OMe)2-Bn COOEt Acetyl 49 % 
Table 23 List of Pyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine 32-33  
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7. PROJECT IN COLLABORATION WITH THE UNIVERSITY OF 
NOTTINGHAM 
7.1  Introduction 
During my PhD project, I spent 8 months (May-December 2012) at the  School of Chemistry of 
Nottingham for an international collaboration with Prof. Sir. C. J. Moody. In this period I worked 
on a project about the synthesis of two natural products belonging to the family of xanthones.  
Xanthones are a group of natural products which have been shown to provide various medically 
beneficial effects and that are all built around the central “xanthone” core. (Figure 27) 
Figure 27 
 
Xanthone-containing fruit (e.g. mangosteen) have long been known to possess medicinal properties, 
and have been used in traditional Chinese medicine for many years.  
The overall benefits of each xanthone derivate can vary; however there are certain properties which 
are common amongst all natural products possessing this xanthone core. For example, they display 
anti-inflammatory
[25]
, anti-bacterial
[26]
, and anti-oxidant
[27]
 properties. They are also shown to have 
anti-cancer potential
[28]
, and, in some cases show activity against chloroquine- resistant strain of 
malaria
[29]
.  
The anti-inflammatory properties of these molecules come from their ability to inhibit the platelet-
activating factor (PAF). PAF is a phospholipid activator, and mediator of many things such as 
platelet aggregation, degranulation, inflammation and anaphylaxis
[30,31]
. The PAF is produced by 
the body to attack and eliminate a foreign or unwanted entity in the system, however it can be 
produced at the wrong times (e.g. allergies and asthma), which can lead to severe health problems 
and potentially death. 
Alongside inhibition of PAF, there are also drugs which inhibit cyclooxygenase (COX) to treat 
inflammation. In the body, COX produces prostaglandins, which promote the production of a lining 
to the stomach which protects it from acid, but which also promote the aggregation of platelets and 
cause inflammation (cf. PAF). But while inhibition of COX, leads to well known side-effects (cf. 
NSAIDs Non-Steroidal Anti-Inflammatory drugs), using xanthones to inhibit PAF rather than COX, 
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could potentially lead to drugs which could provide relief from inflammation and pain with fewer 
side-effects
[25]
. Moreover compounds which inhibit the specific binding between PAF and receptors 
(found in a variety of cell membranes including those from platelets), have been extensively sought 
to be used as leads in the development of therapeutic agents in a variety of inflammatory, 
respiratory, immunological, and cardiovascular disorders.  
The anti-cancer properties of these molecules are due to the planar, aromatic nature of the xanthone 
ring system, which means that is possible for them to intercalate with deoxyribonucleic acid (DNA). 
This ability to bind DNA has been proven by numerous biological studies to be a key feature in 
anticancer medicine 
[32,33]
 as it is by binding to the DNA that anti-cancer drugs are able to inhibit the 
growth and cause death of the cancer cells. 
The synthesis of a new xanthone compounds might further develop drugs which excel in binding 
with DNA and might therefore become potent anticancer drugs. 
Xanthones have been shown to possess strong antibacterial properties, especially against 
methicillin-resistant Staphylococcus aureus (MRSA) and Bacillus subtilis. Indeed, rubraxanthone 
itself has been shown to be one of the most effective antibacterial and bactericidal molecules in the 
xanthone family
[34]
. Rubraxanthone is also active against Escherichia coli and Pseudomonas 
aureginosa where most of other xanthones are not. Furthermore, rubraxanthone has been shown to 
be an anti-oxidant, and therefore may possess yet more biologically beneficial use. 
It is also encouraging to note the similarities between rubraxanthone and α-mangostin (Figure 28) 
when discussing the potential significance and impact that rubraxanthone may have in the medicinal 
world.  
Figure 28 
 
                                      Rubraxantone                                α-mangostin 
For example, α-mangostin has been shown to have inhibithory effects against HIV[35] and 
Alzheimer’s disease [36]. It has also been shown to exhibit a protective effect on cardiac reperfusion 
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damage due to the way it can alleviate oxidative stress
[37]
. It has additionally been shown to work 
side-by-side with cisplatin and betulinic acid to provide cancer treatment without the common side-
effects produced in the absence of α-mangostin[38]. While the tests performed on rubraxanthone and 
α-mangostin have largely been different, and therefore the similarities are currently hypothetical, it 
is encouraging that there have been incidences when both compounds have been analysed 
together
[39]
. Indeed, where they have been both subjected to the same analytical tests, rubraxanthone 
has been shown to be of comparable, and sometimes even greater, strength than α-mangostin[40,41]. 
 
7.2  General synthesis of xanthones 
The very first synthesis of xanthones was obtained from the distillation of a mixture of a phenol, a 
phenolic acid, and acetic anhydride
[42]
 yet this route is now archaic in both its approach and yield 
(which was extremely poor). As time progressed, higher yielding routes for the synthesis of 
xanthones were developed, with better selectivity, yet often requiring the use of strong acids
[43]
, or 
toxic metal catalysts
[44]
, both of which could cause problems with the successful synthesis of 
rubraxanthone, not only because they could alter the double bonds in the key geranyl chain
[45]
, but 
also because they are toxic and therefore not ideal to use in the synthesis of a potential drug 
molecule. The first documented synthesis of α-mangostin is a prime example of the usage of 
dangerous chemicals and a long synthetic route to obtain the required xanthone
[46]
. In 2005, Larock 
suggested a synthesis of xanthones using mild reagents (Scheme 18) at a reasonable temperature 
which gave high yield and high selectivity, the most basic example of which is shown in the 
following scheme
[47]
. 
Scheme 18 
 
This method can produce either the desired xanthone, or a by-product in the form of a benzoate. To 
cause preferential production of the xanthone over the benzoate requires alteration of the reaction 
conditions and the reagents used. 
The first step of the Larock reaction is to produce an aryne by the attack of a fluoride anion on the 
TMS group, which produces a triple bond on the benzene ring by the tandem expulsion of the 
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highly reactive triflate leaving group (this method of creating an aryne was first described by 
Kobayashi in 1983)
[48]
. 
It was found that, in the simple model shown above, the source of this fluoride anion must be from 
CsF (rather than TBAF, for example), as CsF gives a far better ratio of the xanthone to benzoate 
(Scheme 19). It was also discovered that the usage of MeCN as a solvent gave a high yield (80%), 
but poor selectivity (40:60 benzoate : xanthone). As the route of the reaction is decided by the ease 
of proton abstraction (readily available protons result in the creation of the benzoate), a less polar 
solvent was theorized to solve this selectivity issue
[47]
. However, solvents which were much less 
polar resulted in very poor yield; thus it was found that a good compromise was to use THF, which, 
although a slightly less polar solvent, still gave high yields. 
Through experimentation, Larock found that the ideal temperature for this reaction was 65°C, as 
this increased the yield and speed of reactivity. Lower temperatures gave a much poorer yield 
(20%), with a high selectivity, while higher temperatures gave a good yield, but poor selectivity. 
When the reaction was performed at 65°C, a 75% yield was obtained with only a trace of by-
product. 
Scheme 19 
 
The Larock reaction proceeds via an aryne intermediate. These intermediates are incredibly useful 
when creating new C-C bonds, as an aryne can be attacked by a nucleophile on one side and attack 
an electrophile from the other, creating two new neighbouring bonds. 
When performing these reactions, it is important to consider the regioselectivity. For example, in 
our case, it is possible to get a regioisomer where the geranyl chain is at the bottom of the left hand 
ring rather than the top. The ultimate outcome is governed by the location of charge on the newly 
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created triple bond in the aryne. To be precise, the point at which the most negative charge resides 
on the triple bond will be where it attacks the ester group, and the other side, where the most 
positive charge lies, will be where the alcohol will attack (Figure 29).  
Figure 29 
 
There are two effects that may affect the regioselectivity of this reaction, the first of which being the 
steric hindrance of the benzyl group, and the second being the inductive electronic effects of the 
oxygen. However, it has been found that when directly in opposition to one another, (the steric 
control directs the substitution meta, while electronics dictate that the addition must be ortho), the 
electronics play a far more influential role than sterics, by stabilizing the aryl-caesium complex
[49]
. 
These findings have also been found by Stoltz in a paper discussing regioselecticity in arynes
[50]
. It 
was also found by Stoltz in the same paper, that in the aryne shown in Figure 29, the two effects 
work in tandem to one another, as both electronic and steric effects necessitate that the addition of a 
nucleophile (which is the first step due to highly electrophilic nature of the triple bond) must be 
meta to the benzyloxy group, as discussed below. The reaction proceeds extremely fast due to the 
low lying LUMO of the aryne orbital, which means that there is a smaller energy gap between the 
LUMO and the HOMO of an incoming nucleophile, thus resulting in a faster reactivity than most 
other systems
[51]
. 
When considering how the reaction proceeds and how the regioselectivity is governed, it is of 
utmost importance to understand that the orbitals of the triple bond in an aryne ring are orthogonal 
to those of the rest of the ring system, and as such are not influenced by the usual resonance forms 
seen in reactions on a benzene ring. As shown in Figure 30, any donation of electrons via resonance 
into the  system (such as the oxygen groups would do in Figure 29) will not be felt by the 
orthogonal orbitals of the triple bond. 
Figure 30 
 
Figure 30 An orbital map of an aryne, showing the plane in which the triple bond sits. 
δ- 
δ+ 
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The triple bond, however, is a very easily polarized system (a soft electrophile), which means that 
an electron withdrawing group ortho to the triple bond will polarize the bond effectively and result 
in the nucleophile attacking at meta position. This selectivity is seen because the attack of a 
nucleophile from that position will cause the temporary negative charge to reside close to the 
electron withdrawing group, which will stabilize the transition state. 
A benzyloxy group would usually be considered an electron donating group on a benzene ring, as 
resonance forms would stabilize nucleophilic attack at the ortho position, because the resultant 
negative charge would reside farthest from the electron donating group. However, as the triple bond 
in an aryne ring is orthogonal to the pi-system, this resonance ability does not affect the polarisation 
of the triple bond, which is governed instead exclusively by inductive effects. This means that as 
oxygen is an electronegative atom, the benzyloxy group acts to be electron withdrawing, and so 
polarises the triple bond in such a way that the initial nucleophilic attack occurs at the bottom of the 
triple bond (as shown in Figure 31), such that the negative charge resides ortho to the electron 
withdrawing site, thus stabilizing the transition state. From here, the resulting anion attacks the 
electrophilic ester (which is held in a favourable position). This reaction is highly favourable, 
because not only there is a residual negative charge from the previous reaction which will be fairly 
unstable until it reacts, the resonance forms of the benzyloxy groups are now accessible. Therefore, 
in the absence of protons (which can quench the intermediate and produce the benzoate by-
product), the reaction will cyclise to form the desired xanthone. 
Figure 31 
 
Figure 31. Illustration of how an electon withdrawing group governs the regioselectivity of a                                 
nucleophilic attack on an aryne. 
Our retrosynthetic analysis of rubraxanthone employed a Larock xanthone synthesis as a key step, 
leading to highly functionalised salycilate and silyl aryl triflate fragments A and B (Scheme 20). 
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Scheme 20 
 
These fragment could be synthetised from 2,5-dimethoxybenzaldehyde and phloroglucinol 
respectively (Scheme 21). 
Scheme 21 
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7.3  Synthesis of two fragments: 
8.3.1 Fragment A 
As regards the fragment A, the first approach followed was that shown in the scheme below 
(Scheme 22).  
The synthesis was started from 2,5-dimethoxybenzaldehyde 34 which underwent Dakin oxidation to 
give 2,5-dimethoxyphenol with good yield. This was then protected with Cs2CO3 and benzyl 
bromide, to give the product 36, which in turn was brominated in 4-position with NBS to give the 
product 37 in excellent yield. 
Scheme 22 
 
Unfortunately, however, all attempts to exchange with lithium in order to introduce the carboxy-
amide function, didn’t lead to the desired product 40. 
Therefore benzyl ether 36 was subjected to Vilsmeier-Haak formylation to give the corresponding 
aldehyde 38, which was immediately subjected to further oxidation with NaClO2 obtaining the 
corresponding acid 39 (Scheme 23). Treatment with SOCl2 at reflux, and then with HNEt2, finally 
gave the desired product 40. 
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Scheme 23 
 
So, the next step would be the introduction of the geranyl chain in the ortho position to the carboxy-
amide function, but unfortunately, this reaction failed to proceed under several conditions. 
Intrigued by this total lack of reactivity shown, it was attempted an exchange with D2O, in order to 
understand the reason for the failure of the reaction, but the resulting NMR clearly showed the 
absence of reactivity of the substrate with the sec-BuLi. 
Even attempts with tert-BuLi showed the same result.  
To clarify this issue, we have taken as a model 2,4,5-trimethoxybenzoic acid 42, and brought upon 
it the same attempts made previously on the benzyl derivative, but getting completely opposite 
results. 
Scheme 24 
 
In fact, trimethoxy derivative 43, obtained from 2,4,5-trimethoxybenzoic acid 42 under the same 
conditions as the corresponding benzyl-ether 40 (Scheme 24), not only reacted with sec-BuLi, 
exchanging with D2O in the desired position, but reacted with geranyl bromide giving the product 
44 and in high yield. 
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As the benzyl group appeared to be the cause of the problem, an alternative protecting group was 
sought. The triisopropylsilyl ethers 46 and isopropyl 48 were prepared (Scheme 25), and while with 
the second had the same problems as the benzyl-ether 40 (it does not exchange with D2O), with the 
TIPS-ether 46, we were able to introduce the geranyl chain in the desired position and in good 
yield. 
Scheme 25 
 
On the derivative 47 thus obtained, it was therefore decided to complete the fragment by selective 
demethylation of the methoxyl ortho to the carboxy-amide, and the conversion of the amide to its 
methyl ester. 
The attempt to demethylation was performed with six different methods in order to choose the one 
with the best yield, using respectively BCl3, AlCl3, MgBr2, MgI2, TMSCl/NaI as Lewis acids, and 
also with LiOH as nucleophile agent. While attempts with the last three reagents failed, the attempts 
with the first three Lewis acids gave demethylation, but unfortunately also altered the geranyl chain 
(Scheme 26), giving an inseparable mixture of isomers. 
It is likely that the double bond in position 2-3 of the geranyl chain undergoes a shift to position 1-2 
moving into conjugation.  
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Scheme 26 
 
In view of these results, the conversion to the methyl ester 51 was attempted, but again without 
success.  
Scheme 27 
 
In fact, from the reaction mixture, instead of isolating the desired methyl ester 51 (Scheme 27), we 
recovered the product TIPS deprotected 52, and subsequent methylation of the hydroxyl 44. 
View the impossibility to pursue this route with the TIPS protecting group, we decided to re-enter 
again the benzyl as in our initial synthetic analysis, especially since in the fragment B we had two 
additional benzyl groups to remove (Scheme 28). 
The product 47 was then deprotected with TBAF in THF in quantitative yield, and subsequently 
benzylated with Cs2CO3 as a base and benzyl bromide in acetonitrile (product 41). The new 
derivative obtained then was also subjected to demethylation with AlCl3, BCl3 and MgBr2 and with 
Me3OBF4 in an attempt to convert the amide to ester. 
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Scheme 28 
 
But unfortunately also in this case we did not get the desired results. In fact, while the attempt with 
trimethyloxonium tetrafluoroborate failed, all three attempts of demethylation lead to the isolation 
of the product 52 in which the benzyl group is removed, while the methoxy group is unchanged. 
A last, an attempt was made by reversing the synthetic sequence trying to do the demethylation 
even before entering the geranyl chain. 
The derivative 46 was then successfully demethylated in quantitative yield with BCl3 in DCM, and 
then used for the reaction in order to introduce the geranyl chain passing through the formation of a 
di-anion. But given the failure of this attempt, we tried to protect the now free hydroxyl group with 
TMSCl, and then insert the chain. All this was done in one step, since it was impossible to purify 
the intermediate via chromatography column, but also in this case the desired product was not 
obtained (Scheme 29). 
It was also tried the protection of the hydroxyl with the TES, and the TIPS but even in these cases 
the new derivative 56 was not recovered. When you protect the hydroxyl with the TIPS is possible 
to isolate the product via chromatography column, but also in this case the next step failed. 
Scheme 29 
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Considering the great difficulties to continue the synthesis without damage to the geranyl chain, we 
decided to change and plan an entirely new synthetic route that would start with totally different 
products, allowing us to form the xanthone core first, and only subsequently introduce the geranyl 
chain. 
Moreover this synthetic route would have allowed us to obtain also a second natural product with 
the same substituents in the same positions: toxyloxanthone B (Figure 32). 
Figure 32 
 
This new route started from 2,3-dihydroxybenzoic acid 57, that, was converted in near-quantitative 
yield to the corresponding methyl-ester 58, which in turn, undergoes selective benzylation of the 
hydroxyl in position 3, and subsequent Elbs’s oxidation[52], to give the corresponding diphenol 60 
(Scheme 30). The yield of this reaction is very low, only 15%, but the possibility to recover 65% of 
the starting material back with a simple filtration, combined with the simple reagents required, led 
us also to carry on this path. 
Scheme 30 
 
The newly introduced hydroxyl group, was then protected using chloromethyl methyl ether 
(MOMCl), thus giving the new fragment A 61, ready to be used in the reaction with the second 
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fragment (B), to obtain the xanthone 63 according to the method described by Larock and fully 
described in the introduction. 
 
8.3.2 Fragment B 
The isolation of the fragment B was found to be much easier than to fragment A, as its synthesis 
was found to be known in the literature. 
The synthetic route devised by Stoltz
[50]
, started from  phloroglucinol 64 (1,3,5-trihydroxybenzene), 
which was mono-protected using TIPSCl and imidazole, thus obtaining the silyl ether 65 in good 
yields. This reaction proceeds by using an excess of phloroglucinol 64 (3 equivalents) in DMF at 
low concentration. The use of less solvent, stoichiometric amount of base and protecting agent, 
would lead to obtain a mixture of mono, bis and tris substituted products, as the desired mono-
protected product turns out to be more active towards the second protection compared to the starting 
material itself (Scheme 31). The derivative 65 thus obtained, was then benzylated on the two 
remaining free hydroxyls, and without further purification, TIPS-deprotected. A bromination with 
NBS in DCM at -78 ° C, allowed us to obtain in good yield the derivative 67, which has been 
subjected to the final step to obtain the silyl-aryl triflate 62. 
Scheme 31 
 
This final reaction proceeds in two steps, first with HMDS in THF at reflux, obtaining an 
intermediate in which the TMS group protects the free phenolic oxygen, and then, immediately 
after, with nBuLi and triflic anhydride at -100°C. 
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The initial addition of nBuLi causes a retro-Brook reaction in which the TMS is transferred from 
oxygen to the ortho position on the benzene ring. This is due to the fact that, the exchange caused 
on that position, from nBuLi with bromine, creates a situation in which the TMS, can re-arrange in 
the adjacent position, leaving the negative charge on the oxygen, so that it can form the strong link 
with the counter-ion litium. 
The subsequent addition of triflic anhydride, forms the desired silyl-aryl triflate 62, in turn ready to 
be reacted with the previous fragment (A), to obtain the xanthone 63 according to the method 
described by Larock and fully described in the introduction. 
 
8.4 Towards the synthesis of Rubraxantone and of Toxyloxantone B 
Having obtained two fragments 61 and 62, so next step should be try to fuse them together as 
described by Larock. But contrary to our expectations, the ratio between the two possible products 
(the desired xanthone and the open intermediate 68), was found to be in favour the undesidered 
product, in disagreement as to what described by Larock (1 to 1 against the 9 to 1 by Larock 
reported) (Scheme 32). 
Intrigued by that ratio obtained, contrary to what described Larock, since the only available source 
of protons is from the reaction of the intermediate with a second molecule of phenol (see Scheme 
16), we decided to try to make the fragment A first react with one equivalent of NaH, before adding 
the CsF and fragment B. Proceeding in this way, the total yield of the reaction was always the same 
(70%), but it was possible to improve the ratio between the two products obtained, thus passing 
from a 1 to 1, to a 3 to 2. 
Scheme 32 
 
Furthermore the isolated product 68, was collected, and reacted in two steps, first with LiOH in 
methanol, to give the corresponding acid, and then with trifluoroacetic anhydride to give xanthone 
63 (scheme 33).  
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Scheme 33 
 
Having obtained the key product 63, the next step was to remove the MOM, with trifluoroacetic 
acid in dichloromethane as solvent, giving the product 69 with the free hydroxyl with excellent 
yield (Scheme 34). 
Scheme 34 
 
In the case of toxyloxanthone B, derivative 69, underwent an alkylation on the phenol, with 3-
chloro-3-methyl-1-butyne, to give the product 70 in good yield, followed by a Claisen 
rearrangement to afford the product of intramolecular cyclization 71 in only toluene to reflux, and 
finally, a selective debenzylation gave the desired xanthone 72 (Scheme 35). 
This final step, the same for both natural products, required more attention, as the conditions to 
remove the benzyl must not alter the double bonds in the geranyl chain. This means that the 
common methods used to remove the benzyl such as the use of Lewis acids or H2-Pd / C, were not 
convenient. However, in the literature there are several examples in which this reaction is 
performed in the presence of double bonds susceptible to secondary reactions. Initial attemps used 
ammonium formate as a hydrogen donor
[53]
, but while working at room temperature the reaction 
didn’t proceed, when we heated the reaction mixture, the starting material was decomposed. A last 
attempt was made by using BCl3 and pentamethylbenzene
[54]
, giving the desiderated and final 
product in good yield. 
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Scheme 35 
 
In the case of rubraxantone, the derivative 69 should undergo a Friedel Crafts alkylation, with the 
intent to enter the geranyl in the ortho position to the one free hydroxyl. This reaction was tried 
with different methods reported in literature
[55-58]
, but none of them gave the desired product. In 
reactions with gerianiol and different Lewis acids, not strong enough to remove the benzyl groups, 
such as boron trifluoride-diethyl etherate, Scandium triflate and Zinc chloride, and also Aluminum 
chloride, gave only starting material back. Another attempt was made by using potassium carbonate 
as base and geranyl bromide, in an attempt to exploit the present conjugation and obtain the C-
alkylation
[56]
, but in our case the product obtained, was the product of O-alkylation. Other attempts 
should be tried, but unfortunately could not be carried out due to time constraints. 
 
8.5 Conclusion and future work 
The synthesis of toxyloxanthone B was completed, while few steps remain before the synthesis of 
rubraxanthone will be completed. In this case, once the geranyl chain is introduced, all that remains 
is the methylation of phenol, and finally the removal of the three benzyl groups (Scheme 32). This 
step will require close attention as the conditions required to remove the benzyl groups, must not 
alter the double bonds in the geranyl chain.  
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9. EXPERIMENTAL 
All melting points were taken on a Buchi-Tottoli capillary apparatus and were uncorrected. IR 
spectra were determined with a Shimadzu IR Affinity-1 spectrophotometer. 
1
H and 
13
C NMR 
spectra were measured in DMSO-d6 or CDCl3 solutions, unless otherwise specified, at 200 and 50.3 
MHz respectively, using a Bruker AC series 200 MHz spectrometer (TMS as internal reference). 
Column chromatography was performed with Merck silica gel 230-400 Mesh ASTM or with a 
SEPACORE BÜCHI chromatography apparatus or with BIOTAGE 40i chromatography apparatus. 
Microwave experiments were carried out using a CEM Discover Labmate
TM
. 
9.1.1 Preparation of ethyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-
carboxylate (9a) 
Preparation of 2,2,2-Trichloro-1-(1H-pyrrol-2-yl)ethanone (5). 
To 8 mL of diethyl ether, 5.5 mL of trichloroacetyl chloride (49.2 mmol) were added, and the 
solution was stirred at room temperature for 3 hours. A solution of pyrrole (3 g, 44.7 mmol) in 
diethyl ether (25 mL) was added and the mixture was stirred for another hour. Very slowly the 
reaction mixture was neutralized with a solution of K2CO3 (3.9 g in 11.7 mL of H2O). The two 
phases were separated and the organic fraction was filtered on celite. The phase was recovered, 
dried on Na2SO4 and concentrated under reduced pressure. Quantitative yield. The spectroscopic 
data are in agreement with the literature.
[12]
 
Preparation of Ethyl 1H-pyrrole-2-carboxylate (6). 
To a solution of potassium ethylate (4 g, 49.2 mmol) in ethanol (120 mL), a solution of 5 (9.5 g, 
44.7 mmol) in dichloromethane (75 mL) was added. After 30 minutes at room temperature, the 
reaction mixture was evaporated. The residue was dissolved with HCl 2 N (45 mL) and diethyl 
ether (105 mL). The two phases were separated and the acqueos fraction was extracted with diethyl 
ether (2 x 80 mL). The organic phase was washed with a satured solution of Na2CO3 (100 mL). The 
organic fraction was dried on Na2SO4 and concentrated under reduced pressure to give the crude 
product that was purified by flash column chromatography (dichloromethane). Yield 95%. The 
spectroscopic data are in agreement with the literature.
 [12]
 
Preparation of 5-[5-(Ethoxycarbonyl)-1H-pyrrol-3-yl]-5-oxopentanoic acid (7).  
A suspension of AlCl3 (12 g, 90 mmol) and glutaric anhydride (3.40 g, 30 mmol) in dry 
dichloromethane, (60 mL) was stirred at room temperature for one hour. A solution of 6 (2.1 g, 15  
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mmol) in dry dichloromethane (30 mL), was added and the reaction mixture was stirred for another 
hour and 30 minutes. Ice and water were added (80 mL), and the two phases were separated. The 
acqueous fraction was extracted with ethyl acetate (3 x 60 mL). The organic phases were collected, 
dried on Na2SO4, and concentrated under reduced pressure to give the crude product that was 
purified by flash column chromatography (dichloromethane : ethyl acetate 1:1). Yield: 91%, light 
brown solid; mp: 81.4 – 82.3 oC; IR: 3337 (OH broad), 1702 (CO), 1696 (CO), 1653 (CO) cm-1; 1H 
NMR (DMSO-d6) (ppm): 1.29 (3H, t, J = 6.7 Hz, CH3), 1.70 – 1.86 (2H, m, CH2), 2.27 (2H, t, J = 
6.2 Hz, CH2), 2.80 (2H, t, J = 6.2 Hz, CH2), 4.26 (2H, q, J = 6.7 Hz, CH2), 7.13 (1H, s, H-4), 7.72 
(1H, s, H-2), 12.07 (1H, s, OH), 12.51 (1H, s, NH); 
13
C NMR (DMSO-d6) (ppm): 14.2 (q), 19.6 (t), 
32.9 (t), 37.9 (t), 60.1 (t), 114.0 (d), 123.6 (s), 125.8 (s), 127.8 (d), 160.1 (s), 174.2 (s), 194.6 (s). 
Preparation of 5-[5-(ethoxycarbonyl)-1H-pyrrol-3-yl]pentanoic acid (8).  
To a solution of 7 (1.5 g, 6 mmol) in trifluoracetic acid (13 mL), triethylsilane (3.3 mL, 21 mmol) 
was added and the reaction mixture was stirred at room temperature for one night (16 h). The 
solvent was evaporated and brine (40 mL) was added to the residue. The solid formed was filtered 
and purified by flash column chromatography (dichloromethane : ethyl acetate 1:1). Yield: 80%, 
brown solid; mp: 84.6 – 85.4 oC; IR: 3355 (OH broad), 1700 (CO), 1653 (CO) cm-1;  1H NMR 
(DMSO-d6) (ppm): 1.26 (3H, t, J = 7.1 Hz, CH3), 1.41 – 1.62 (4H, m, CH2 x 2), 2.21 (2H, t, J = 6.4 
Hz, CH2), 2.39 (2H, t, J = 6.4 Hz, CH2), 4.20 (2H, q, J = 7.1 Hz, CH2), 6.60 (1H, s, H-4), 6.79 (1H, 
s, H-2), 11.55 (1H, s, OH), 11.99 (1H, s, NH); 
13
C NMR (DMSO-d6) (ppm): 14.4 (q), 24.1 (t), 25.7 
(t), 29.9 (t), 33.5 (t), 59,3 (t), 114.5 (d), 121.5 (s), 121.7 (d), 124.5 (s), 160.4 (s), 174.5 (s). 
Preparation of Ethyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate (9a).  
Trifluoroacetic anhydride (3.5 mL, 25.2 mmol) was added to a solution of 8 (1 g, 4.2 mmol), in dry 
dichloromethane (10 mL), and the reaction mixture was stirred for three hours at room temperature. 
The solvent was evaporated and a satured solution of  NaHCO3 (40 mL) was added to the residue. 
The solid formed, was filtered and purified by flash column chromatography (dichloromethane). 
Yield: 70%, white solid; mp: 76.7 – 76.9 oC; IR: 3415 (NH), 1709 (CO), 1633 (CO) cm-1; 1H NMR 
(DMSO-d6) (ppm): 1.28 (3H, t, J = 6.9 Hz, CH3), 1.60 – 1.97 (4H, m, CH2 x 2), 2.63 (2H, t, J = 6.6 
Hz, CH2), 2.79 (2H, t, J = 6.6 Hz, CH2), 4.24 (2H, q, J = 6.9 Hz, CH2), 6.67 (1H, s, H-3), 11.91 
(1H, s, NH); 
13
C NMR (DMSO-d6) (ppm): 14.1 (q), 21.5 (t), 25.4 (t), 26.0 (t), 41.2 (t), 60.2 (t), 
115.7 (d), 125.9 (s), 131.9 (s), 132.7 (s), 160.0 (s), 192.1 (s). 
 
 
80 
 
9.1.2 Preparation of 4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9c) 
Preparation of 1-(Phenylsulfonyl)-1H-pyrrole (10). 
To a solution of pyrrole (2.72 mL, 40 mmol) in dry THF (28 mL), under N2 atmosphere at -78 
o
C, 
24 mL of LDA (2M in THF/heptanes/ethylbenzene, 48 mmol) were added and the mixture was 
heated until room temperature and stirred for 2 hours. The reaction mixture was then cooled again 
at -78 
o
C, and a solution of phenylsulfonil chloride (5.6 mL, 48 mmol) in dry THF (25 mL) was 
added. After 2 hours and half, the reaction was heated to room temperature, and 5 mL of water were 
added. The reaction mixture was distilled in vacuo and the residue was washed with a solution of 
NH4Cl (20 g) in HCl 0.1 M (140 mL). The solution was extracted with dichloromethane (3 x 100 
mL) and the organic phase was dried on Na2SO4 and evaporated. The residue was purified by flash 
column chromatography (dichloromethane). Quantitative yield. The spectroscopic data are in 
agreement with the structure of the commercial product. 
Preparation of 5-oxo-5-[1-(Phenylsulfonyl)-1H-pyrrol-3-yl]pentanoic acid (11)  
A suspension of AlCl3 (8 g, 60 mmol) and glutaric anhydride (2.3 g, 20 mmol) in dry 
dichloromethane, (40 mL) was stirred at room temperature for one hour. A solution of 10 (2 g, 10 
mmol) in dry dichloromethane (20 mL), was added and the reaction mixture was stirred for another 
hour and 30 minutes. Ice and water were added (80 mL), and the two phases were separated. The 
acqueous fraction was extracted with dichloromethane (3 x 40 mL). The organic phases were 
collected, and dried on Na2SO4, and concentrated under reduced pressure to give the crude product 
that was purified by flash column chromatography (dichloromethane : ethyl acetate 6:4). Yield: 
80%, light brown solid; mp: 111.6 – 111.8 oC; IR: 3550 (OH), 1706 (CO), 1675 (CO) cm-1;  1H 
NMR (DMSO-d6) (ppm): 1.72 – 1.83 (2H, m, CH2), 2.26 (2H, t, J = 7.3 Hz, CH2), 2.85 (2H, t, J = 
7.3 Hz, CH2), 6.67 (1H, dd, J = 3.3, 1.8 Hz, H-4), 7.45 (1H, dd, J = 3.3, 1.8 Hz, H-5), 7.64 – 7.86 
(3H, m, H-3’, H-4’and H-5’), 8.06 – 8.13 (2H, m, H-2’and H-6’), 8.21 (1H, s, H-2), 12.07 (1H, s, 
OH); 
13
C NMR (DMSO-d6) (ppm): 19.2 (t), 32.8 (t), 38.0 (t), 112.0 (d), 122.2 (d), 125.4 (d), 127.2 
(d x 2), 128.6 (s), 130.1 (d x 2), 135.1 (d), 137.3 (s), 174.1 (s), 194.7 (s). 
Preparation of 5-[1-(Phenylsulfonyl)-1H-pyrrol-3- yl]pentanoic acid (12). 
An amalgam of zinc (8.5 g, 130 mmol) and mercury(II) chloride (2.96 g, 10.9 mmol) in water (12 
mL) and HCl 12 M (0.7 mL) was prepared; after 30 minutes the acqueous phase was eliminated and 
11 (3.5 g, 10.9 mmol), water (5 mL), toluene (50 mL) and HCl 12 M (12.5 mL) were added. The 
reaction mixture was heated to reflux for 4 hours, and the two phases were separated. The acqueous 
phase was extracted with dichloromethane (3 x 30 mL) and the organic fractions were collected, 
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dried on Na2SO4 and evaporated. The residue was purified by flash column chromatography 
(dichloromethane : ethyl acetate 9:1). Yield: 75%, white solid; mp: 84.0 – 84.2 oC; IR: 3548 (OH), 
1701 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.46 (4H, t, J = 7.2 Hz, CH2 x 2), 2.19 (2H, t, J = 7.2 
Hz, CH2), 2.34 (2H, t, J = 7.2 Hz, CH2), 6.24 (1H, dd, J = 2.9, 1.5 Hz, H-4), 7.10 (1H, s, H-2), 7.24 
(1H, dd, J = 2.9, 1.5 Hz, H-5), 7.57 – 7.79 (3H, m, H-3’, H-4’ and H-5’), 7.89 – 7.95 (2H, m, H-
2’and H-6’), 11.99 (1H, s, OH); 13C NMR (DMSO-d6) (ppm): 24.0 (t), 25.7 (t), 28.8 (t), 33.3 (t), 
115.1 (d), 117.5 (d), 121.2 (d), 126.5 (d x 2), 129.3 (s), 129.7 (d x 2), 134.3 (d), 138.3 (s), 174.4 (s). 
Preparation of 1-(Phenylsulfonyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9b). 
Trifluoroacetic anhydride (5.4 mL, 39 mmol) was added to a solution of 12 (2 g, 6.5 mmol), in dry 
dichloromethane (20 mL), and the reaction mixture was stirred for three hours at room temperature. 
The solvent was evaporated and a satured solution of  NaHCO3 (40 mL) was added to residue. The 
solid formed, was filtered and purified by flash column chromatography (dichloromethane). Yield: 
75%, white solid; mp: 99.3 – 99.6 oC; IR: 1659 (CO) cm-1;  1H NMR (DMSO-d6) (ppm): 1.63 – 
1.78 (4H, m, CH2 x 2), 2.53 (2H, t, J = 5.9 Hz, CH2), 2.77 (2H, t, J = 5.9 Hz, CH2), 6.39 (1H, d, J = 
3.2 Hz, H-3), 7.59 – 7.76 (3H, m, H-3’, H-4’ and H-5’), 7.81 (1H, d, J = 3.2 Hz, H-2), 7.96 (2H, dd, 
J = 8.2, 1.6 Hz, H-2’ and H-6’); 13C NMR (DMSO-d6) (ppm): 21.0 (t), 24.4 (t), 25.8 (t), 40.9 (t), 
113.3 (d), 127.5 (d x 2), 129.0 (d x 2), 129.1 (d), 131.0 (s), 133.8 (d), 139.0 (s), 139.6 (s), 190.2 (s). 
Preparation of 4,5,6,7-Tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9c). 
A solution of NaOH (1.66 g, 41.52 mmol) in ethanol (15 mL) was added to a suspension of 9b (3 g, 
10.4 mmol) in ethanol (15 mL), and the resulting mixture was heated to reflux for 3 hours. The 
reaction mixture was concentrated under reduce pressure and the residue poured into ice and water 
(20 mL) and acidified with HCl 6 M. The solution was extracted with dichloromethane (3 x 30 mL) 
and the organic phases was collected, dried on Na2SO4 and evaporated. The residue was purified by 
flash column chromatography (dichloromethane) Yield: 80%, white solid, mp: 55.1 – 55.3 oC; IR: 
3438 (NH), 1617 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.69 – 1.90 (4H, m, CH2 x 2), 2.56 (2H, 
t, J = 6.2 Hz, CH2), 2.79 (2H, t, J = 6.2 Hz, CH2), 6.01 (1H, d, J = 2.8 Hz, H-3), 6.95 (1H, d, J = 2.8 
Hz, H-2), 11.38 (1H, s, NH); 
13
C NMR (DMSO-d6) (ppm): 22.3 (t), 26.0 (t), 27.1 (t), 41.4 (t), 110.6 
(d), 124.5 (d), 129.3 (s), 132.1 (s), 190.5 (s). 
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9.2 Functionalization of Ethyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-
2-carboxylate (9a) and of  
4,5,6,7-Tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9c) 
To a solution of the appropriate ketone ethyl 8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-
carboxylate (9a) or 4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9c) (9 mmol) in dry DMF (17 
mL), NaH (10 mmol) was added at 0 °C and the reaction was stirred for one hour and half at room 
temperature. The appropriate alkyl or alkylaryl halide (13.5 mmol) was added at  0 °C, and the 
reaction mixture was stirred at room temperature or at higher temperature (max 80 °C) up to 
completeness. Then the reaction was poured into ice and brine, and in the case of formation of a 
precipitate, the solid was filtered. In the absence of precipitate, the aqueous solution was extracted 
with dichloromethane (3 x 50 mL). The organic phase was dried over Na2SO4 and the solvent 
evaporated at reduced pressure. The crude product was purified by chromatography column 
(dichloromethane). 
Ethyl 1-methyl-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate (9d). This 
compound was obtained from reaction of 9a with iodomethane in DMF in 2 hours at room 
temperature. Yield: 94%, white solid; mp: 51.3 – 51.5 °C; IR: 1705 (CO), 1642 (CO) cm-1; 1H 
NMR (DMSO-d6) (ppm): 1.28 (3H, t, J = 7.1 Hz, CH3), 1.68 – 1.77 (4H, m, CH2 x 2), 2.64 (2H, t, J 
= 6.6 Hz, CH2), 2.75 (2H, t, J = 6.6 Hz, CH2), 4.06 (3H, s, CH3), 4.25 (2H, q, J = 7.1 Hz, CH2), 6.74 
(1H, s, H-3);
 13
C NMR (DMSO-d6) (ppm): 14.1 (q), 20.8 (t), 24.4 (t), 24.8 (t), 34.3 (q), 41.4 (t), 
60.2 (t), 116.6 (d), 126.3 (s), 132.8 (s), 133.5 (s), 160.3 (s), 194.1 (s). 
Ethyl 1-benzyl-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate (9e). This 
compound was obtained from reaction of 9a with benzyl bromide in DMF in 2 hours at room 
temperature. Yield: 96%, white solid; mp: 46.6 – 47.4 °C; IR: 1710 (CO), 1645 (CO) cm-1; 1H 
NMR (DMSO-d6) (ppm): 1.21 (3H, t, J = 7.1 Hz, CH3), 1.60 – 1.80 (4H, m, CH2 x 2), 2.60 (2H, t, J 
= 6.6 Hz, CH2), 2.81 (2H, t, J = 6.6 Hz, CH2), 4.18 (2H, q, J = 7.1 Hz, CH2), 6.01 (2H, s, CH2), 6.84 
(1H, s, H-3), 6.88 (2H, s, H-2’ and H-6’), 7.11 – 7.32 (3H, m, H-3’, H-4’ and H-5’); 13C NMR 
(DMSO-d6) (ppm): 14.0 (q), 20.7 (t), 24.3 (t), 24.7 (t), 41.4 (t), 48.4 (t), 60.3 (t), 117.7 (d), 125.6 (d 
x 2), 126.1 (s), 126.6 (d), 128.3 (d x 2), 133.0 (s), 133.8 (s), 139.2 (s), 160.1 (s), 194.2 (s). 
Ethyl 1-(2-methoxybenzyl)-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2carboxylate 
(9f). This compound was obtained from reaction of 9a with 2-methoxybenzylchloride in DMF in a 
night (16 hours) at room temperature. Yield: 78%, white solid; mp: 121.0 – 121.2 °C; IR: 1709 
(CO), 1645 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.18 (3H, t, J = 7.1 Hz, CH3), 1.64 – 1.81 (4H, 
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m, CH2 x 2), 2.57 (2H, t, J = 5.7 Hz, CH2), 2.80 (2H, t, J = 5.7 Hz, CH2), 3.83 (3H, s, CH3), 4.14 
(2H, q, J = 7.1 Hz, CH2), 5.92 (2H, s, CH2), 6.01 (1H, d, J = 7.4 Hz, H-3’), 6.75 (1H, t, J = 7.4 Hz, 
H-5’), 6.88 (1H, s, H-3), 6.96 (1H, d, J = 7.4 Hz, H-6’), 7.16 (1H, t, J = 7.4 Hz, H-4’); 13C NMR 
(DMSO-d6) (ppm): 13.9 (q), 20.7 (t), 24.3 (t), 24.8 (t), 41.3 (t), 44.8 (t), 55.2 (q), 60.2 (t), 110.1 (d), 
117.5 (d), 120.3 (d), 124.2 (d), 126.5 (s), 127.5 (d), 127.7 (s), 133.4 (s), 133.5 (s), 155.7 (s), 159.9 
(s), 194.0 (s). 
Ethyl 1-(3-methoxybenzyl)-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2carboxylate 
(9g). This compound was obtained from reaction of 9a with 3-methoxybenzylchloride in DMF in 8 
hours at room temperature. Yield: 81%, white solid; mp: 65.5 – 65.8 °C; IR: 1709 (CO), 1646 (CO) 
cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.22 (3H, t, J = 7.1 Hz, CH3), 1.65 - 1.80 (4H, m, CH2 x 2), 2.60 
(2H, t, J = 5.6 Hz, CH2), 2.81 (2H, t, J = 5.6 Hz, CH2), 3.67 (3H, s, CH3), 4.19 (2H, q, J = 7.1 Hz, 
CH2), 5.98 (2H, s, CH2), 6.38 – 6.41 (2H, m, H-2’ and H-6’), 6.76 (1H, dd, J = 8.1, 2.3 Hz, H-4’), 
6.87 (1H, s, H-3), 7.17 (1H, t, J = 8.1 Hz, H-5’); 13C NMR (DMSO-d6) (ppm): 14.0 (q), 20.7 (t), 
24.3 (t), 24.7 (t), 41,4 (t), 48.2 (t), 54.8 (q), 60.4 (t), 111.5 (d), 111.6 (d), 117.6 (d), 117.7 (d), 126.2 
(s), 129.4 (d), 133.0 (s), 133.8 (s), 140.9 (s), 159.2 (s), 160.1 (s), 194.2 (s). 
Ethyl 1-(4-methoxybenzyl)-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate 
(9h). This compound was obtained from reaction of 9a with 4-methoxybenzylchloride in DMF in 6 
hours at room temperature. Yield: 79%, white solid; mp: 73.2 – 73.6 °C; IR: 1709 (CO), 1645 (CO) 
cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.23 (3H, t, J = 7.1 Hz, CH3), 1.63 – 1.79 (4H, m, CH2 x 2), 2.60 
(2H, t, J = 5.6 Hz, CH2), 2.79 (2H, t, J = 5.6 Hz, CH2), 3.69 (3H, s, CH3), 4.20 (2H, q, J = 7.1 Hz, 
CH2), 5.93 (2H, s, CH2), 6.78 – 6.81 (4H, m, Ar), 6.83 (1H, s, H-3); 
13
C NMR (DMSO-d6) (ppm): 
14.0 (q), 20.7 (t), 24.2 (t), 24.7 (t), 41.4 (t), 47.6 (t), 54.9 (q), 60.4 (t), 113.6 (d x 2), 117.7 (d), 126.1 
(s), 127.2 (d x 2), 131.0 (s), 132.9 (s), 133.9 (s), 158.0 (s), 160.2 (s), 194.4 (s). 
Ethyl 1-(2,5-dimethoxybenzyl)-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate 
(9i). This compound was obtained from reaction of 9a with 2,5-dimethoxybenzylchloride in DMF 
in a night (16 hours) at room temperature. Yield: 81%, white solid; mp: 92.8 – 93.4 °C; IR: 1711 
(CO), 1647 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.20 (3H, t, J = 7.1 Hz, CH3), 1.65 – 1.81 (4H, 
m, CH2 x 2), 2.59 (2H, t, J = 5.6 Hz, CH2), 2.84 (2H, t, J = 5.6 Hz, CH2), 3.54 (3H, s, CH3), 3.78 
(3H, s, CH3), 4.16 (2H, q, J = 7.1 Hz, CH2), 5.53 (1H, d, J = 2.9 Hz, H-6’), 5.90 (2H, s, CH2), 6.72 
(1H, dd, J = 8.8, 2.9 Hz, H-4’), 6.89 (1H, d, J = 8.8 Hz, H-3’), 6.90 (1H, s, H-3); 13C NMR 
(DMSO-d6) (ppm): 13.9 (q), 20.7 (t), 24.4 (t), 24.7 (t), 41.3 (t), 44.8 (t), 55.0 (q), 55.6 (q), 60.3 (t), 
110.3 (d), 110.8 (d), 111.6 (d), 117.5 (d), 126.5 (s), 129.1 (s), 133.3 (s), 133.6 (s), 149.9 (s), 153.1 
(s), 159.9 (s), 194.0 (s).  
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Ethyl 1-(3,5-dimethoxybenzyl)-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-carboxylate 
(9j). This compound was obtained from reaction of 9a with 3,5-dimethoxybenzylchloride in DMF 
in a night (16 hours) at room temperature. Yield: 83%, white solid; mp: 71.8 – 72.0 °C; IR: 1707 
(CO), 1647 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.22 (3H, t, J = 7.1 Hz, CH3), 1.72 (4H, m, 
CH2 x 2), 2.61 (2H, t, J = 6.9 Hz, CH2), 2.82 (2H, t, J = 6.9 Hz, CH2), 3.65 (6H, s, CH3 x 2), 4.19 
(2H, q, J = 7.1 Hz, CH2), 5.94 (4H, s, CH2, H-2’ and H-6’), 6.32 (1H, s, H-4’), 6.88 (1H, s, H-3); 
13
C NMR (DMSO-d6) (ppm): 14.1 (q), 20.8 (t), 24.4 (t), 24.8 (t), 41.4 (t), 48.2 (t), 55.0 (q x 2), 60.4 
(t), 97.8 (d), 103.7 (d x 2), 117.8 (d), 126.3 (s), 133.1 (s), 133.9 (s), 141.9 (s), 160.1 (CO), 160.5 (s 
x 2), 194.3 (s). 
Ethyl 1-(3,4,5-trimethoxybenzyl)-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-
carboxylate (9k). This compound was obtained from reaction of 9a with 3,4,5-
trimethoxybenzylchloride in DMF in 5 hours at 80 °C. Yield: 80%, white solid; mp: 70 – 70.2 °C; 
IR: 1709 (CO), 1646 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.24 (3H, t, J = 7.1 Hz, CH3), 1.66 – 
1.80 (4H, m, CH2 x 2), 2.64 (2H, t, J = 5.6 Hz, CH2), 2.82 (2H, t, J = 5.6 Hz, CH2), 3.60 (3H, s, 
CH3), 3.64 (6H, s, CH3 x 2), 4.22 (2H, q, J = 7.1 Hz, CH2), 5.97 (2H, s, CH2), 6.16 (2H, s, H-2’ and 
H-6’), 6.88 (1H, s, H-3); 13C NMR (DMSO-d6) (ppm): 14.0 (q), 20.8 (t), 24.3 (t), 24.7 (t), 41.4 (t), 
48.1 (t), 55.6 (q x 2), 59.9 (q), 60.4 (t), 102.9 (d x 2), 117.8 (d), 126.3 (s), 133.1 (s), 133.9 (s), 135.0 
(s), 136.2 (s), 152.8 (s x 2), 160.2 (s), 194.4 (s).  
1-Methyl-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9l). This compound was obtained 
from reaction of 9c with iodomethane in DMF in 2 hours at room temperature. Yield: 88%, 
colourless oil; IR: 1639 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.69 – 1.75 (4H, m, CH2 x 2), 2.55 
(2H, J = 6.2 Hz, CH2), 2.74 (2H, t, J = 6.2 Hz, CH2), 3.79 (3H, s, CH3), 5.96 (1H, d, J = 2.4 Hz, H-
3), 6.98 (1H, d, J = 2.4 Hz, H-2); 
13
C NMR (DMSO-d6) (ppm): 21.0 (t), 24.6 (t), 25.7 (t), 36.9 (q), 
41.0 (t), 108.7 (d), 128.5 (s), 129.9 (d), 135.3 (s), 191.6 (s). 
1-Benzyl-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9m). This compound was obtained 
from reaction of 9c with benzyl bromide in DMF in 4 hours at room temperature. Yield: 92 %, 
beige solid; mp: 54.2 – 54.4 °C; IR: 1623 (CO) cm-1; 1H NMR (DMSO-d6) (ppm): 1.65 – 1.73 (4H, 
m, CH2 x 2), 2.50 (2H, t, J = 6.2 Hz, CH2), 2.77 (2H, t, J = 6.2 Hz, CH2), 5.51 (2H, s, CH2), 6.07 
(1H, d, J = 2.4 Hz, H-3), 7.04 (2H, d, J = 6.9 Hz, H-2’and H-6’), 7.19 (1H, d, J = 2.4 Hz, H-2), 7.24 
– 7.29 (3H, m, H-3’, H-4’ and H-5’); 13C NMR (DMSO-d6) (ppm): 20.9 (t), 24.4 (t), 25.5 (t), 40.9 
(t), 51.1 (t), 109.6 (d), 126.53 (d x 2), 126.9 (d), 127.9 (s), 128.3 (d x 2), 129.7 (d), 136.1 (s), 139.3 
(s), 191.6 (s). 
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1-(2-Methoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9n). This compound 
was obtained from reaction of 9c with 2-methoxybenzylchloride in DMF in a night (16hours) at 
room temperature. Yield: 93 %, grey solid; mp: 64.5 – 64.9 °C; IR: 1628 (CO) cm-1; 1H NMR 
(CDCl3) (ppm): 1.79 – 1.85 (4H, m, CH2 x 2), 2.61 (2H, t, J = 6.2 Hz, CH2), 2.82 (2H, t, J = 6.2 Hz, 
CH2), 3.85 (3H, s, CH3), 5.55 (2H, s, CH2), 5.99 (1H, d, J = 2.5 Hz, H-3), 6.76 – 6.88 (4H, m, H-3’, 
H-4’, H-5’ and H-6’), 7.17 (1H, d, J = 2.5 Hz, H-2); 13C NMR (CDCl3) (ppm): 21.5 (t), 24.9 (t), 
26.4 (t), 41.6 (t), 47.4 (t), 55.3 (q), 109.4 (d), 110.0 (d), 120.6 (d), 127.2 (s), 128.1 (d), 128.4 (d), 
128.9 (s), 129.4 (d), 136.4 (s), 156.7 (s), 192.8 (s). 
1-(3-Methoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9o). This compound 
was obtained from reaction of 9c with 3-methoxybenzylchloride in DMF in 4 hours at room 
temperature. Yield: 84 %, white solid; mp: 53.1 – 53.4 °C; IR: 1629 (CO) cm-1; 1H NMR (DMSO-
d6) (ppm): 1.69 – 1.72 (4H, m, CH2 x 2), 2.50 (2H, t, J = 5.9 Hz, CH2), 2.77 (2H, t, J = 5.9 Hz, 
CH2), 3.69 (3H, s, CH3), 5.48 (2H, s, CH2),  6.07 (1H, d, J = 2.4 Hz, H-3), 6.58 – 6.62 (2H, m, H-2’ 
and H-6’), 6.79 (1H, dd, J = 7.9, 2.3 Hz, H-4’), 7.16 – 7.24 (2H, m, H-2 and H-5’); 13C NMR 
(DMSO-d6) (ppm): 20.9 (t), 24.4 (t), 25.5 (t), 40.9 (t), 51.0 (t), 54.8 (q), 109.6 (d), 112.0 (d), 112.4 
(d), 118.6 (d), 127.9 (s), 129.4 (d), 129.8 (d), 136.1 (s), 140.9 (s), 159.2 (s), 191.7 (s).  
1-(4-Methoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9p). This compound 
was obtained from reaction of 9c with 4-methoxybenzylchloride in DMF in a night (16 hours) at 
room temperature. Yield: 96 %, white solid; mp: 63.0 – 63.3 °C; IR: 1635 (CO) cm-1; 1H NMR 
(CDCl3) (ppm): 1.77 – 1.83 (4H, m, CH2 x 2), 2.61 (2H, t, J = 6.3 Hz, CH2), 2.80 (2H, t, J = 6.3 Hz, 
CH2), 3.77 (3H, s, CH3), 5.46 (2H, s, CH2), 6.00 (1H, d, J = 2.5 Hz, H-3), 6.78 – 6.86 (3H, m, H-2, 
H-3’ and H-5’), 7.06 – 7.11 (2H, m, H-2’ and H-6’); 13C NMR (CDCl3) (ppm): 21.4 (t), 24.9 (t), 
26.4 (t), 41.6 (t), 51.9 (t), 55.2 (q), 109.6 (d), 113.9 (d x 2), 128.6 (d), 128.7 (d x 2), 128.8 (s), 130.6 
(s), 136.8 (s), 158.8 (s), 192.8 (s). 
1-(2,5-Dimethoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9q). This 
compound was obtained from reaction of 9c with 2,5-dimethoxybenzylchloride in DMF in 2 hours 
at room temperature. Yield: 90 %, beige solid; mp: 85.0 – 85.4 °C; IR: 1634 (CO) cm-1; 1H NMR 
(CDCl3) (ppm): 1.79 – 1.85 (4H, m, CH2 x 2), 2.62 (2H, t, J = 6.1 Hz, CH2), 2.81 (2H, t, J = 6.1 Hz, 
CH2), 3.67 (3H, s, CH3), 3.81 (3H, s, CH3), 5.52 (2H, s, CH2), 5.99 (1H, d, J = 2.6 Hz, H-3), 6.35 
(1H, d, J = 2.5 Hz, H-6’), 6.73 (1H, d, J = 2.6 Hz, H-2), 6.75 – 6.78 (1H, m, H-4’), 6.80 – 6.84 (1H, 
m, H-3’); 13C NMR (CDCl3) (ppm): 21.5 (t), 24.9 (t), 26.4 (t), 41.6 (t), 47.4 (t), 55.5 (q), 55.9 (q), 
109.5 (d), 111.0 (d), 112.3 (d), 114.4 (d), 128.5 (s), 128.9 (s), 129.4 (d), 136.5 (s), 150.9 (s), 153.7 
(s), 192.7 (s). 
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1-(3,5-Dimethoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9r). This 
compound was obtained from reaction of 9c with 3,5-dimethoxybenzylchloride in DMF in 2 hours 
at room temperature. Yield: 90 %, grey solid; mp: 60.8 – 61.7 °C; IR: 1625 (CO) cm-1; 1H NMR 
(CDCl3) (ppm): 1.78 – 1.84 (4H, m, CH2), 2.61 (2H, t, J = 6.0 Hz, CH2), 2.81 (2H, t, J = 6.0 Hz, 
CH2), 3.73 (6H, s, CH3 x 2), 5.48 (2H, s, CH2), 6.01 (1H, d, J = 2.5 Hz, H-3), 6.22 (2H, d, J = 2.2 
Hz, H-2’ and H-6’), 6.32 (1H, t, J = 2.2 Hz, H-4’), 6.79 (1H, d, J = 2.5 Hz, H-2); 13C NMR (CDCl3) 
(ppm): 21.5 (t), 24.9 (t), 26.4 (t), 41.6 (t), 52.4 (t), 55.2 (q x 2), 99.0 (d), 104.9 (d x 2), 109.8 (d), 
128.8 (s), 129.1 (d), 136.7 (s), 141.1 (s), 160.9 (s x 2), 192.8 (s).  
1-(3,4,5-Trimethoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9s). This 
compound was obtained from reaction of 9c with 3,4,5-trimethoxybenzylchloride in DMF in a night 
(16 hours) at room temperature. Yield: 89 %, beige solid; mp: 64.6 – 65.3 °C; IR: 1635 (CO) cm-1; 
1
H NMR (CDCl3) (ppm): 1.79 – 1.85 (4H, m, CH2 x 2), 2.63 (2H, t, J = 6.1 Hz, CH2), 2.82 (2H, J = 
6.1 Hz, CH2), 3.79 (6H, s, CH3 x 2), 3.81 (3H, s, CH3), 5.47 (2H, s, CH2), 6.03 (1H, d, J = 2.5 Hz, 
H-3), 6.33 (2H, s, H-2’ and H-6’), 6.81 (1H, d, J = 2.5 Hz, H-2); 13C NMR (CDCl3) (ppm): 21.5 (t), 
25.0 (t), 26.4 (t), 41.6 (t), 52.5 (t), 56.0 (q x 2), 60.8 (q), 104.0 (d x 2), 109.8 (d), 128.9 (s), 129.0 
(d), 134.3 (s), 136.9 (s), 137.0 (s), 153.3 (s x 2), 192.9 (s). 
 
9.3 Preparation of 7-[(dimethylamino)methylidene]-1-substituted-4,5,6,7-
tetrahydrocyclohepta[b]pyrrol-8(1H)one (13) 
Different conditions have been used depending on the series.  
METHOD A: To a solution of ketones 9d-k (1.3 mmol) in dry DMF (2.5 mL), TBDMAM (2 
mmol) was added and the reaction mixture was irradiated under microwave conditions (Power 50 
W; Time 20-40 min; Pressure (max) 100 psi; Temperature (max) 120°C). 
METHOD B: To a solution of ketones 9d-k (1.3 mmol) in dry DMF (2.5 mL), DMFDMA (1.4 
mol) was added and the reaction mixture was irradiated under microwave conditions (Power 50 W; 
Time 40-120 min; Pressure (max) 100 psi; Temperature (max) 120°C). 
METHOD C: To a solution of ketones 9b,l-s (1.3 mmol) in dry DMF (2.5 mL) DMFDMA (13 
mmol) was added and the reaction mixture was irradiated under microwave conditions (Power 150 
W; Time 40-120 min; Pressure (max) 150 psi; Temperature (max) 130°C).  
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At the end in all the cases, when the reactions were completed, the reaction mixtures was poured 
into ice and brine and in the precipitate was filtered off. In the absence of precipitate, the aqueous 
phase was extracted with AcOEt (3 x 30 mL). The organic layer was dried (Na2SO4) and the solvent 
removed in vacuo.  
Ethyl 7-[(dimethylamino)methylidene]-1-methyl-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (13d). This compound was obtained from reaction 
of 9d under MW conditions (Method A, 20 min). Yield: 99 %, pale yellow solid; mp: 110.8 – 111.0 
°C; IR: 1700 (CO), 1636 (CO), cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.27 (3H, t, J = 6.9 Hz, CH3), 
1.70 – 1.80 (2H, m, CH2), 2.32 (2H, t, J = 6.2 Hz, CH2), 2.46 (2H, t, J = 6.2 Hz, CH2), 3.09 (6H, s, 
CH3 x 2), 3.96 (3H, s, CH3), 4.22 (2H, q, J = 6.9 Hz, CH2), 6.67 (1H, s, H-3), 7.46 (1H, s, CH); 
13
C 
NMR (DMSO-d6) (ppm): 14.2 (q), 22,8 (t), 23.0 (t), 29.6 (t), 33.8 (q), 43.0 (q x 2), 59.6 (t), 105.2 
(s), 115.7 (d), 123.9 (s), 125.5 (s), 136.7 (s), 150.0 (d), 160.4 (s), 186.4 (s). 
Ethyl 7-[(dimethylamino)methylidene]-1-benzyl-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (13e). This compound was obtained from reaction 
of 9e under MW conditions (Method A, 20 min; Method B, 80 min). Quantitative yield (Method 
A), 73% (Method B), pale yellow solid; mp: 130.3 - 131 °C; IR: 1704 (CO), 1635 (CO), cm
-1
; 
1
H 
NMR (CDCl3) (ppm): 1.26 (3H, t, J = 7.1 Hz, CH3), 1.72 – 1.86 (2H, m, CH2), 2.36 (2H, t, J = 6.9 
Hz, CH2), 2.62 (2H, t, J = 6.9 Hz, CH2), 3.07 (6H, s, CH3 x 2), 4.21 (2H, q, J = 7.1 Hz, CH2), 6.08 
(2H, s, CH2), 6.78 (1H, s, H-3), 7.10 – 7.22 (5H, m, Ar), 7.54 (1H, s, CH); 
13
C NMR (DMSO-d6) 
(ppm): 14.1 (q), 22.8 (t), 23.0 (t), 29.8 (t), 43.0 (q x 2), 47.4 (t), 59.7 (t), 104.9 (s), 116.7 (d), 123.5 
(s), 125.6 (s), 125.7 (d x 2), 126.6 (d), 128.3 (d x 2), 133.8 (s), 139.8 (s), 150.3 (d), 160.2 (s), 186.4 
(s). 
Ethyl 7-[(dimethylamino)methylidene]-1-(2-methoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (13f). This compound was obtained from reaction 
of 9f under MW conditions (Method A, 20 min; Method B, 40 min). Yield: 97% (Method A), 70% 
(Method B), yellow solid; mp: 139 °C; IR: 1717 (CO), 1646 (CO) cm
-1
; 
1
H NMR (DMSO-d6) 
(ppm): 1.17 (3H, t, J = 7.0 Hz, CH3), 1.73 – 1.78 (2H, m, CH2), 2.29 (2H, t, J = 6.3 Hz, CH2), 2.54 
(2H, t, J = 6.3 Hz, CH2), 3.05 (6H, s, CH3 x 2), 3.80 (3H, s, CH3), 4.11 (2H, q, J = 7.0 Hz, CH2), 
5.90 (2H, s, CH2), 6.01 (1H, d, J = 7.1 Hz, H-3’), 6.68 – 7.01 (3H, m, H-3, H-5’ and H-6’), 7.14 
(1H, t, J = 7.2 Hz, H-4’), 7.39 (1H, s, CH);  13C NMR (DMSO-d6) (ppm): 14.0 (q), 22.8 (t), 23.1 (t), 
29.8 (t), 43.0 (q x 2), 43.8 (t), 55.2 (q), 59.6 (t), 104.9 (s), 110.0 (d), 116.5 (d), 120.2 (d), 123.9 (s), 
124.3 (d), 126.1 (s), 127.5 (d), 128.3 (s), 137.0 (s), 150.3 (d), 155.6 (s), 160.0 (s), 186.2 (s). 
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Ethyl 7-[(dimethylamino)methylidene]-1-(3-methoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (13g). This compound was obtained from reaction 
of 9g under MW conditions (Method A, 20 min; Method B, 40 min). Yield: 92% (Method A), 87% 
(Method B), yellow solid; mp: 87.3 – 88.1 °C; IR: 1707 (CO), 1636 (CO) cm-1; 1H NMR (DMSO-
d6) (ppm): 1.21 (3H, t, J = 7.0 Hz, CH3), 1.73 – 1.79 (2H, m, CH2), 2.28 (2H, t, J = 6.7 Hz, CH2), 
2.57 (2H, t, J = 6.7 Hz, CH2), 3.08 (6H, s, CH3 x 2), 3.66 (3H, s, CH3), 4.16 (2H, q, J = 7.0 Hz, 
CH2), 5.95 (2H, s, CH2), 6.37 – 6.49 (2H, m, H-2’ and H-6’), 6.70 – 6.78 (2H, m, H-4’ and H-3), 
7.15 (1H, t, J = 7.9 Hz, H-5’), 7.46 (1H, s, CH); 13C NMR (DMSO-d6) (ppm): 14.1 (q), 22.8 (t), 
23.0 (t), 29.8 (t), 43.0 (q x 2), 47.3 (t), 54.8 (q), 59.7 (t), 104.9 (s), 111.6 (d), 111.7 (d), 116.7 (d), 
117.8 (d), 123.5 (s), 126.3 (s), 129.4 (d), 136.6 (s), 141.4 (s), 150.4 (d), 159.2 (s), 160.2 (s), 186.4 
(s). 
Ethyl 7-[(dimethylamino)methylidene]-1-(4-methoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (13h). This compound was obtained from reaction 
of 9h under MW conditions (Method A, 40 min; Method B, 40 min). Yield: 95% (Method A), 75% 
(Method B), brown oil; IR: 1706 (CO), 1635 (CO) cm
-1
;  
1
H NMR (DMSO-d6) (ppm): 1.22 (3H, t, J 
= 7.1 Hz, CH3), 1.70 – 1.77 (2H, m, CH2), 2.25 (2H, t, J = 6.7 Hz, CH2), 2.54 (2H, t, J = 6.7 Hz, 
CH2), 3.08 (6H, s, CH3 x 2), 3.68 (3H, s, CH3), 4.17 (2H, q, J = 7.1 Hz, CH2), 5.87 (2H, s, CH2), 
6.74 (1H, s, H-3), 6.76 – 6.90 (4H, m, Ar), 7.48 (1H, s, CH); 13C NMR (DMSO-d6) (ppm): 14.2 (q), 
22.8 (t), 23.0 (t), 29.8 (t), 43.1 (q x 2), 46.6 (t), 55.0 (q), 59.8 (t), 104.9 (s), 113.7 (d x 2), 116.9 (d), 
123.4 (s), 126.4 (s), 127.4 (d x 2), 131.7 (s), 136.5 (s), 150.3 (d), 158.1 (s), 160.3 (s), 186.6 (s). 
Ethyl 7-[(dimethylamino)methylidene]-1-(3,5-dimethoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (13j). This compound was obtained from reaction 
of 9j under MW conditions (Method A, 20 min; Method B, 110 min). Yield: 94% (Method A), 77% 
(Method B), pale yellow solid; mp: 139.2 – 140 °C; IR: 1714 (CO), 1698 (CO) cm-1; 1H NMR 
(CDCl3) (ppm): 1.28 (3H, t, J = 7.1 Hz, CH3), 1.73 – 1.87 (2H, m, CH2), 2.39 (2H, t, J = 6.8 Hz, 
CH2), 2.62 (2H, t, J = 6.8 Hz, CH2), 3.07 (6H, s, CH3 x 2), 3.67 (6H, s, CH3 x 2), 4.22 (2H, q, J = 
7.1 Hz, CH2), 6.06 (2H, s, CH2), 6.16 (2H, s, H-2’ and H-6’), 6.24 (1H, s, H-4’), 6.77 (1H, s, H-3), 
7.55 (1H, s, CH); 
13
C NMR (CDCl3) (ppm): 14.4 (q), 16.6 (t), 23.7 (t), 30.3 (t), 43.3 (q x 2), 48.6 
(t), 55.1 (q x 2), 60.0 (t), 99.0 (d), 104.3 (d x 2), 107.1 (s), 117.0 (d), 125.2 (s), 127.6 (s), 136.6 (s), 
142.8 (s), 150.3 (d), 160.9 (s x 2), 161.0 (s), 188.7 (s).  
Ethyl 7-[(dimethylamino)methylene]-8-oxo-1-(3,4,5-trimethoxybenzyl)-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (13k). This compound was obtained from reaction 
of 9k under MW conditions (Method A, 40 min). Yield: 99%, brown oil; IR: 1707 (CO), 1635 (CO) 
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cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.23 (3H, t, J = 7.0 Hz, CH3), 1.70 – 1.79 (2H, m, CH2), 2.30 
(2H, t, J = 6.8 Hz, CH2), 2.51 (2H, t, J = 6.8 Hz, CH2), 2.91 (6H, s, CH3 x 2), 3.59 (3H, s, CH3), 
3.62 (6H, s, CH3 x 2), 4.19 (2H, q, J = 7.0 Hz, CH2), 5.90 (2H, s, CH2), 6.20 (2H, s, H-2’ and H-6’), 
6.77 (1H, s, H-3), 7.51 (1H, s, CH); 
13
C NMR (DMSO-d6) (ppm): 14.2 (q), 22.7 (t), 23.1 (t), 29.8 
(t), 43.1 (q x 2), 47.2 (t), 55.6 (q x 2), 59.8 (t), 59.9 (q), 103.2 (d x 2), 104.9 (s), 116.8 (d), 123.6 (s), 
126.3 (s), 135.5 (s), 136.2 (s), 136.7 (s), 150.6 (d), 152.7 (s x 2), 160.3 (s), 186.5 (s). 
 7-[(Dimethylamino)methylidene]-1-(phenylsulfonyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-
8(1H)-one (13b). This compound was obtained from reaction of 9b under MW conditions (Method 
C, 80 min). Yield: 90%; grey solid; mp: 172.6 – 173 °C; IR: 1653 (CO) cm-1; 1H NMR (DMSO-d6) 
(ppm): 1.74 (2H, t, J = 6.6 Hz, CH2), 2.30 – 2.49 (4H, m, CH2 x 2), 3.06 (6H, s, CH3 x 2), 6.26 (1H, 
d, J = 2.7 Hz, H-3), 7.33 (1H, s, CH), 7.57 – 7.71 (4H, m, H-2, H-3’, H-4’ and H-5’), 8.03 (2H, d, J 
= 7.1 Hz, H-2’, H-6’); 13C NMR (DMSO-d6) (ppm): 22.8 (t), 23.0 (t), 29.2 (t), 42.9 (q x 2), 104.1 
(s), 112.3 (d), 125.6 (d), 127.4 (d x 2), 128.8 (d x 2), 131.3 (s), 132.6 (s), 133.6 (d), 139.4 (s), 149.7 
(d), 184.1 (s). 
7-[(Dimethylamino)methylidene]-1-methyl-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one 
(13l). This compound was obtained from reaction of 9l under MW conditions (Method C, 80 min). 
Yield: 89%, brown oil; IR: 1623 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.71 – 1.81 (2H, m, CH2), 
2.34 (2H, t, J = 6.6 Hz, CH2), 2.55 (2H, t, J = 6.6 Hz, CH2), 3.04 (6H, s, CH3 x 2), 3.72 (3H, s, 
CH3), 5.85 (1H, d, J = 2.1 Hz, H-3), 6.80 (1H, d, J = 2.1 Hz, H-2), 7.24 (1H, s, CH); 
13
C NMR 
(DMSO-d6) (ppm): 23.6 (t), 23.9 (t), 29.6 (t), 35.4 (q), 42.8 (q x 2), 105.8 (s), 107.3 (d), 126.7 (d), 
128.0 (s), 130.2 (s), 148.1 (d), 186.9 (s). 
7-[(Dimethylamino)methylidene]-1-benzyl-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one 
(13m). This compound was obtained from reaction of 9m under MW conditions (Method C, 120 
min). Yield: 95 %; yellow oil; IR: 1636 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.70 – 1.79 (2H, 
m, CH2), 2.26 (2H, t, J = 6.5 Hz, CH2), 2.56 (2H, t, J = 6.5 Hz, CH2), 3.03 (6H, s, CH3 x 2), 5.46 
(2H, s, CH2), 5.93 (1H, d, J = 2.3 Hz, H-3), 6.97 – 7.06 (3H, m, H-2, H-2’ and H-6’), 7.19 – 7.30 
(4H, m, H-3’, H-4’, H-5’ and CH); 13C NMR (DMSO-d6) (ppm): 23.6 (t), 23.7 (t), 29.8 (t), 42.8 (q 
x 2), 50.1 (t), 105.5 (s), 108.0 (d), 126.3 (d), 126.4 (d x 2), 126.8 (d), 128.2 (d x 2), 128.6 (s), 129.7 
(s), 139.9 (s), 148.4 (d), 186.9 (s). 
7-[(dimethylamino)methylidene]-1-(2-methoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-
8(1H)-one (13n). This compound was obtained from reaction of 9n under MW conditions (Method 
C, 40 min). Yield: 96%, brown oil; IR: 1632 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.79 – 1.86 (2H, 
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m, CH2), 2.42 (2H, t, J = 6.9 Hz, CH2), 2.65 (2H, t, J = 6.9 Hz, CH2), 3.06 (6H, s, CH3 x 2), 3.83 
(3H, s, CH3), 5.54 (2H, s, CH2), 5.94 (1H, d, J = 2.3 Hz, H-3), 6.75 – 6.86 (4H, m, Ar, H-2), 7.13 – 
7.21 (1H, m, Ar), 7.39 (1H, s, CH); 
13
C NMR (CDCl3) (ppm): 24.1 (t), 24.3 (t), 30.3 (t), 43.2 (q x 
2), 46.3 (t), 55.2 (q), 107.4 (s), 108.0 (d), 109.9 (d), 120.5 (d), 124.7 (s), 126.7 (d), 128.0 (d), 128.1 
(d), 129.9 (s), 130.6 (s), 148.5 (d), 156.7 (s), 188.9 (s).   
7-[(dimethylamino)methylidene]-1-(3-methoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-
8(1H)-one (13o). This compound was obtained from reaction of 9o under MW conditions (Method 
C, 80 min). Yield: 91%, brown oil; IR: 1633 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.72 – 1.78 
(2H, m, CH2), 2.28 (2H, t, J = 6.5 Hz, CH2), 2.48 – 2.56 (2H, m, CH2), 3.03 (6H, s, CH3 x 2), 3.67 
(3H, s, CH3), 5.43 (2H, s, CH2), 5.94 (1H, d, J = 2.3 Hz, H-3), 6.55 – 6.59 (2H, m, H-2’ and H-6’), 
6.76 (1H, d, J = 2.3 Hz, H-4’), 6.97 (1H, d, J = 2.3 Hz, H-2), 7.13 – 7.25 (2H, m, H-5’, CH); 13C 
NMR (DMSO-d6) (ppm): 23.6 (t), 23.7 (t), 29.8 (t), 42.8 (q x 2), 49.9 (t), 54.8 (q), 105.5 (s), 108.0 
(d), 112.0 (d), 112.2 (d), 118.5 (d), 126.4 (d), 128.5 (s), 129.3 (d), 129.8 (s), 141.5 (s), 148.4 (d), 
159.2 (s), 186.9 (s). 
7-[(dimethylamino)methylidene]-1-(4-methoxybenzyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-
8(1H)-one (13p). This compound was obtained from reaction of 9p under MW conditions (Method 
C, 40 min). Yield: 96 %, brown oil; IR: 1633 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.78 – 1.85 (2H, 
m, CH2), 2.38 (2H, t, J = 6.6 Hz, CH2), 2.64 (2H, t, J = 6.6 Hz, CH2), 3.07 (6H, s, CH3 x 2), 3.76 
(3H, s, CH3), 5.42 (2H, s, CH2), 5.94 (1H, d, J = 2.4 Hz, H-3), 6.71 (1H, d, J = 2.4 Hz, H-2), 6.78 – 
6.84 (2H, m, H-3’ and H-5’), 7.02 – 7.11 (2H, m, H-2’ and H-6’), 7.39 (1H, s, CH); 13C NMR 
(CDCl3) (ppm): 24.1 (t), 24.3 (t), 30.2 (t), 43.2 (q x 2), 50.8 (t), 55.2 (q), 107.4 (s), 108.1 (d), 113.8 
(d x 2), 126.1 (d), 128.5 (d x 2), 130.3 (s), 130.4 (s), 131.5 (s), 148.6 (d), 158.6 (s), 188.9 (s). 
7-[(dimethylamino)methylidene]-1-(2,5-dimethoxybenzyl)-4,5,6,7-
tetrahydrocyclohepta[b]pyrrol-8(1H)-one (13q). This compound was obtained from reaction of 
9q under MW conditions (Method C, 40 min). Yield: 93 %, brown oil; IR: 1633 (CO) cm
-1
; 
1
H 
NMR (CDCl3) (ppm): 1.76 – 1.90 (2H, m, CH2), 2.44 (2H, t, J = 6.7 Hz, CH2), 2.65 (2H, t, J = 6.7 
Hz, CH2), 3.06 (6H, s, CH3 x 2), 3.64 (3H, s, CH3), 3.79 (3H, s, CH3), 5.52 (2H, s, CH2), 5.94 (1H, 
d, J = 2.4 Hz, H-3), 6.31 (1H, d, J = 2.4 Hz, H-2), 6.65 – 6.81 (3H, m, H-3’, H-4’ and H-6’), 7.39 
(1H, s, CH); 
13
C NMR (CDCl3) (ppm): 24.2 (t), 24.4 (t), 30.3 (t), 43.2 (q x 2), 46.4 (t), 55.6 (q), 
55.8 (q), 107.4 (s), 108.2 (d), 110.9 (d), 112.3 (d), 114.0 (d), 126.7 (d), 129.3 (s), 130.0 (s), 130.5 
(s), 148.6 (d), 150.8 (s), 153.7 (s), 188.8 (s).  
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7-[(dimethylamino)methylidene]-1-(3,5-dimethoxybenzyl)-4,5,6,7-
tetrahydrocyclohepta[b]pyrrol-8(1H)-one (13r). This compound was obtained from reaction of 
9r under MW conditions (Method C, 40 min). Yield: 90 %, brown oil; IR: 1635 (CO) cm
-1
; 
1
H 
NMR (CDCl3) (ppm): 1.76 – 1.90 (2H, m, CH2), 2.42 (2H, t, J = 6.7 Hz, CH2), 2.65 (2H, t, J = 6.7 
Hz, CH2), 3.06 (6H, s, CH3 x 2), 3.71 (6H, s, CH3 x 2), 5.46 (2H, s, CH2), 5.95 (1H, d, J = 2.5 Hz, 
H-3), 6.22 (2H, d, J = 2.2 Hz, H-2’, H-6’), 6.29 (1H, t, J = 2.2 Hz, H-4’), 6.72 (1H, d, J = 2.5 Hz, 
H-2), 7.39 (1H, s, CH); 
13
C NMR (CDCl3) (ppm): 24.1 (t), 24.3 (t), 30.3 (t), 43.2 (q x 2), 51.3 (t), 
55.2 (q x 2), 99.1 (d), 104.7 (d x 2), 107.3 (s), 108.3 (d), 126.5 (d), 130.2 (s), 130.5 (s), 141.9 (s), 
148.6 (d), 160.8 (s x 2), 188.8 (s). 
7-[(dimethylamino)methylidene]-1-(3,4,5-trimethoxybenzyl)-4,5,6,7-
tetrahydrocyclohepta[b]pyrrol-8(1H)-one (13s). This compound was obtained from reaction of 9s 
under MW conditions (Method C, 120 min). Yield: 86 %, brown oil; IR: 1653 (CO) cm
-1
; 
1
H NMR 
(CDCl3) (ppm): 1.77 – 1.90 (2H, m, CH2), 2.41 (2H, t, J = 6.6 Hz, CH2), 2.66 (2H, t, J = 6.6 Hz, 
CH2), 3.08 (6H, s, CH3 x 2), 3.77 (6H, s, CH3 x 2), 3.79 (3H, s, CH3), 5.46 (2H, s, CH2), 5.97 (1H, 
d, J = 2.5 Hz, H-3), 6.31 (2H, s, H-2’, H-6’), 6.74 (1H, d, J = 2.5 Hz, H-2), 7.41 (1H, s, CH); 13C 
NMR (CDCl3) (ppm): 24.2 (t), 24.3 (t), 30.3 (t), 43.2 (q x 2), 51.4 (t), 55.9 (q x 2), 60.8 (q), 103.7 
(d x 2), 107.2 (s), 108.3 (d), 126.4 (d), 130.4 (s), 130.5 (s), 135.2 (s), 136.8 (s), 148.7 (d), 153.2 (s x 
2), 188.8 (s). 
 
9.4 Preparation of ethyl 7-(hydroxymethylidene)-1-substituted-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (14) 
To a suspension of t-BuO
-
K
+
 (13.5 mmol) in dry toluene (12 mL), at 0 °C under N2 atmosphere, a 
solution of the appropriate ketone 9d-k (4.5 mmol) in toluene (40 mL) was added and the reaction 
mixture was stirred at room temperature for one hour and half. A solution of ethyl formate (1.09 
mL, 13.5 mmol) in dry toluene (12 mL) was added, and the mixture was stirred up to completeness 
(1.5 – 4 hours). The solvent was removed in vacuo and to residue was added water (50 mL). The 
aqueous phase was acidified with HCl 3N and extracted with dichloromethane (2 x 60 mL). The 
organic phase was dried on Na2SO4, and evaporated. The crude product was then purified by 
chromatography column (dichloromethane). 
Ethyl 7-(hydroxymethylidene)-1-methyl-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-
carboxylate (14d). This compound was obtained from reaction of 9d. Yield: 80%, brown oil. IR: 
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3415 (OH), 1704 (CO), 1620 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.36 (3H, t, J = 7.1 Hz, CH3), 
1.84 – 1.97 (2H, m, CH2), 2.22 (2H, t, J = 6.9 Hz, CH2), 2.69 (2H, t, J = 6.9 Hz, CH2), 4.11 (3H, s, 
CH3), 4.31 (2H, q, J = 7.1 Hz, CH2), 6.70 (1H, s, H-3), 7.76 (1H, d, J = 7.9 Hz, CH), 14.93 (1H, d, J 
= 7.9 Hz, OH); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 25.0 (t), 25.9 (t), 28.5 (t), 35.0 (q), 60.5 (t), 
114.0 (s), 117.0 (d), 127.5 (s), 129.7 (s), 132.8 (s), 160.9 (s), 172.3 (d), 186.3 (s). 
Ethyl 7-(hydroxymethylene)-1-benzyl-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[b]pyrrole-2-
carboxylate (14e). This compound was obtained from reaction of 9e. Yield: 90%, brown oil. IR: 
3391 (OH), 1702 (CO), 1619 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.29 (3H, t, J = 7.1 Hz, CH3), 
1.84 – 1.95 (2H, m, CH2), 2.13 (2H, t, J = 6.8 Hz, CH2), 2.69 (2H, t, J = 6.8 Hz, CH2), 4.24 (2H, q, 
J = 7.1 Hz, CH2), 5.99 (2H, s, CH2), 6.83 (1H, s, H-3), 6.92 – 7.00 (2H, m, H-2’ and H-6’), 7.16 – 
7.29 (3H, m, H-3’, H-4’ and H-5’), 7.71 (1H, d, J = 8.0 Hz, CH), 14.77 (1H, d, J = 8.0 Hz, OH); 13C 
NMR (CDCl3) (ppm): 14.2 (q), 24.5 (t), 25.7 (t), 28.8 (t), 49.2 (t), 60.5 (t), 113.9 (s), 117.9 (d), 
126.1 (d x 2), 126.9 (d), 127.0 (s), 128.3 (d x 2), 130.2 (s), 132.7 (s), 139.2 (s), 160.6 (s), 172.5 (d), 
186.5 (s). 
Ethyl 7-(hydroxymethylene)-1-(2-methoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (14f). This compound was obtained from reaction 
of 9f. Yield: 80%, brown oil. IR: 3400 (OH), 1711 (CO), 1638 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 
1.26 (3H, t, J = 7.2 Hz, CH3), 1.86 – 1.99 (2H, m, CH2), 2.16 (2H, t, J = 6.4 Hz, CH2), 2.70 (2H, t, J 
= 6.4 Hz, CH2), 3.82 (3H, s, CH3), 4.21 (2H, q, J = 7.2 Hz, CH2), 5.94 (2H, s, CH2), 6.40 (1H, d, J = 
6.7 Hz, H-3’), 6.77 – 6.81 (2H, m, H-5’, H-6’), 6.83 (1H, s, H-3), 7.16 (1H, t, J = 6.7 Hz, H-4’), 
7.70 (1H, d, J = 8.1 Hz, CH), 14.72 (1H, d, J = 8.1 Hz, OH); 
13
C NMR (CDCl3) (ppm): 14.2 (q), 
24.5 (t), 25.7 (t), 28.9 (t), 45.6 (t), 55.2 (q), 60.4 (t), 109.8 (d), 113.8 (s), 117.6 (d), 120.3 (d), 125.8 
(d), 127.6 (s), 127.8 (d), 128.1 (s), 129.8 (s), 133.2 (s), 156.3 (s), 160.5 (s), 172.3 (d), 186.4 (s). 
Ethyl 7-(hydroxymethylene)-1-(3-methoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (14g). This compound was obtained from reaction 
of 9g. Yield: 68%, colourless oil; IR: 3389 (OH), 1707 (CO), 1622 (CO)  cm
-1
; 
1
H NMR (CDCl3) 
(ppm): 1.30 (3H, t, J = 7.1 Hz, CH3), 1.88 – 1.98 (2H, m, CH2), 2.15 (2H, t, J = 6.7 Hz, CH2), 2.69 
(2H, t, J = 6.7 Hz, CH2), 3.73 (3H, s, CH3), 4.24 (2H, q, J = 7.1 Hz, CH2), 5.97 (2H, s, CH2), 6.52 
(1H, d, J = 2.3 Hz, H-6’), 6.57 (1H, s, H-2’), 6.72 (1H, dd, J = 8.2 J = 2.3 Hz, H-4’), 6.82 (1H, s, H-
3), 7.15 (1H, t, J = 8.2 Hz, H-5’), 7.72 (1H, s, CH), 14.76 (1H, s, OH); 13C NMR (CDCl3) (ppm): 
14.2 (q), 24.6 (t), 25.8 (t), 28.8 (t), 49.1 (t), 55.1 (q), 60.5 (t), 111.8 (d), 112.2 (d), 113.9 (s), 117.9 
(d), 118.4 (d), 127.1 (s), 129.4 (d), 130.2 (s), 132.7 (s), 140.9 (s), 159.6 (s), 160.6 (s), 172.5 (d), 
186.5 (s). 
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Ethyl 7-(hydroxymethylene)-1-(4-methoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (14h). This compound was obtained from reaction 
of 9h. Yield: 73%, pale yellow oil. IR: 3399 (OH), 1706 (CO), 1619 (CO) cm
-1
; 
1
H NMR (CDCl3) 
(ppm): 1.31 (3H, t, J = 7.1 Hz, CH3), 1.83 – 1.97 (2H, m, CH2), 2.12 (2H, t, J = 6.6 Hz, CH2), 2.67 
(2H, t, J = 6.6 Hz, CH2), 3.75 (3H, s, CH3), 4.23 (2H, q, J = 7.1 Hz, CH2), 5.91 (2H, s, CH2), 6.74 
(1H, s, H-3), 6.76 – 6.82 (2H, m, H-3’ and H-5’), 6.91 – 7.00 (2H, m, H-2’ and H-6’), 7.73 (1H, d, J 
= 7.8 Hz, CH), 14.80 (1H, d, J = 7.8 Hz, OH); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 24.4 (t), 25.7 (t), 
28.9 (t), 48.6 (t), 55.2 (q), 60.5 (t), 113.7 (d x 2), 113.9 (s), 117.9 (d), 126.9 (s), 127.7 (d x 2), 130.2 
(s), 131.4 (s), 132.6 (s), 158.5 (s), 160.7 (s), 172.5 (d), 186.6 (s). 
Ethyl 1-(2,5-dimethoxybenzyl)-7-(hydroxymethylene)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (14i). This compound was obtained from reaction 
of 9i. Yield: 76%, yellow oil, IR: 3398 (CO), 1709 (CO), 1623 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 
1.27 (3H, q, J = 7.1 Hz, CH2), 1.85 – 1.99 (2H, m, CH2), 2.17 (2H, t, J = 6.6 Hz, CH2), 2.70 (2H, t, 
J = 6.6 Hz, CH2), 3.64 (3H, s, CH3), 3.78 (3H, s, CH3), 4.22 (2H, q, J = 7.1 Hz, CH2), 5.92 (2H, s, 
CH2), 6.02 (1H, d, J = 2.7 Hz, H-6’), 6.63 – 6.77 (2H, m, H-3’ and H-4’), 6.83 (1H, s, H-3), 7.70 
(1H, d, J = 8.2 Hz, CH), 14.73 (1H, d, J = 8.2 Hz, OH); 
13
C NMR (CDCl3) (ppm): 14.2 (q), 24.5 (t), 
25.8 (t), 28.8 (t), 45.6 (t), 55.5 (q), 55.8 (q), 60.4 (t), 110.6 (d), 111.1 (d), 113.0 (d), 113.8 (s), 117.7 
(d), 127.5 (s), 129.4 (s), 129.8 (s), 133.1 (s), 150.6 (s), 153.5 (s), 160.5 (s), 172.2 (d), 186.4 (s). 
Ethyl 1-(3,5-dimethoxybenzyl)-7-(hydroxymethylene)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (14j). This compound was obtained from reaction 
of 9j. Yield: 68%, yellow oil. IR: 3398 (CO), 1706 (CO), 1609 (CO) cm
-1
; 
1
H NMR (CDCl3) 
(ppm): 1.30 (3H, t, J = 7.1 Hz, CH3), 1.85 – 1.94 (2H, m, CH2), 2.15 (2H, t, J = 6.7 Hz, CH2), 2.69 
(2H, t, J = 6.7 Hz, CH2), 3.70 (6H, s, CH3), 4.25 (2H, q, J = 7.1 Hz, CH2), 5.95 (2H, s, CH2), 6.11 
(2H, d, J = 2.2 Hz, H-2’ and H-6’), 6.28 (1H, t, J = 2.2 Hz, H-4’), 6.82 (1H, s, H-3), 7.71 (1H, d, J = 
7.9 Hz, CH), 14.78 (1H, d, J = 7.9 Hz, OH); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 24.5 (t), 25.8 (t), 
28.8 (t), 49.1 (t), 55.2 (q x 2), 60.5 (t), 98.8 (d), 104.1 (d x 2), 113.9 (s), 118.0 (d), 127.1 (s), 130.2 
(s), 132.7 (s), 141.8 (s), 160.6 (s), 160.8 (s x 2), 172.4 (d), 186.6 (s).  
Ethyl 7-(hydroxymethylene)-8-oxo-1-(3,4,5-trimethoxybenzyl)-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (14k). This compound was obtained from reaction 
of 9k. Yield: 60%, yellow oil. IR: 3410 (OH), 1710 (CO), 1647 (CO) cm
-1
; 
1
H NMR (CDCl3) 
(ppm): 1.33 (3H, t, J = 7.1 Hz, CH3), 1.88 – 1.98 (2H, m, CH2), 2.13 (2H, t, J = 6.8 Hz, CH2), 2.68 
(2H, t, J = 6.8 Hz, CH2), 3.74 (6H, s, CH3 x 2), 3.78 (3H, s, CH3), 4.28 (2H, q, J = 7.1 Hz, CH2), 
5.94 (2H, s, CH2), 6.28 (2H, s, H-2’ and H-6’), 6.81 (1H, s, H-3), 7.74 (1H, d, J = 8.0 Hz, CH), 
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14.83 (1H, d, J = 8.0 Hz, OH); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 24.4 (t), 25.7 (t), 28.9 (t), 48.9 
(t), 55.9 (q x 2), 60.6 (t), 60.8 (q), 100.0 (s), 103.7 (d x 2), 114.0 (s) 118.0 (d), 126.7(s), 130.3 (s), 
134.9 (s), 136.9 (s), 153.1 (s x 2), 160.8 (s), 172.5 (d), 186.9 (s).  
 
9.5 Preparation of ethyl 7-[(diethylamino)methylidene]-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (15) 
To a solution of 14d,h (1.3 mmol) in dry toluene (2.5 mL), was added diethylamine (2 mmol) and 
the reaction mixture was stirred at 80°C for one night (16 hours). The solvent was removed in 
vacuo and the residue used in the next step.  
Ethyl 7-[(diethylamino)methylene]-1-methyl-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (15d). This compound was obtained from reaction 
of 14d. Quantitative yield, red oil; IR: 1700 (CO), 1629 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.22 
(6H, t, J = 7.1 Hz, CH3 x 2), 1.35 (3H, t, J = 7.1 Hz, CH3), 1.73 – 1.86 (2H, m, CH2), 2.34 (2H, t, J 
= 6.8 Hz, CH2), 2.58 (2H, t, J = 6.8 Hz, CH2), 3.35 (4H, q, J = 7.1 Hz, CH2 x 2), 4.12 (3H, s, CH3), 
4.28 (2H, q, J = 7.1 Hz, CH2), 6.71 (1H, s, H-3), 7.59 (1H, s, CH); 
13
C NMR (CDCl3) (ppm): 14.4 
(q), 14.8 (q x 2), 23.7 (t x 2), 23.9 (t), 29.6 (t), 34.4 (q), 47.7 (t), 60.0 (t), 106.2 (s), 115.8 (d), 125.1 
(s), 126.9 (s), 136.8 (s), 148.3 (d), 161.3 (s), 184.4 (s). 
Ethyl 7-[(diethylamino)methylene]-1-(4-methoxybenzyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[b]pyrrole-2-carboxylate (15h). This compound was obtained from reaction 
of 14h. Quantitative yield, red oil; IR: 1695 (CO), 1627 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.18 – 
1.34 (9H, m, CH3 x 3), 1.73 – 1.82 (2H, m, CH2), 2.28 (2H, t, J = 6.8 Hz, CH2), 2.60 (2H, t, J = 6.8 
Hz, CH2), 3.33 (4H, q, J = 7.1 Hz, CH2 x 2), 3.73 (3H, s, CH3), 4.22 (2H, q, J = 7.1 Hz, CH2), 5.97 
(2H, s, CH2), 6.74 (2H, d, J = 8.5 Hz, H-3’ and H-5’), 6.76 (1H, s, H-3), 6.99 (2H, d, J = 8.5 Hz, H-
2’ and H-6’), 7.59 (1H, s, CH); 13C NMR (CDCl3) (ppm): 14.3 (q), 14.7 (q x 2), 23.7 (t), 23.8 (t), 
29.6 (t), 47.6 (t x 2), 47.9 (t), 55.2 (q), 60.0 (t), 106.0 (s), 113.6 (d x 2), 116.8 (d), 124.6 (s), 127.4 
(s), 127.7 (d x 2), 132.3 (s), 136.6 (s), 148.5 (d), 158.2 (s), 161.0 (s), 188.4 (s). 
 
9.6.1  Preparation of Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-9(1H)-ones (16) 
To a solution of appropriate enaminone 13 (2 mmol), in dry ethanol (40 mL) under N2 atmosphere, 
phenylsulfonylacetonitrile (3 mmol) was added. The reaction mixture was heated to reflux until the 
disappearance of the starting material (20-48 h). The solvent was evaporated, and the residue was 
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dissolved in toluene (40 mL). Acetic acid (2 mmol) was added and the reaction mixture was heated 
to reflux with the Dean-Stark apparatus for 24 hours. The solvent was evaporated and the residue 
was purified by chromatography column (dichloromethane : ethyl acetate 8:2). 
Ethyl 1-methyl-9-oxo-8-(phenylsulfonyl)-1,4,5,6,9,10-hexahydropyrrolo[3',2':6,7] 
cyclohepta[1,2-b]pyridine-2-carboxylate (16d). This compound was obtained from reaction of 
13d. Yield: 51%, yellow solid; mp: 301-302 °C; Rf: (DCM: EtOAc 8:2) 0.19; IR: 3408 (NH), 1701 
(CO), 1642 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.28 (3H, t, J = 7.0 Hz, CH3), 2.07 (2H, t, J = 
5.9 Hz, CH2), 2.32 – 2.46 (4H, m, CH2 x 2), 4.04 (3H, s, CH3), 4.24 (2H, q, J = 7.0 Hz, CH2), 6.85 
(1H, s, H-3), 7.58 – 7.83 (4H, m, Ar), 8.01 (1H, d, J = 7.0 Hz, Ar), 8.33 (1H, s, H-7), 12.30 (1H, s, 
NH); 
13
C NMR (DMSO-d6) (ppm): 14.2 (q), 22.1 (t), 23.1 (t), 32.4 (t), 34.6 (q), 60.3 (t), 116.4 (d), 
128.2 (d x 2), 128.8 (d x 2), 129.0 (d), 129.2 (s), 130.4 (s), 133.4 (d), 137.3 (s), 140.2 (s), 146.2 (s), 
157.0 (s), 160.2 (s), 163.8 (s), 186.5 (s). 
Ethyl 1-benzyl-9-oxo-8-(phenylsulfonyl)-1,4,5,6,9,10-hexahydropyrrolo[3',2':6,7] 
cyclohepta[1,2-b]pyridine-2-carboxylate (16e). This compound was obtained from reaction of 
13e. Yield: 40%, yellow solid; mp: 256-257 °C; Rf: (DCM: EtOAc 8:2) 0.21; IR: 3407 (NH), 1700 
(CO), 1642 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.23 (3H, t, J = 7.1 Hz, CH3), 2.04 – 2.12 (2H, 
m, CH2), 2.16 – 2.28 (2H, m, CH2), 2.35 – 2.46 (2H, m, CH2), 4.20 (2H, q, J = 7.1 Hz, CH2), 5.82 
(2H, s, CH2), 6.61 (2H, dd, J = 6.0, 2.1 Hz, H-2’ and H-6’), 6.95 (1H, s, H-3), 7.09 (3H, dd, J = 6.0, 
2.1 Hz, H-3’, H-4’ and H-5’), 7.55 – 7.74 (3H, m, H-3’’, H-4’’ and H-5’’), 7.90 – 7.97 (2H, m, H-
2’’ and H-6’’), 8.19 (1H, s, H-7), 12.48 (1H, s, NH); 13C NMR (DMSO-d6) (ppm): 14.1 (q), 22.0 
(t), 28.2 (t), 32.3 (t), 48.5 (t), 60.0 (t), 117.7 (d), 124.5 (s), 125.5 (d x 2), 127.1 (d), 128.1 (d x 2), 
128.3 (d x 2), 128.4 (d), 128.9 (d x 2), 133.4 (d), 138.2 (s), 138.4 (s), 140.2 (s), 154.0 (s), 155.7 (s), 
157.2 (s), 157.3 (s), 160.2 (s), 170.3 (s). 
Ethyl 1-(2-methoxybenzyl)-9-oxo-8-(phenylsulfonyl)-1,4,5,6,9,10-hexahydropyrrolo[3',2':6,7] 
cyclohepta[1,2-b]pyridine-2-carboxylate (16f). This compound was obtained from reaction of 13f. 
Yield: 46%, yellow solid; mp: 249-250 °C; Rf: (DCM: EtOAc 8:2) 0.26; IR: 3402 (NH), 1706 
(CO), 1646 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.24 (3H, t, J = 7.1 Hz, CH3), 1.99 – 2.06 (4H, 
m, CH2 x 2), 2.35 – 2.42 (2H, m, CH2), 3.45 (3H, s, CH3), 4.20 (2H, q, J = 7.1 Hz, CH2), 5.76 (2H, 
s, CH2), 6.13 – 6.16 (1H, m, H-3’), 6.59 – 6.73 (2H, m, H-5’ and H-6’), 6.94 (1H, s, H-3), 7.09 (1H, 
t, J = 7.4 Hz, H-4’), 7.58 – 7.75 (3H, m, H-3’’, H-4’’ and H-5’’), 7.96 (2H, d, J = 7.0 Hz, H-2’’ and 
H-6’’), 8.17 (1H, s, H-7), 12.56 (1H, s, NH); 13C NMR (DMSO-d6) (ppm): 14.1 (q), 21.9 (t), 29.0 
(t), 32.4 (t), 43.9 (t), 54.9 (q), 59.9 (t), 110.2 (d), 117.3 (d), 117.4 (d), 118.8 (d), 120.0 (d), 125.9 (s), 
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126.0 (s), 128.1 (d x 2), 128.2 (s), 128.4 (d), 128.5 (s), 128.8 (d x 2), 128.9 (s), 129.1 (s), 133.4 (d), 
138.9 (s), 140.0 (s), 142.1 (s), 155.6 (s), 160.3 (s).  
Ethyl 1-(3-methoxybenzyl)-9-oxo-8-(phenylsulfonyl)-1,4,5,6,9,10-hexahydropyrrolo[3',2':6,7] 
cyclohepta[1,2-b]pyridine-2-carboxylate (16g). This compound was obtained from reaction of 
13g. Yield: 39%, pale brown solid; mp: 289-290 °C; Rf: (DCM: EtOAc 8:2) 0.21; IR: 3424 (NH), 
1720 (CO), 1639 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.24 (3H, t, J = 6.8 Hz, CH3), 2.09 – 2.41 
(6H, m, CH2 x 3), 3.53 (3H, s, CH3), 4.21 (2H, q, J = 6.8 Hz, CH2), 5.77 (2H, s, CH2), 6.18 (1H, s, 
H-2’) 6.22 (1H, d, J = 8.4 Hz, H-6’), 6.68 (1H, dd, J = 8.4, J = 1.8 Hz, H-4’), 6.96 (1H, s, H-3), 
7.03 (1H, t, J = 8.4 Hz, H-5’), 7.57 – 7.75 (3H, m, H-3’’, H-4’’ and H-5’’), 7.96 (2H, d, J = 7.3 Hz, 
H-2’’ and H-6’’), 8.23 (1H, s, H-7), 12.59 (1H, s, NH); 13C NMR (DMSO-d6) (ppm): 14.1 (q), 25.2 
(t), 29.0 (t), 34.8 (t), 46.4 (t), 54.7 (q), 60.1 (t), 111.1 (d), 117.6 (d), 117.8 (d), 119.5 (s), 121.5 (d), 
128.1 (d x 2), 128.9 (d), 129.5 (d x 2), 133.4 (d), 136.4 (d), 140.1 (s), 141.6 (s), 151.8 (s), 154.0 (s), 
154.8 (s), 159.1 (s), 160.2 (s), 171.4 (s), 175.0 (s), 182.0 (s). 
Ethyl 1-(4-methoxybenzyl)-9-oxo-8-(phenylsulfonyl)-1,4,5,6,9,10-hexahydropyrrolo[3',2':6,7] 
cyclohepta[1,2-b]pyridine-2-carboxylate (16h). This compound was obtained from reaction of 
13h. Yield: 48%, yellow solid; mp: 251-252 °C; Rf: (DCM: EtOAc 8:2) 0.23; IR: 3380 (NH), 1700 
(CO), 1653 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.27 (3H, t, J = 7.1 Hz, CH3), 2.13 – 2.37 (6H, m, 
CH2 x 3), 3.71 (3H, s, CH3), 4.26 (2H, q, J = 7.1 Hz, CH2), 5.82 (2H, s, CH2), 6.64 – 6.75 (4H, m, 
H-2’, H-3’, H-5’ and H-6’), 7.07 (1H, s, H-3), 7.26 – 7.53 (3H, m, H-3’’. H-4’’ and H-5’’), 7.96 
(2H, d, J = 7.6 Hz, H-2’’ and H-6’’), 8.31 (1H, s, H-7), 12.64 (1H, s, NH); 13C NMR (CDCl3) 
(ppm): 14.3 (q), 22.8 (t), 29.1 (t), 33.2 (t), 49.5 (t), 55.2 (q), 60.7 (t), 113.9 (d x 2), 118.2 (d), 119.7 
(s), 126.5 (s), 126.7 (s), 127.2 (d x 2), 128.4 (d x 2), 128.7 (s), 129.0 (d x 2), 129.2 (s), 130.4 (s), 
133.3 (d), 139.6 (s), 143.9 (s), 145.8 (d), 158.8 (s), 159.1 (s), 160.6 (s). 
1-Methyl-8-(phenylsulfonyl)-4,5,6,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-
9(1H)-one (16l). This compound was obtained from reaction of 13l. Yield: 49%, yellow solid; mp: 
331-332 °C; Rf: (DCM: EtOAc 8:2) 0.21; IR: 3418 (NH), 1635 (CO) cm
-1
; 
1
H NMR (DMSO-d6) 
(ppm): 1.45 – 1.59 (2H, m, CH2), 2.01 – 2.11 (2H, m, CH2), 2.35 – 2.48 (2H, m, CH2), 3.68 (3H, s, 
CH3), 6.06 (1H, d, J = 2.1 Hz, H-3), 6.95 (1H, d, J = 2.1 Hz, H-2), 7.57 – 7.68 (3H, m, H-3’’, H-4’’ 
and H-5’’), 8.00 (2H, d, J = 6.9 Hz, H-2’’ and H-6’’), 8.22 (1H, s, H-7), 11.94 (1H, s, NH); 13C 
NMR (DMSO-d6) (ppm): 23.9 (t), 28.9 (t), 33.2 (t), 35.1 (q), 108.7 (d), 120.3 (s), 127.6 (d), 128.0 
(d x 2), 128.7 (d x 2), 129.3 (s), 133.1 (d), 138.5 (s), 140.6 (s), 142.3 (d), 149.7 (s), 150.6 (s), 157.1 
(s). 
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1-Benzyl-8-(phenylsulfonyl)-4,5,6,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-
9(1H)-one (16m). This compound was obtained from reaction of 13m. Yield: 40%, pale brown 
solid; mp: 315-316 °C; Rf: (DCM: EtOAc 8:2) 0.26; IR: 3405 (NH), 1641 (CO) cm
-1
; 
1
H NMR 
(DMSO-d6) (ppm): 2.03 (2H, t, J = 6.1 Hz, CH2), 2.12 – 2.20 (2H, m, CH2), 2.43 (2H, t, J = 6.1 Hz, 
CH2), 5.34 (2H, s, CH2), 6.14 (1H, d, J = 2.4 Hz, H-3), 6.67 – 6.75 (2H, m, H-2’ and H-6’), 7.03 – 
7.12 (3H, m, H-3’, H-4’ and H-5’), 7.16 (1H, d, J = 2.4 Hz, H-2), 7.56 – 7.70 (3H, m, H-3’’, H-4’’ 
and H-5’’), 7.87 – 7.96 (2H, m, H-2’’ and H-6’’), 8.06 (1H, s, H-7), 12.25 (1H, s, NH); 13C NMR 
(DMSO-d6) (ppm): 23.1 (t), 28.6 (t), 33.1 (t), 51.2 (t), 109.1 (d), 117.6 (s), 122.5 (s), 126.1 (d x 2), 
127.2 (d), 127.7 (d), 127.8 (d x 2), 128.0 (d), 128.1 (d x 2), 128.5 (s), 128.7 (d x 2), 129.8 (s), 130.3 
(s), 133.1 (d), 138.5 (s), 166.3 (s), 175.4 (s).  
1-(2-Methoxybenzyl)-8-(phenylsulfonyl)-4,5,6,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
b]pyridin-9(1H)-one (16n). This compound was obtained from reaction of 13n. Yield: 43%, 
yellow solid; mp: 290-291°C; Rf: (8:2 DCM: EtOAc) 0.58; IR: 3419 (NH), 1635 (CO) cm
-1
; 
1
H 
NMR (DMSO-d6) (ppm): 2.01 – 2.17 (4H, m, CH2 x 2), 2.40 (2H, m, CH2), 3.42 (3H, s, CH3), 5.21 
(2H, s, CH2), 6.11 (1H, d, J = 2.5 Hz, H-3), 6.49 (1H, d, J = 7.3 Hz, H-3’), 6.65 – 6.75 (2H, m, H-
5’ and H-6’), 7.08 (1H, d, J = 2.5 Hz, H-2), 7.11 – 7.16 (1H, m, H-4’), 7.55 – 7.73 (3H, m, H-3’’, 
H-4’’ and H-5’’), 7.96 (2H, d, J = 6.7 Hz, H-2’’ and H-6’’), 8.12 (1H, s, H-7), 12.26 (1H, s, NH); 
13
C NMR (DMSO-d6) (ppm): 22.7 (t), 32.9 (t), 46.1 (t), 54.9 (q), 71.0 (t), 109.0 (d), 110.3 (d), 120.0 
(d), 126.1 (s), 127.3 (d), 127.4 (s), 127.5 (d), 127.9 (d), 128.0 (d x 2), 128.1 (s), 128.7 (d x 2), 129.0 
(s), 130.0 (s), 133.1 (d), 140.5 (s), 143.8 (d), 145.1 (s), 155.7 (s), 157.0 (s). 
1-(3-Methoxybenzyl)-8-(phenylsulfonyl)-4,5,6,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
b]pyridin-9(1H)-one (16o). This compound was obtained from reaction of 13o. Yield: 37%, yellow 
solid; mp: 274-275°C; Rf: (8:2 DCM: EtOAc) 0.24; IR: 3406 (NH), 1634 (CO) cm
-1
; 
1
H NMR 
(DMSO-d6) (ppm): 1.96 – 2.25 (6H, m, CH2 x 3), 3.52 (3H, s, CH3), 5.32 (2H, s, CH2), 6.14 (1H, d, 
J = 2.4 Hz, H-3), 6.25 – 6.36 (2H, m, H-2’ and H-6’), 6.67 (1H, d, J = 8.0 Hz, H-4’), 7.01 (1H, t, J 
= 8.0 Hz, H-5’), 7.16 (1H, d, J = 2.4 Hz, H-2), 7.55 – 7.74 (3H, m, H-3’’, H-4’’ and H-5’’), 7.94 
(2H, d, J = 7.2 Hz, H-2’’ and H-6’’), 8.10 (1H, s, H-7), 12.29 (1H, s, NH); 13C NMR (DMSO-d6) 
(ppm): 33.1 (t), 41.3 (t), 51.2 (t), 54.7 (q), 71.1 (t), 109.1 (d), 111.4 (d), 112.8 (d), 112.9 (s), 118.2 
(d), 127.5 (s), 127.8 (d x 2), 128.2 (s), 128.7 (d x 2), 129.3 (d), 129.8 (s), 132.6 (d), 133.1 (d), 133.9 
(d), 139.8 (s), 140.6 (s), 157.1 (s), 159.1 (s), 169.1 (s). 
1-(4-methoxybenzyl)-8-(phenylsulfonyl)-4,5,6,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
b]pyridin-9(1H)-one (16p). This compound was obtained from reaction of 13p. Yield: 48%, 
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yellow solid; mp: 265-266°C; Rf: (8:2 DCM: EtOAc) 0.4; IR: 3454 (NH), 1639 (CO) cm
-1
; 
1
H 
NMR (DMSO-d6) (ppm): 2.03 – 2.17 (4H, m, CH2 x 2), 2.38 – 2.46 (2H, m, CH2), 3.64 (3H, s, 
CH3), 5.23 (2H, s, CH2), 6.11 (1H, d, J = 2.3 Hz, H-3), 6.65 – 6.69 (4H, m, Ar), 7.12 (1H, d, J = 
2.3 Hz, H-2), 7.57 – 7.70 (3H, m, H-3’’, H-4’’ and H-5’’), 7.96 (2H, d, J = 6.9 Hz, H-2’’ and H-
6’’), 8.10 (1H, s, H-7), 12.26 (1H, s, NH); 13C NMR (DMSO-d6) (ppm): 23.1 (t), 28.6 (t), 50.6 (t), 
54.9 (q), 71.1 (t), 109.0 (d), 113.5 (d), 123.0 (d), 127.4 (d x 2), 127.5 (d x 2), 127.8 (d x 2), 128.7 (d 
x 2), 130.1 (s), 133.1 (d), 134.0 (s), 140.5 (s), 140.6 (s), 146.2 (s), 152.6 (s), 157.1 (s), 158.2 (s), 
158.3 (s). 
 
9.6.2 Functionalization of Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-9(1H)-ones  
(19-20) 
To a solution of the appropriate pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridin-9(1H)-one 16d,h,l,p (0.4 
mmol) in dry DMF (8 mL), NaH (0.44 mmol) was added and the reaction mixture was stirred for 
one hour and half. Iodomethane (0.6 mmol) was added and the reaction mixture was stirred up to 
completeness. Then the reaction was poured into ice and brine, and the precipitate formed, was 
filtered and purified by chromatography column (dichloromethane). 
Ethyl 1,10-dimethyl-9-oxo-8-(phenylsulfonyl)-1,4,5,6,9,10-
hexahydropyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridine-2-carboxylate (19d). This compound was 
obtained from reaction of 16d. Yield: 30%, yellow solid; mp: 110-111°C; Rf: (8:2 DCM: EtOAc) 
0.47; IR: 1700 (CO), 1652 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.37 (3H, t, J = 7.2 Hz, CH3), 2.04 
– 2.26 (4H, m, CH2 x 2), 2.46 – 2.63 (2H, m, CH2), 3.42 (3H, s, CH3), 3.71 (3H, s, CH3), 4.32 (2H, 
q, J = 7.2 Hz, CH2), 6.90 (1H, s, H-3), 7.54 – 7.63 (3H, m, H-3’’, H-4’’ and H-5’’), 8.19 (2H, d, J = 
8.2 Hz, H-2’’ and H-6’’), 8.34 (1H, s, H-7); 13C NMR (CDCl3) (ppm): 14.8 (q), 22.0 (t), 29.7 (t), 
32.9 (t), 35.4 (q), 35.7 (q), 60.5 (t), 116.6 (d), 119.6 (s), 126.0 (s), 127.6 (s), 127.7 (s), 128.6 (d x 2), 
129.1 (s), 129.2 (d x 2), 133.4 (d), 139.6 (s), 143.6 (d), 145.3 (s), 157.9 (s), 160.8 (s). 
Ethyl 9-methoxy-1-methyl-8-(phenylsulfonyl)-1,4,5,6-
tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridine-2-carboxylate (20d). This compound was 
obtained from reaction of 16d. Yield: 59%, pale yellow solid; mp: 153-154°C; Rf: (DCM) 0.15; IR: 
1696 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.36 (3H, t, J = 7.0 Hz, CH3), 2.15 – 2.27 (2H, m, CH2), 
2.45 (2H, t, J = 6.9 Hz, CH2), 2.58 (2H, t, J = 6.9 Hz, CH2), 3.93 (3H, s, CH3), 4.11 (3H, s, CH3), 
4.31 (2H, q, J = 7.0 Hz, CH2), 6.86 (1H, s, H-3), 7.49 – 7.62 (3H, m, H-3’’, H-4’’ and H-5’’), 8.05 
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(2H, d, J = 8.2 Hz, H-2’’ and H-6’’), 8.29 (1H, s, H-7); 13C NMR (CDCl3) (ppm): 14.4 (q), 23.4 (t), 
30.3 (t), 32.6 (t), 34.5 (q), 54.1 (q), 60.0 (t), 116.8 (d), 120.4 (s), 124.8 (s), 126.5 (s), 128.6 (d x 2), 
128.7 (d x 2), 130.3 (s), 133.3 (d), 134.0 (s), 140.5 (d), 140.6 (s), 153.9 (s), 157.5 (s), 161.2 (s). 
Ethyl 9-methoxy-1-(4-methoxybenzyl)-8-(phenylsulfonyl)-1,4,5,6-
tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridine-2-carboxylate (20h). This compound was 
obtained from reaction of 16h. Yield: 73%, pale yellow solid; mp: 71-72°C; Rf: (DCM) 0.14; IR: 
1699 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.28 (3H, t, J = 7.1 Hz, CH3), 2.17 (2H, t, J = 6.8 Hz, 
CH2), 2.43 – 2.55 (4H, m, CH2 x 2), 3.61 (3H, s, CH3), 3.71 (3H, s, CH3), 4.22 (2H, q, J = 7.1 Hz, 
CH2), 5.92 (2H, s, CH2), 6.67 (2H, d, J = 8.9 Hz, H-3’ and H-5’), 6.75 (2H, d, J = 8.9 Hz, H-2’ and 
H-6’), 6.93 (1H, s, H-3), 7.46 – 7.63 (3H, m, H-3’’, H-4’’ and H-5’’), 8.00 (2H, d, J = 6.8 Hz, H-2’’ 
and H-6’’), 8.26 (1H, s, H-7); 13C NMR (CDCl3) (ppm): 14.3 (q), 23.2 (t), 29.7 (t), 32.9 (t), 48.4 (t), 
54.0 (q), 55.1 (q), 60.0 (t), 113.5 (d x 2), 117.7 (d), 120.6 (s), 120.7 (s), 124.2 (s), 126.9 (d x 2), 
128.5 (d x 2), 128.6 (d x 2), 130.1 (s), 131.6 (s), 133.3 (d), 133.9 (s), 140.5 (s), 140.6 (d), 154.0 (s), 
157.6 (s), 158.2 (s), 160.7 (s).   
1,10-Dimethyl-8-(phenylsulfonyl)-4,5,6,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
b]pyridin-9(1H)-one (19l). This compound was obtained from reaction of 16l. Yield: 20%, brown 
solid; mp: 136-137°C; Rf: (8:2 DCM: EtOAc) 0.44; IR: 1647 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 
1.62 – 1.70 (2H, m, CH2), 2.04 – 2.15 (2H, m, CH2), 2.48 – 2.62 (2H, m, CH2), 3.44 (3H, s, CH3), 
3.49 (3H, s, CH3), 6.13 (1H, d, J = 2.4 Hz, H-3), 6.77 (1H, d, J = 2.4 Hz, H-2), 7.52 – 7.59 (3H, m, 
H-3’’, H-4’’ and H-5’’), 8.15 – 8.22 (2H, m, H-2’’ and H-6’’), 8.30 (1H, s, H-7); 13C NMR (CDCl3) 
(ppm): 22.5 (t), 29.7 (t), 33.7 (t), 35.4 (q), 35.7 (q), 109.3 (d), 119.0 (s), 122.7 (s), 125.6 (s), 126.2 
(d), 128.5 (d x 2), 129.1 (d x 2), 129.8 (s), 133.2 (d), 140.0 (s), 143.6 (d), 147.3 (s), 158.3 (s). 
9-Methoxy-1-methyl-8-(phenylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
b]pyridine (20l). This compound was obtained from reaction of 16l. Yield: 74%, yellow solid; mp: 
188-189°C; Rf: (DCM) 0.26; 
1
H NMR (CDCl3) (ppm): 2.10 – 2.20 (2H, m, CH2), 2.60 – 2.70 (4H, 
m, CH2 x 2), 3.88 (3H, s, CH3), 3.91 (3H, s, CH3), 6.05 (1H, d, J = 2.5 Hz, H-3), 6.71 (2H, d, J = 
2.5 Hz, H-2), 7.46 – 7.59 (3H, m, H-3’’, H-4’’ and H-5’’), 8.03 (2H, d, J = 8.3 Hz, H-2’’ and H-
6’’), 8.18 (1H, s, H-7); 13C NMR (CDCl3) (ppm): 25.6 (t), 31.0 (t), 31.4 (t), 37.0 (q), 54.0 (q), 108.9 
(d), 118.0 (s), 126.9 (d), 127.2 (s), 128.4 (d x 2), 128.5 (d x 2), 128.8 (s), 128.9 (s), 133.0 (d), 140.0 
(d), 141.1 (s), 154.6 (s), 157.3 (s).  
9-methoxy-1-(4-methoxybenzyl)-8-(phenylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3',2':6,7] 
cyclohepta[1,2-b]pyridine (20p). This compound was obtained from reaction of 16p. Yield: 68%, 
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pale yellow solid; mp: 92-93°C; Rf: (DCM) 0.22; 
1
H NMR (CDCl3) (ppm): 2.18 (2H, t, J = 6.0 Hz, 
CH2), 2.54 – 2.61 (4H, m, CH2 x 2), 3.69 (3H, s, CH3), 3.74 (3H, s, CH3), 5.45 (2H, s, CH2), 6.11 
(1H, d, J = 2.6 Hz, H-3), 6.70 – 6.75 (3H, m, H-2, H-3’ and H-5’), 6.88 (2H, d, J = 8.7 Hz, H-2’ 
and H-6’), 7.44 – 7.61 (3H, m, H-3’’, H-4’’ and H-5’’), 7.97 – 8.02 (2H, m, H-2’’ and H-6’’), 8.17 
(1H, s H-7); 
13
C NMR (CDCl3) (ppm): 24.9 (t), 31.1 (t), 32.2 (t), 50.9 (t), 53.8 (q), 55.2 (q), 109.6 
(d), 113.8 (d x 2), 118.3 (s), 125.7 (d), 127.3 (s), 127.7 (d x 2), 128.4 (d x 2), 128.5 (d x 2), 128.9 
(s), 129.0 (s), 131.0 (d), 133.0 (s), 140.1 (d), 141.0 (s), 154.9 (s), 157.5 (s), 158.7 (s). 
 
9.7.1 Preparation of Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (21) 
To a solution of the appropriate enaminone 13 or hydroxymethylenketones 14 (1.5 mmol) in 
ethanol (6 mL), and acetic acid (3 mL), hydroxylamine hydrochloride (1.65 mmol) was added and 
the reaction mixture was heated to reflux for one hour. Then the reaction mixture was poured into 
ice and brine, and in the case of formation of a precipitate, the solid was filtered. In the absence of 
precipitate, the aqueous solution was extracted with dichloromethane (3 x 20 mL). The organic 
phase was dried over Na2SO4 and the solvent evaporated at reduced pressure. The crude product 
was then purified by chromatography column (dichloromethane : ethyl acetate 95 : 5). 
9-(Phenylsulfonyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (21b). 
This compound was obtained from reaction of 13b. Yield: 60%, orange solid; mp: 140.3 – 141.0 
°C; 
1
H NMR (CDCl3) (ppm): 1.88 – 1.98 (2H, m, CH2), 2.65 – 2.77 (4H, m, CH2 x 2), 6.20 (1H, d, 
J = 3.3 Hz, H-7), 7.49 – 7.62 (4H, m, H-8, H-3’, H-4’ and H-5’), 7.96 (1H, s, H-3), 8.06 (2H, d, J = 
7.9 Hz, H-2’ and H-6’); 13C NMR (CDCl3) (ppm): 23.5 (t), 23.7 (t), 28.0 (t), 113.1 (d), 113.9 (s), 
118.9 (s), 125.6 (d), 128.1 (d x 2), 128.9 (d x 2), 133.1 (s), 133.8 (d), 138.9 (s), 151.5 (d), 156.1 (s). 
Ethyl 9-methyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-8-
carboxylate (21d). This compound was obtained from reaction of 14d. Yield: 90%, white solid; 
mp: 91.7 °C IR: 1699 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.36 (3H, t, J = 7.1 Hz, CH3), 1.89 – 
2.00 (2H, m, CH2), 2.74 – 2.85 (4H, m, CH2 x 2), 4.24 – 4.35 (5H, m, CH2 and CH3), 6.76 (1H, s, 
H-7), 8.08 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 14.4 (q), 23.4 (t), 24.5 (t), 28.1 (t), 35.2 (q), 60.1 
(t), 114.8 (s), 114.9 (s), 118.0 (d), 124.2 (s), 126.1 (s), 151.8 (d), 158.3 (s), 161.1 (s). 
Ethyl 9-benzyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-8-carboxylate 
(21e). This compound was obtained from reaction of 14e. Yield: 60%, grey solid; mp: 149.4 °C IR: 
1695 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.30 (3H, t, J = 7.1 Hz, CH3), 1.92 – 2.00 (2H, m, CH2), 
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2.71 – 2.89 (4H, m, CH2 x 2), 4.24 (2H, q, J = 7.1 Hz, CH2), 6.17 (2H, s, CH2), 6.87 (1H, s, H-7), 
6.99 – 7.07 (2H, m, H-2’ and H-6’), 7.13 – 7.30 (3H, m, H-3’, H-4’ and H-5’), 8.00 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 23.4 (t), 24.5 (t), 28.2 (t), 50.1 (t), 60.2 (t), 115.1 (s), 119.0 (d), 
124.2 (s), 125.5 (s), 126.1 (d x 2), 126.7 (s), 126.8 (d), 128.3 (d x 2), 139.0 (s), 151.7 (d), 157.8 (s), 
160.8 (s). 
Ethyl 9-(2-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-
8-carboxylate (21f). This compound was obtained from reaction of 14f. Yield: 60%, white solid; 
mp: 137.5 – 138.3 °C IR: 1700 (CO) cm-1; 1H NMR (CDCl3) (ppm): 1.26 (3H, t, J = 7.1 Hz, CH3), 
1.89 – 2.06 (2H, m, CH2), 2.77 (2H, t, J = 6.1 Hz, CH2), 2.86 (2H, t, J = 6.1 Hz, CH2), 3.89 (3H, s, 
CH3), 4.20 (2H, q, J = 7.1 Hz, CH2), 6.11 (2H, s, CH2), 6.29 (1H, d, J = 7.5 Hz, H-3’), 6.68 – 6.88 
(3H, m, H-7, H-5’, H-6’), 7.13 (1H, t, J = 8.1 Hz, H-4’), 7.97 (1H, s, H-3); 13C NMR (CDCl3) 
(ppm): 14.2 (q), 23.5 (t), 24.5 (t), 28.2 (t), 46.5 (t), 55.3 (q), 60.1 (t), 109.8 (d), 114.9 (s), 118.8 (d), 
120.3 (d), 124.7 (s), 125.0 (d), 125.8 (s), 126.5 (s), 127.5 (d), 128.0 (s), 151.6 (d), 156.2 (s), 158.0 
(s), 160.6 (s). 
Ethyl 9-(3-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-
8-carboxylate (21g). This compound was obtained from reaction of 14g. Yield: 82%, pale yellow 
solid; mp: 98 – 98.4 °C IR: 1696 (CO) cm-1; 1H NMR (CDCl3) (ppm): 1.30 (3H, t, J = 7.1 Hz, 
CH3), 1.91 – 2.00 (2H, m, CH2), 2.72 – 2.87 (4H, m, CH2 x 2), 3.71 (3H, s, CH3), 4.24 (2H, q, J = 
7.1 Hz, CH2), 6.15 (2H, s, CH2), 6.54 – 6.73 (3H, m, H-2’, H-4’ and H-6’), 6.86 (1H, s, H-7), 7.14 
(1H, t, J = 7.9 Hz, H-5’), 8.00 (1H, s, H-3); 13C NMR (CDCl3) (ppm): 14.3 (q), 23.4 (t), 24.5 (t), 
28.2 (t), 49.9 (t), 55.0 (q), 60.2 (t), 111.8 (d), 112.0 (d), 115.0 (s), 118.4 (d), 119.0 (d), 124.3 (s), 
125.5 (s), 126.7 (s), 129.3 (d), 140.7 (s), 151.7 (d), 157.8 (s), 159.6 (s), 160.8 (s). 
Ethyl 9-(4-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-
8-carboxylate (21h). This compound was obtained from reaction of 14h. Yield: 81%, white solid; 
mp: 94.9 °C IR: 1690 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.32 (3H, t, J = 7.1 Hz, CH3), 1.88 – 
1.99 (2H, m, CH2), 2.72 – 2.86 (4H, m, CH2 x 2), 3.74 (3H, s, CH3), 4.26 (2H, q, J = 7.1 Hz, CH2), 
6.09 (2H, s, CH2), 6.76 (2H, d, J = 6.8 Hz, H-3’ and H-5’), 6.85 (1H, s, H-7), 7.01 (2H, d, J = 8.6 
Hz, H-2’ and H-6’), 8.02 (1H, s, H-3); 13C NMR (CDCl3) (ppm): 14.3 (q), 23.4 (t), 24.5 (t), 28.2 (t), 
49.4 (t), 55.1 (q), 60.2 (t), 113.7 (d x 2), 115.0 (s), 119.0 (d), 124.3 (s), 125.5 (s), 126.7 (s), 127.6 (d 
x 2), 131.1 (s), 151.8 (d), 157.8 (s), 158.4 (s), 160.9 (s). 
Ethyl 9-(2,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (21i). This compound was obtained from reaction of 14i. Yield: 74%, 
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white solid; mp: 94.9 °C IR: 1690 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.26 (3H, t, J = 7.1 Hz, 
CH3), 1.93 – 2.02 (2H, m, CH2), 2.74 – 2.88 (4H, m, CH2 x 2), 3.60 (3H, s, CH3), 3.85 (3H, s, CH3), 
4.20 (2H, q, J = 7.1 Hz, CH2), 5.91 (1H, d, J = 2.6 Hz, H-6’), 6.08 (2H, s, CH2), 6.63 (1H, dd, J = 
8.7, 2.6 Hz, H-4’), 6.76 (1H, d, J = 8.7 Hz, H-3’), 6.87 (1H, s, H-7), 7.97 (1H, s, H-3); 13C NMR 
(CDCl3) (ppm): 14.2 (q), 23.5 (t), 24.5 (t), 28.2 (t), 46.5 (t), 55.4 (q), 55.9 (q), 60.1 (t), 110.4 (d), 
110.6 (d), 112.6 (d), 114.9 (s), 118.9 (d), 124.5 (s), 125.6 (s), 126.5 (s), 129.5 (s), 150.6 (s), 151.6 
(d), 153.5 (s), 157.9 (s), 160.6 (s).  
Ethyl 9-(3,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (21j). This compound was obtained from reaction of 14j. Yield: 
82%, white solid; mp: 114 °C IR: 1701 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.31 (3H, t, J = 7.1 
Hz, CH3), 1.92 – 2.00 (2H, m, CH2), 2.64 – 2.86 (4H, m, CH2 x 2), 3.70 (6H, s, CH3 x 2), 4.24 (2H, 
q, J = 7.1 Hz, CH2), 6.07 – 6.28 (4H, m, CH2, H-2’ and H-6’), 6.26 (1H, s, H-4’), 6.86 (1H, s, H-7), 
8.00 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 23.4 (t), 24.5 (t), 28.2 (t), 50.0 (t), 55.2 (q x 
2), 60.2 (t), 98.6 (d), 100.0 (s), 104.1 (d x 2), 115.1 (s), 119.1 (d), 124.2 (s), 126.7 (s), 141.6 (s), 
151.7 (d), 157.8 (s), 160.7 (s x 2), 160.8 (s). 
Ethyl 9-(3,4,5-trimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (21k). This compound was obtained from reaction of 14k. Yield: 
72%, pale yellow solid; mp: 112.9 – 113.1 °C IR: 1696 (CO) cm-1; 1H NMR (CDCl3) (ppm): 1.33 
(3H, t, J = 7.1 Hz, CH3), 1.88 – 1.99 (2H, m, CH2), 2.73 – 2.87 (4H, m, CH2 x 2), 3.72 (6H, s, CH3 
x 2), 3.77 (3H, s, CH3), 4.28 (2H, q, J = 7.1 Hz, CH2), 6.11 (2H, s, CH2), 6.29 (2H, s, H-2’ and H-
6’), 6.86 (1H, s, H-7), 8.04 (1H, s, H-3); 13C NMR (CDCl3) (ppm): 14.4 (q), 23.6 (t), 24.5 (t), 28.1 
(t), 49.8 (t), 55.9 (q x 2), 60.3 (t), 60.8 (q), 100.0 (s), 103.5 (d x 2), 115.1 (s), 119.1 (d), 124.2 (s), 
125.5 (s), 126.9 (s), 134.6 (s), 151.8 (d), 153.1 (s x 2), 157.8 (s), 161.0 (s).  
9-Methyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (21l). This 
compound was obtained from reaction of 13l. Yield: 75%, white solid; mp: 60.4 °C; 
1
H NMR 
(CDCl3) (ppm): 1.89 – 2.00 (2H, m, CH2), 2.74 (2H, t, J = 6.0 Hz, CH2), 2.87 (2H, J = 6.0 Hz, 
CH2), 3.95 (3H, s, CH3), 5.95 (1H, d, J = 2.5 Hz, H-7), 6.58 (1H, d, J = 2.5 Hz, H-8), 8.01 (1H, s, 
H-3); 
13
C NMR (CDCl3) (ppm): 23.2 (t), 24.4 (t), 28.8 (t), 37.6 (q), 99.9 (s), 109.3 (d), 111.1 (s), 
125.5 (d), 127.3 (s), 151.4 (d), 159.7 (s).  
9-Benzyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (21m). This 
compound was obtained from reaction of 13m. Yield: 83%, pale yellow solid; mp: 61.3°C; 
1
H 
NMR (CDCl3) (ppm): 1.88 – 2.00 (2H, m, CH2), 2.72 (2H, t, J = 6.2 Hz, CH2), 288 (2H, t, J = 6.2 
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Hz, CH2), 5.52 (2H, s, CH2), 6.02 (1H, d, J = 2.6 Hz, H-7), 6.67 (1H, d, J = 2.6 Hz, H-8), 7.12 – 
7.33 (5H, m, Ar), 7.94 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 23.1 (t), 24.3 (t), 28.8 (t), 53.0 (t), 
110.2 (d), 111.4 (s), 119.1 (s), 125.2 (d), 126.9 (d x 2), 127.3 (d), 127.7 (s), 128.5 (d x 2), 138.3 (s), 
151.4 (d), 159.3 (s).  
9-(2-Methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (21n). 
This compound was obtained from reaction of 13n. Yield: 70%, pale yellow solid; mp: 80.4°C; 
1
H 
NMR (CDCl3) (ppm): 1.91 – 2.02 (2H, m, CH2), 2.74 (2H, t, J = 5.5 Hz, CH2), 2.90 (2H, t, J = 5.5 
Hz, CH2), 3.87 (3H, s, CH3), 5.54 (2H, s, CH2), 6.01 (1H, d, J = 2.6 Hz, H-7) 6.65 (1H, d, J = 2.6 
Hz, H-8), 6.71 – 6.89 (3H, m, Ar), 7.15 – 7.23 (1H, m, Ar), 7.95 (1H, s, H-3); 13C NMR (CDCl3) 
(ppm): 23.2 (t), 24.4 (t), 28.8 (t), 48.2 (t), 55.3 (q), 109.9 (d), 110.0 (d), 111.2 (s), 119.2 (s), 120.6 
(d), 125.3 (d), 127.0 (s), 127.3 (s), 127.5 (d), 128.4 (d), 151.3 (d), 156.5 (s), 159.5 (s). 
9-(3-Methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (21o). 
This compound was obtained from reaction of 13o. Yield: 83%, pale yellow solid; mp: 67.6 °C; 
1
H 
NMR (CDCl3) (ppm): 1.89 – 2.00 (2H, m, CH2), 2.73 (2H, t, J = 5.5 Hz, CH2), 2.88 (2H, t, J = 5.5 
Hz, CH2), 3.74 (3H, s, CH3), 5.50 (2H, s, CH2), 6.02 (1H, d, J = 2.6 Hz, H-7) 6.68 (1H, d, J = 2.6 
Hz, H-8), 6.71 – 6.78 (3H, m, H-2’, H-4’ and H-6’), 7.20 (1H, t, J = 7.9 Hz, H-5’), 7.95 (1H, s, H-
3); 
13
C NMR (CDCl3) (ppm): 23.2 (t), 24.4 (t), 28.8 (t), 52.9 (t), 55.1 (q), 110.2 (d), 111.4 (s), 112.5 
(d), 112.7 (d), 119.1 (s), 119.2 (d), 125.2 (d), 127.7 (s), 129.6 (d), 140.0 (s), 151.4 (d), 159.3 (s), 
159.7 (s). 
9-(4-Methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (21p). 
This compound was obtained from reaction of 13p. Yield: 68%, pale yellow solid; mp: 101 °C; 
1
H 
NMR (CDCl3) (ppm): 1.88 – 1.99 (2H, m, CH2), 2.73 (2H, t, J = 5.8 Hz, CH2), 2.88 (2H, t, J = 5.8 
Hz, CH2), 3.76 (3H, s, CH3), 5.45 (2H, s, CH2), 6.01 (1H, d, J = 2.5 Hz, H-7) 6.68 (1H, d, J = 2.5 
Hz, H-8), 6.82 (2H, d, J = 8.5 Hz, H-3’ and H-5’), 7.12 (2H, d, J = 8.5 Hz, H-2’ and H-6’), 7.95 
(1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 23.2 (t), 24.4 (t), 28.8 (t), 52.5 (t), 55.2 (q), 110.0 (d), 111.5 
(s), 113.9 (d x 2), 118.9 (s), 124.9 (d), 127.7 (s), 128.5 (d x 2), 130.2 (s), 151.9 (d), 158.8 (s), 156.9 
(s).  
9-(2,5-Dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole 
(21q). This compound was obtained from reaction of 13q. Yield: 78%, white solid; mp: 116.6°C 
1
H 
NMR (CDCl3) (ppm): 1.90 – 2.01 (2H, m, CH2), 2.74 (2H, t, J = 6.2 Hz, CH2), 2.89 (2H, t, J = 6.2 
Hz, CH2), 3.63 (3H, s, CH3), 3.83 (3H, s, CH3), 5.51 (2H, s, CH2), 6.00 (1H, d, J = 2.6 Hz, H-7), 
6.29 (1H, d, J = 2.6 Hz, H-8), 6.67 – 6.82 (3H, m, H-3’, H-4’ and H-6’), 7.95 (1H, s, H-3); 13C 
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NMR (CDCl3) (ppm): 23.2 (t), 24.4 (t), 28.8 (t), 48.2 (t), 55.5 (q), 55.9 (q), 110.6 (d), 110.9 (d), 
111.2 (s), 112.1 (d), 114.0 (d), 119.2 (s), 125.4 (d), 127.4 (s), 128.2 (s), 150.8 (s), 151.3 (d), 153.6 
(s), 159.4 (s).  
9-(3,5-Dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole 
(21r). This compound was obtained from reaction of 13r. Yield: 76%, yellow solid; mp: 118.6°C 
1
H NMR (CDCl3) (ppm): 1.89 – 2.00 (2H, m, CH2), 2.73 (2H, t, J = 6.0 Hz, CH2), 2.88 (2H, t, J = 
6.0 Hz, CH2), 3.72 (6H, s, 2 x CH3), 5.46 (2H, s, CH2), 6.01 (1H, d, J = 2.6 Hz, H-7), 6.27 (2H, d, J 
= 2.2 Hz, H-2’, H-6’), 6.32 (1H, t, J = 2.2 Hz, H-4’), 6.67 (1H, d, J = 2.6 Hz, H-8), 7.95 (1H, s, H-
3); 
13
C NMR (CDCl3) (ppm): 23.2 (t), 24.3 (t), 28.8 (t), 53.0 (t), 55.2 (q x 2), 99.1 (d), 104.8 (d x 2), 
110.2 (d), 111.4 (s), 119.1 (s), 125.2 (d), 127.7 (s), 140. 8 (s), 151.4 (d), 159.3 (s), 160.9 (s x 2).   
9-(3,4,5-Trimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole 
(21s). This compound was obtained from reaction of 13s. Yield: 74%, white solid; mp: 104.5 °C IR: 
1683 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.89 – 2.00 (2H, m, CH2), 2.74 (2H, t, J = 6.0 Hz, CH2), 
2.88 (2H, t, J = 6.0 Hz, CH2), 3.77 (6H, s, CH3 x 2), 3.80 (3H, s, CH3), 5.45 (2H, s, CH2), 6.02 (1H, 
d, J = 2.6 Hz, H-7), 6.39 (2H, s, H-2’ and H-6’), 6.69 (1H, d, J = 2.6 Hz, H-8), 7.97 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 23.3 (t), 24.4 (t), 28.8 (t), 53.2 (t), 56.0 (q x 2), 60.8 (q), 104.1 (d x 2), 
110.2 (d), 111.5 (s), 119.1 (s), 125.1 (d), 127.9 (s), 133.8 (s), 137.1 (s), 151.5 (d), 153.3 (s x 2), 
159.3 (s).  
Methyl 9-benzyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-8-
carboxylate (21t). This compound was obtained from reaction of 13t (crude product). Yield: 72%, 
white solid; mp: 150.3 °C 
1
H NMR (CDCl3) (ppm): 1.89 – 2.00 (2H, m, CH2), 2.77 (2H, t, J = 6.2 
Hz, CH2), 2.84 (2H, t, J = 6.2 Hz, CH2), 3.78 (3H, s, CH3), 6.17 (2H, s, CH2), 6.86 (1H, s, H-7), 
6.98 (2H, s, J = 9.7 Hz, H-2’ and H-6’), 7.12 – 7.28 (3H, m, H-3’, H-4’ and H-5’), 8.01 (1H, s, H-
3); 
13
C NMR (CDCl3) (ppm): 23.3 (t), 24.5 (t), 28.1 (t), 50.0 (t), 51.3 (q), 115.1 (s), 119.1 (d), 123.8 
(s), 125.6 (s), 126.0 (d x 2), 126.7 (s), 126.8 (d), 128.3 (d x 2), 138.9 (s), 151.7 (d), 157.7 (s), 161.2 
(s).   
 
9.7.2  Preparation of chloro-pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (22) 
To a solution of 21 (1 mmol) in dry DMF (5 mL), was added a solution of  N-chlorosuccinimide 
(1.5 mmol) in dry DMF (2 mL) and the reaction mixture was stirred for one night at room 
temperature (16 hours). Then, the reaction mixture was poured into ice and brine, and in the case of 
formation of a precipitate, the solid was filtered. In the absence of precipitate, the aqueous solution 
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was extracted with dichloromethane (3 x 30 mL). The organic phase was dried over Na2SO4 and the 
solvent evaporated at reduced pressure. The crude product was then purified by chromatography 
column (dichloromethane : ethyl acetate 98 : 2). 
Ethyl 7-chloro-9-methyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-8-
carboxylate (22d). This compound was obtained from reaction of 21d. Yield: 50%, white solid; 
mp: 88.2 °C IR: 1695 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.43 (3H, t, J = 7.1 Hz, CH3), 1.94 – 
2.04 (2H, m, CH2), 2.77 – 2.89 (4H, m, CH2 x 2), 4.29 (3H, s, CH3), 4.40 (2H, q, J = 7.1 Hz, CH2), 
8.08 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 14.4 (q), 23.3 (t), 24.6 (t), 25.4 (t), 36.2 (q), 60.7 (t), 
115.7 (s), 119.5 (s), 121.4 (s), 124.1 (s), 124.5 (s), 151.7 (d), 157.7 (s), 160.6 (s). 
Ethyl 7-chloro-9-benzyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole-8-
carboxylate (22e).  This compound was obtained from reaction of 21e. Yield: 57%, white solid; 
mp: 141.8 – 142.4 °C; IR: 1696 (CO) cm-1; 1H NMR (CDCl3) (ppm): 1.32 (3H, t, J = 7.1 Hz, CH3), 
1.90 – 2.02 (2H, m, CH2), 2.73 – 2.89 (4H, m, CH2 x 2), 4.30 (2H, q, J = 7.1 Hz, CH2), 6.12 (2H, s, 
CH2), 6.99 (2H, d, J = 7.2 Hz, H-2’, H-6’), 7.14 – 7.26 (3H, m, H-3’, H-4’, H-5’), 8.02 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 14.2 (q), 23.1 (t), 24.4 (t), 25.3 (t), 50.8 (t), 60.8 (t), 116.1 (s), 120.4 (s), 
121.2 (s), 124.1 (s), 124.8 (s), 126.0 (d x 2), 127.0 (d), 128.4 (d x 2), 138.5 (s), 151.7 (d), 157.0 (s), 
160.3 (s). 
Ethyl 7-chloro-9-(2-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (22f). This compound was obtained from reaction of 21f. Yield: 
74%,  yellow solid; mp: 159.8 °C; IR: 1696 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.26 (3H, t, J = 
7.1 Hz, CH3), 1.92 – 2.03 (2H, m, CH2), 2.77 (2H, t,  J = 5.8 Hz, CH2), 2.87 (2H, t, J = 5.8 Hz, 
CH2), 3.85 (3H, s, CH3), 4.26 (2H, q, J = 7.1 Hz, CH2), 6.05 (2H, s, CH2), 6.41 (1H, d, J = 7.4 Hz, 
H-3’), 6.71 – 6.85 (2H, m, H-5’ and H-6’), 7.14 (1H, t, J = 7.4 Hz, H-4’), 8.00 (1H, s, H-3); 13C 
NMR (CDCl3) (ppm): 14.0 (q), 23.2 (t), 24.4 (t), 25.3 (t), 42.3 (t), 55.3 (q), 60.7 (t), 109.8 (d), 115.8 
(s), 120.0 (s), 120.4 (d), 121.5 (s), 124.3 (s), 124.5 (s), 125.4 (d), 127.4 (s), 127.8 (d), 151.6 (d), 
156.2 (s), 157.2 (s), 160.1 (s).   
Ethyl 7-chloro-9-(3-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (22g). This compound was obtained from reaction of 21g. Yield: 
65%, green solid; mp: 92.8 – 93.5 °C; IR: 1695 (CO) cm-1; 1H NMR (CDCl3) (ppm): 1.33 (3H, t, J 
= 7.1 Hz, CH3), 1.90 – 2.02 (2H, m, CH2), 2.73 – 2.89 (4H, m, CH2 x 2), 3.72 (3H, s, CH3), 4.30 
(2H, q, J = 7.1 Hz, CH2), 6.10 (2H, s, CH2), 6.53 – 6.61 (2H, m, H-2’, H-6’), 6.70 (1H, dd, J = 7.9, 
2.3 Hz, H-4’), 7.15 (1H, t, J = 7.9 Hz, H-5’), 8.03 (1H, s, H-3); 13C NMR (CDCl3) (ppm): 14.2 (q), 
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23.1 (t), 24.4 (t), 25.3 (t), 50.6 (t), 55.1 (q), 60.8 (t), 111.9 (d), 112.1 (d), 116.1 (s), 118.3 (d), 120.4 
(s), 121.1 (s), 124.7 (s), 129.4 (d), 138.4 (s), 140.2 (s), 151.7 (d), 157.0 (s), 159.6 (s), 160.3 (s).  
Ethyl 7-chloro-9-(4-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (22h). This compound was obtained from reaction of 21h. Yield: 
70%, white solid; mp: 118.1 °C; IR: 1695 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.34 (3H, t, J = 7.1 
Hz, CH3), 1.89 – 2.01 (2H, m, CH2), 2.73 – 2.87 (4H, m, CH2 x 2), 3.73 (3H, s, CH3), 4.32 (2H, q, J 
= 7.1 Hz, CH2), 6.05 (2H, s, CH2), 6.76 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.97 (2H, d, J = 8.7 Hz, 
H-2’ and H-6’), 8.04 (1H, s, H-3); 13C NMR (CDCl3) (ppm): 14.2 (q), 23.1 (t), 24.4 (t), 25.3 (t), 
50.1 (t), 55.2 (t), 60.8 (q), 113.8 (d x 2), 116.1 (s), 120.3 (s), 121.1 (s), 123.9 (s), 124.8 (s), 127.6 (d 
x 2), 130.6 (s), 151.8 (d), 151.1 (s), 158.6 (s), 160.4 (s). 
Ethyl 7-chloro-9-(2,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (22i). This compound was obtained from reaction of 21i. Yield: 68%,  
white solid; mp: 147.2 °C IR: 1696 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.28 (3H, t, J = 7.1 Hz, 
CH3), 1.92 – 2.03 (2H, m, CH2), 2.77 (2H, t, J = 6.0 Hz, CH2), 2.86 (2H, t, J = 6.0 Hz, CH2), 3.62 
(3H, s, CH3), 3.82 (3H, s, CH3), 4.27 (2H, q, J = 7.1 Hz, CH2), 5.98 – 6.06 (3H, m, CH2 and H-6’), 
6.65 (1H, dd, J = 8.8, 2.6 Hz, H-4’), 6.76 (1H, d, J = 8.8 Hz, H-3’), 8.01 (1H, s, H-3); 13C NMR 
(CDCl3) (ppm): 14.0 (q), 23.1 (t), 24.4 (t), 25.3 (t), 47.2 (t), 55.5 (q), 55.8 (q), 60.7 (t), 110.5 (d), 
110.7 (d), 113.0 (d), 115.9 (s), 120.2 (s), 121.3 (s), 124.2 (s), 124.5 (s), 128.8 (s), 150.6 (s), 151.6 
(d), 153.4 (s), 157.1 (s), 160.0 (s).   
Ethyl 7-chloro-9-(3,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-
d][1,2]oxazole-8-carboxylate (22j). This compound was obtained from reaction of 21j. Yield: 
70%, white solid; mp: 165.5 °C; IR: 1701 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.26 (3H, t, J = 7.1 
Hz, CH3), 1.94 – 2.03 (2H, m, CH2), 2.79 (2H, t, J = 6.0 Hz, CH2), 2.87 (2H, t, J = 6.0 Hz, CH2), 
3.58 (3H, s, CH3), 3.87 (3H, s, CH3), 4.21 (2H, q, J = 7.1 Hz, CH2), 5.50 (1H, d, J = 2.6 Hz, H-2’), 
6.13 (2H, s, CH2), 6.34 (1H, d, J = 2.6 Hz, H-6’), 6.91 (1H, s, H-4’), 7.99 (1H, s, H-3); 
13
C NMR 
(CDCl3) (ppm): 14.2 (q), 23.4 (t), 24.5 (t), 28.2 (t), 49.1 (t), 55.2 (q), 56.2 (q), 60.2 (t), 97.2 (d), 
102.9 (d), 111.7 (s), 115.1 (s), 119.1 (d), 124.5 (s), 125.7 (s), 126.6 (s), 139.2 (s), 151.6 (d), 155.7 
(s), 157.6 (s), 158.9 (s), 160.5 (s). 
8-Chloro-9-methyl-4,5,6,9-tetrahydropyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazole (22l). This 
compound was obtained from reaction of 21l. Yield: 49%, white solid; mp: 66.9 – 67.2 °C; 1H 
NMR (CDCl3) (ppm): 1.87 – 1.99 (2H, m, CH2), 2.71 – 2.83 (4H, m, CH2 x 2), 3.92 (3H, s, CH3), 
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5.95 (1H, s, H-7), 8.02 (1H, s, H-3); 
13
C NMR (CDCl3) (ppm): 23.2 (t), 24.3 (t), 28.6 (t), 33.6 (q), 
99.9 (s), 108.4 (d), 111.4 (s), 120.2 (s), 126.2 (s), 151.5 (d), 158.9 (s).  
 
9.8 Preparation of Pyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidin-2-amine (24-29) 
 
 General synthesis for the amine derivates 24 
To a suspension of sodium methoxide (20 mmol) in dry ethanol (15 mL), guanidine nitrate (10 
mmol) and a solution of appropriate enaminone 13 (2 mmol) in dry ethanol (20 mL) were added. 
The reaction mixture was heated to reflux for 1 hour and 45 minutes. After completeness the 
reaction mixture was poured into brine (50 mL), and the precipitate formed, was purified by 
chromatography column (dichloromethane ethyl acetate 8:2). 
 General synthesis for the substituted amine derivates 25-26 
A solution of appropriate enaminone 13 (1.5 mmol) and phenylguanidine (in the case of derivates 
25) or cycloesilguanidine (in the case of derivates 26) (4.5 mmol) in dry DMF (8 mL), was heated 
at 100 °C for 2 hours. After completeness the reaction mixture was poured into brine (20 mL) and 
the precipitate formed, was purified by chromatography column (dichloromethane).  
 General synthesis for the carboxamide derivates 27-29 
To a solution of NaOH (0.5 mmol), in ethanol (5 mL), a solution of starting material of type 24, 25 
or 26, in ethanol (8 mL) was added, and the reaction mixture was heated to reflux for 3 hours. After 
cooling the solution was evaporated. Water (10 mL) was added, and the mixture was acidified with 
HCl 6M. The solution was extracted with dichloromethane, and the organic phase was collected, 
dried on Na2SO4 and the solvent removed in vacuo, to give the crude acid derivative product which 
was taken up immediately onto next step. 
N,N-diisopropylethylamine (0.55 mmol), 1-hydroxybenzotriazole (0.55 mmol), and EDC (0.55 
mmol) were added to a stirred suspension of the above product in anhydrous THF (8 mL). The 
reaction mixture was stirred at room temperature for ten minutes. Ammonium carbonate (1.5 mmol) 
was added in one portion, and the resulting suspension was stirred at room temperature overnight 
(16 hours). The reaction mixture was concentrated, and a oversatured solution of Na2CO3 (15 mL) 
was added, and stirring was continued for other 2 hours. The suspension was filtered and the solid 
was purified by flash column chromatography (dichloromethane ethyl acetate 8:2). 
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ethyl 2-amino-10-methyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-9-
carboxylate (24d) This compound was obtained from reaction of 13d. Yield: 59%, white solid; mp: 
212 °C; Rf: (DCM : EtOAc 8:2) 0.12; IR: 3520 - 3412 (NH2), 1696 (CO) cm
-1
; 
1
H NMR (CDCl3) 
(ppm): 1.36 (3H, t, J = 7.1 Hz, CH3), 2.03 – 2.16 (2H, m, CH2), 2.42 (2H, t, J = 6.9 Hz, CH2), 2.49 
(2H, t, J = 6.9 Hz, CH2), 4.16 (3H, s, CH3), 4.30 (2H, q, J = 7.1 Hz, CH2), 5.01 (2H, bs, NH2), 6.85 
(1H, s, H-8), 8.17 (1H, s, H-4); 
13
C NMR (CDCl3) (ppm): 14.4 (q), 23.5 (t), 27.4 (t), 31.7 (t), 34.6 
(q), 60.0 (t), 116.8 (d), 123.9 (s), 124.9 (s), 126.6 (s), 133.4 (s), 158.4 (d), 159.5 (s), 161.2 (s), 161.4 
(s). 
ethyl 2-amino-10-benzyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-9-
carboxylate (24e) This compound was obtained from reaction of 13e. Yield: 40%, white solid; mp: 
150 – 151 °C; Rf: (DCM : EtOAc 8:2) 0.23; IR: 3523 - 3411 (NH2), 1700 (CO) cm
-1
; 
1
H NMR 
(CDCl3) (ppm): 1.29 (3H, t, J = 7.1 Hz, CH3), 2.07 – 2.14 (2H, m, CH2), 2.36 (2H, t, J = 6.9 Hz, 
CH2), 2.51 (2H, t, J = 6.9 Hz, CH2), 4.24 (2H, q, J = 7.1 Hz, CH2), 4.92 (2H, bs, NH2), 6.13 (2H, s, 
CH2), 6.85 (2H, d, J = 7.8 Hz, H-2’, H-6’), 6.93 (1H, s, H-8), 7.10 – 7.17 (3H, m, H-3’, H-4’, H-5’), 
8.12 (1H, s, H-4); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 23.5 (t), 27.3 (t), 31.8 (t), 48.7 (t), 60.0 (t), 
117.9 (d), 123.6 (s), 124.7 (s), 126.0 (d x 2), 126.6 (d), 127.3 (s), 128.2 (d x 2), 133.4 (s), 139.7 (s), 
158.5 (d), 159.5 (s), 160.9 (s), 161.4 (s).   
Ethyl 2-amino-10-(4-methoxybenzyl)-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidine-9-carboxylate (24h). This compound was obtained from reaction of 13h. Yield: 
50%, white solid; mp: 78 – 79 °C; Rf: (DCM : EtOAc 8:2) 0.19; IR: 3512 - 3411 (NH2) 1696 (CO) 
cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.31 (3H, t, J = 7.1 Hz, CH3), 2.06 – 2.16 (2H, m, CH2), 2.34 (2H, t, 
J = 6.7 Hz, CH2), 2.49 (2H, t, J = 6.7 Hz, CH2), 3.71 (3H, s, CH3), 4.25 (2H, q, J = 7.1 Hz, CH2), 
4.94 (2H, bs, NH2), 6.06 (2H, s, CH2), 6.69 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.83 (2H, d, J = 8.7 
Hz, H-2’ and H-6’), 6.90 (1H, s, H-8), 8.13 (1H, s, H-4); 13C NMR (CDCl3) (ppm): 14.3 (q), 23.4 
(t), 27.3 (t), 31.9 (t), 48.0 (t), 55.1 (q), 60.0 (t), 113.6 (d x 2), 117.9 (d), 123.6 (s), 124.6 (s), 127.3 
(s), 127.5 (d x 2), 131.8 (s), 133.3 (s), 158.3 (s), 158.6 (d), 159.7 (s), 160.9 (s), 161.4 (s).  
Ethyl 2-(phenylamino)-10-methyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidine-9-carboxylate (25d). This compound was obtained from reaction of 13d. Yield: 
62%, pale yellow solid; mp: 159 °C; Rf: (DCM : EtOAc 8:2) 0.79; IR: 3417 (NH), 1704 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.37 (3H, t, J = 7.1 Hz, CH3), 2.10 – 2.17 (2H, m, CH2), 2.43 – 2.55 (4H, 
m, CH2 x 2), 4.20 (3H, s, CH3), 4.32 (2H, q, J = 7.1 Hz, CH2), 6.87 (1H, s, H-8), 7.02 (1H, t, J = 8.4 
Hz, H-4’), 7.29 (1H, bs, NH), 7.34 (2H, dd, J = 8.4 Hz, J = 2.5 Hz, H-2’ and H-6’), 7.62 (2H, d, J = 
8.4 Hz, H-3’ and H-5’), 8.29 (1H, s, H-4); 13C NMR (CDCl3) (ppm): 14.4 (q), 23.6 (t), 27.5 (t), 32.0 
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(t), 34.8 (q), 60.0 (t), 116.8 (d), 119.0 (d x 2), 122.2 (d), 124.8 (s), 124.9 (s), 126.7 (s), 128.9 (d x 2), 
133.5 (s), 139.7 (s), 158.3 (d), 158.5 (s), 159.0 (s), 161.3 (s).   
Ethyl 2-(phenylamino)-10-benzyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidine-9-carboxylate (25e). This compound was obtained from reaction of 13e. Yield: 60%, 
yellow solid; mp: 147.5 °C; Rf: (DCM : EtOAc 8:2) 0.89; IR: 3417 (NH), 1700 (CO) cm
-1
; 
1
H 
NMR (CDCl3) (ppm): 1.29 (3H, t, J = 7.1 Hz, CH3), 2.11 – 2.20 (2H, m, CH2), 2.39 (2H, t, J = 6.9 
Hz, CH2), 2.54 (2H, t, J = 6.9 Hz, CH2), 4.24 (2H, q, J = 7.1 Hz, CH2), 6.18 (2H, s, CH2), 6.83 (2H, 
dd, J = 8.4, 2.3 Hz, Ar), 6.95 (1H, s, H-8), 7.00 – 7.31 (7H, m, Ar, NH), 7.56 (2H, d, J = 8.4 Hz, 
Ar), 8.23 (1H, s, H-4); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 23.5 (t), 27.5 (t), 32.0 (t), 48.7 (t), 60.1 
(t), 117.9 (d), 119.0 (d x 2), 122.2 (d), 124.6 (s), 124.8 (s), 125.9 (d x 2), 126.6 (d), 127.5 (s), 128.2 
(d x 2), 128.9 (d x 2), 133.4 (s), 139.6 (s), 139.7 (s), 158.3 (d), 158.5 (s), 159.1 (s), 160.9 (s).   
Ethyl 2-(phenylamino)-10-(4-methoxybenzyl)-5,6,7,10-
tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-9-carboxylate (25h). This compound 
was obtained from reaction of 13h. Yield: 43%, pale yellow solid; mp: 132.6 – 133.3 °C; Rf: (DCM 
: EtOAc8:2) 0.80; IR: 3416 (NH), 1696 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.31 (3H, t, J = 7.1 
Hz, CH3), 2.09 – 2.19 (2H, m, CH2), 2.37 (2H, t, J = 6.8 Hz, CH2), 2.51 (2H, t, J = 6.8 Hz, CH2), 
3.70 (3H, s, CH3), 4.25 (2H, q, J = 7.1 Hz, CH2), 6.12 (2H, s, CH2), 6.67 (2H, d, J = 8.9 Hz, H-3’ 
and H-5’), 6.77 (2H, d, J = 8.9 Hz, H-2’ and H-6’), 6.92 (1H, s, H-8), 7.00 (1H, t, J = 8.3 Hz, H-
4’’), 7.22 – 7-32 (3H, m, H-2’’, H-6’’ and NH), 7.57 (2H, d, J = 8.3 Hz, H-3’’ and H-5’’), 8.25 (1H, 
s, H-4); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 23.4 (t), 27.4 (t), 32.1 (t), 47.9 (t), 55.1 (q), 60.1 (t), 
113.6 (d x 2), 117.9 (d), 119.0 (d x 2), 122.2 (d), 124.2 (s), 124.5 (s), 124.6 (s), 127.4 (d x 2), 127.5 
(s), 128.9 (d x 2), 131.7 (s), 133.3 (s), 139.7 (s), 158.3 (d), 158.6 (s), 159.3 (s), 161.0 (s). 
Ethyl 2-(cyclohexylamino)-10-methyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidine-9-carboxylate (26d). This compound was obtained from reaction of 13d. Yield: 
76%, white solid; mp: 140.5 °C; Rf: (DCM : EtOAc 8:2) 0.67; IR: 3427 (NH), 1697 (CO) cm
-1
; 
1
H 
NMR (CDCl3) (ppm): 1.13 – 1.39 (7H, m, CH3, CH2 x 2), 1.57 – 1.85 (4H, m, CH2 x 2), 1.95 – 2.12 
(4H, m, CH2 x 2), 2.37 – 2.51 (4H, m, CH2 x 2), 3.78 – 3.90 (1H, m, CH), 4.18 (3H, s, CH3), 4.30 
(2H, q, J = 7.1 Hz, CH2), 4.97 (1H, d, J = 8.3 Hz, NH), 6.84 (1H, s, H-8), 8.13 (1H, s, H-4); 
13
C 
NMR (CDCl3) (ppm): 14.4 (q), 23.7 (t), 24.9 (t x 2), 25.7 (t), 27.3 (t), 31.7 (t), 33.4 (t x 2), 34.6 (q), 
49.9 (d), 59.9 (t), 116.8 (d), 122.3 (s), 124.6 (s), 126.4 (s), 134.0 (s), 146.3 (s), 158.4 (d), 160.4 (s), 
161.3 (s).  
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Ethyl 2-(cyclohexylamino)-10-benzyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidine-9-carboxylate (26e). This compound was obtained from reaction of 13e. Yield: 81%, 
white solid; mp: 162.1 °C; Rf: (DCM: EtOAc 8:2) 0.70; IR: 3424 (NH), 1700 (CO) cm
-1
; 
1
H NMR 
(CDCl3) (ppm): 1.15 – 1.31 (7H, m, CH3, CH2 x 2), 1.56 – 1.65 (4H, m, CH2 x 2), 1.87 – 1.96 (2H, 
m, CH2), 2.06 – 2.16 (2H, m, CH2), 2.34 (2H, t, J = 6.9 Hz, CH2), 2.51 (2H, t, J = 6.9 Hz, CH2), 
3.65 – 3.70 (1H, m, CH), 4.21 (2H, q, J = 7.1 Hz, CH2), 4.90 (1H, d, J = 8.4 Hz, NH), 6.15 (2H, s, 
CH2), 6.87 (1H, s, H-8), 6.90 – 6.94 (2H, m, H-2’ and H-6’), 7.13 – 7.20 (3H, m, H-3’, H-4’ and H-
5’), 8.09 (1H, s, H-4); 13C NMR (CDCl3) (ppm): 14.3 (q), 23.4 (t), 24.7 (t x 2), 25.7 (t), 27.3 (t), 
32.0 (t), 33.4 (t x 2), 48.7 (t), 49.5 (d), 59.9 (t), 117.9 (d), 122.0 (s), 124.2 (s), 125.9 (d x 2), 126.5 
(d), 127.0 (s), 128.2 (d x 2), 133.9 (s), 139.8 (s), 158.5 (d), 159.2 (s), 160.4 (s), 160.9 (s).  
Ethyl 2-(cyclohexylamino)-10-(4-methoxybenzyl)-5,6,7,10-
tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-9-carboxylate (26h). This compound 
was obtained from reaction of 13h. Yield: 49%, yellow solid; mp: 135.8 °C; Rf: (DCM : EtOAc 
8:2) 0.67; IR: 3428 (NH), 1704 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.12 – 1.33 (7H, m, CH3, CH2 
x 2), 1.55 – 1.68 (4H, m, CH2 x 2), 1.87 – 2.13 (4H, m, CH2 x 2), 2.32 (2H, t, J = 6.9 Hz, CH2), 
2.49 (2H, t, J = 6.9 Hz, CH2), 3.72 (3H, s, CH3), 3.75 – 3.78 (1H, m, CH), 4.23 (2H, q, J = 7.1 Hz, 
CH2), 4.92 (1H, d, J = 8.4 Hz, NH), 6.08 (2H, s, CH2), 6.71 (2H, d, J = 8.4 Hz, H-3’ and H-5’), 6.85 
(2H, d, J = 8.4 Hz, H-2’ and H-6’), 6.90 (1H, s, H-8), 8.11 (1H, s, H-4); 13C NMR (CDCl3) (ppm): 
14.3 (q), 23.4 (t), 24.8 (t x 2), 25.7 (t), 27.2 (t), 32.1 (t), 33.4 (t x 2), 47.9 (t), 49.5 (d), 55.1 (q), 59.9 
(t), 113.6 (d x 2), 117.8 (d), 122.0 (s), 124.0 (s), 127.0 (s), 127.4 (d x 2), 131.9 (s), 133.8 (s), 158.3 
(s), 158.5 (d), 159.3 (s), 160.5 (s), 160.9 (s). 
2-Amino-10-methyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-9-
carboxamide (27d). This compound was obtained from reaction of 24d. Yield: 66%, pale yellow 
solid; mp: 196.2 – 196.8 °C; Rf: (EtOAc) 0.19; IR: 3502 - 3396 (NH2), 3309 - 3212 (NH2) 1662 
(CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.04 – 2.14 (2H, m, CH2), 2.39 – 2.51 (4H, m, CH2 x 2), 4.14 
(3H, s, CH3), 5.26 (2H, s, NH2), 6.06 (2H, s, NH2), 6.51 (1H, s, H-8), 8.14 (1H, s, H-4); 
13
C NMR 
(CDCl3) (ppm): 23.7 (t), 27.4 (t), 31.6 (t), 34.7 (q), 112.8 (d), 123.6 (s), 126.6 (s), 127.3 (s), 132.4 
(s), 158.1 (d), 159.6 (s), 161.5 (s), 163.9 (s).  
2-Amino-10-benzyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-9-
carboxamide (27e). This compound was obtained from reaction of 24e. Yield: 25%, white solid; 
mp: 191.4 – 192.2 °C; Rf: (EtOAc) 0.32; IR: 3481 (NH2), 3420 (NH2), 3313 (NH2), 3250 (NH2) 
1662 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.01 – 2.09 (2H, m, CH2), 2.33 (2H, t, J = 7.1 Hz, CH2), 
2.50 (2H, t, J = 7.1 Hz, CH2), 4.97 (2H, bs, NH2), 5.65 (2H, bs, NH2), 6.13 (2H, s, CH2), 6.55 (1H, 
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s, H-8), 6.85 – 6.90 (2H, m, H-2’ and H-6’), 7.06 – 7.19 (3H, m, H-3’, H-4’ and H-5’), 8.09 (1H, s, 
H-4); 
13
C NMR (CDCl3) (ppm): 23.6 (t), 27.3 (t), 31.8 (t), 48.6 (t), 113.7 (d), 123.4 (s), 126.3 (d x 
2), 126.7 (d), 127.1 (s), 127.3 (s), 128.2 (d x 2), 132.4 (s), 139.8 (s), 158.3 (d), 159.6 (s), 161.3 (s), 
163.3 (s). 
2-Amino-10-(4-methoxybenzyl)-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidine-9-carboxamide (27h). This compound was obtained from reaction of 24h. Yield: 
94%, white solid; mp: 193.7 °C; Rf: (EtOAc) 0.29; IR: 3479 - 3420 (NH2), 3310 - 3246 (NH2), 
1663 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.05 – 2.15 (2H, m, CH2), 2.33 (2H, t, J = 6.9 Hz, CH2), 
2.49 (2H, t, J = 6.9 Hz, CH2), 3.71 (3H, s, CH3), 4.93 (2H, bs, NH2), 5.55 (2H, bs, NH2), 6.09 (2H, 
s, CH2), 6.53 (1H, s, H-8), 6.70 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.86 (2H, d, J = 8.7 Hz, H-2’ 
and H-6’), 8.12 (1H, s, H-4); 13C NMR (CDCl3) (ppm): 23.5 (t), 27.3 (t), 31.8 (t), 47.9 (t), 55.1 (q), 
113.5 (d x 2), 113.7 (d), 123.4 (s), 127.0 (s), 127.3 (s), 127.8 (d x 2), 130.9 (s), 131.9 (s), 132.3 (s), 
158.3 (d), 159.8 (s), 161.3 (s), 163.4 (s). 
10-Methyl-2-(phenylamino)-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-
9-carboxamide (28d). This compound was obtained from reaction of 25d. Yield: 74%, pale yellow 
solid; mp: 253.6 °C; Rf: (DCM : EtOAc 7:3) 0.21; IR: 3401 (NH), 3254 - 3170 (NH2), 1635 (CO) 
cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.10 – 2.17 (2H, m, CH2), 2.43 – 2.55 (4H, m, CH2 x 2), 4.21 (3H, 
s, CH3), 5.72 (2H, bs, NH2), 6.52 (1H, s, H-8), 7.02 (1H, t, J = 8.3 Hz, H-4’), 7.26 – 7.36 (3H, m, 
NH, H-2’ and H-6’), 7.63 (2H, dd, J = 8.3, 1.2 Hz, H-3’ and H-5’); 8.28 (1H, s, H-4); 13C NMR 
(CDCl3) (ppm): 23.7 (t), 27.6 (t), 32.0 (t), 34.9 (q), 112.7 (d), 119.1 (d x 2), 122.2 (d), 124.6 (s), 
126.6 (s), 127.0 (s), 128.9 (d x 2), 132.7 (s), 139.7 (s), 158.2 (d), 158.5 (s), 159.0 (s), 163.5 (s).  
10-Benzyl-2-(phenylamino)-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d]pyrimidine-
9-carboxamide (28e). This compound was obtained from reaction of 25e. Yield: 64%, pale yellow 
solid; mp: 195.7 °C; Rf: (DCM : EtOAc 7:3) 0.42; IR: 3318 (NH), 3273 - 3164 (NH2), 1661 (CO) 
cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.10 – 2.18 (2H, m, CH2), 2.37 (2H, t, J = 6.8 Hz, CH2), 2.53 (2H, t, 
J = 6.8 Hz, CH2), 5.62 (2H, bs, NH2), 6.21 (2H, s, CH2), 6.58 (1H, s, H-8), 6.84 (2H, d, J = 7.4 Hz, 
Ar), 7.01 (1H, t, J = 7.4 Hz, Ar), 7.12 – 7.32 (6H, m, NH, Ar), 7.58 (2H, d, J = 7.9 Hz, Ar), 8.22 
(1H, s, H-4); 
13
C NMR (CDCl3) (ppm): 23.6 (t), 27.5 (t), 32.0 (t), 48.7 (t), 113.7 (d), 119.1 (d x 2), 
122.2 (d), 124.4 (s), 126.2 (d x 2), 126.7 (d), 127.1 (s), 127.4 (s), 128.2 (d x 2), 128.9 (d x 2), 132.5 
(s), 139.7 (s), 139.8 (s), 158.1 (d), 158.5 (s), 159.2 (s), 163.4 (s). 
10-(4-Methoxybenzyl)-2-(phenylamino)-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d]pyrimidine-9-carboxamide (28h). This compound was obtained from reaction of 25h. Yield: 
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54%, pale yellow solid; mp: 195.8 – 196.4 °C; Rf: (7:3 DCM: EtOAc) 0.28; IR: 3399 (NH), 3319 
(NH2), 3204 (NH2), 1668 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.08 – 2.18 (2H, m, CH2), 2.36 (2H, 
t, J = 6.7 Hz, CH2), 2.50 (2H, t, J = 6.7 Hz, CH2), 3.69 (3H, s, CH3), 5.72 (2H, bs, NH2), 6.14 (2H, 
s, CH2), 6.55 (1H, s, H-8), 6.66 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.80 (2H, d, J = 8.7 Hz, H-2’ 
and H-6’), 7.01 (1H, t, J = 7.8 Hz, H-4’’), 7.28 – 7.33 (3H, m, H-2’’, H-6’’ and NH), 7.61 (2H, d, J 
= 7.8 Hz, H-3’’ and H-5’’), 8.23 (1H, s, H-4); 13C NMR (CDCl3) (ppm): 23.5 (t), 27.5 (t), 32.1 (t), 
47.9 (t), 55.1(q), 113.6 (d x 2), 113.7 (d), 119.0 (d x 2), 122.2 (d), 124.3 (s), 127.0 (s), 127.4 (s), 
127.7 (d x 2), 128.9 (d x 2), 131.9 (s), 132.4 (s), 139.7 (s), 158.1 (d), 158.3 (s), 158.6 (s), 159.3 (s), 
163.4 (s).  
2-(Cyclohexylamino)-10-methyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d] 
pyrimidine-9-carboxamide (29d). This compound was obtained from reaction of 26d. Yield: 82%, 
pale pink solid; mp: 204.9 °C; Rf: (EtOAc) 0.48; IR: 3403 (NH), 3276 - 3183 (NH2), 1662 (CO) 
cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.15 – 1.50 (4H, m, CH2 x 2), 1.57 – 1.91 (4H, m, CH2 x 2), 1.98 – 
2.12 (4H, m, CH2 x 2), 2.37 – 2.53 (4H, m, CH2 x 2), 3.75 – 3.84 (1H, m, CH), 4.18 (3H, s, CH3), 
5.04 (1H, d, J = 8.1 Hz, NH), 5.70 (2H, bs, NH2), 6.50 (1H, s, H-8), 8.12 (1H, s, H-4); 
13
C NMR 
(CDCl3) (ppm): 23.8 (t), 24.9 (t x 2), 25.7 (t), 27.4 (t), 31.7 (t), 33.4 (t x 2), 34.8 (q), 49.9 (d), 112.7 
(d), 122.1 (s), 126.3 (s), 126.8 (s), 133.1 (s), 158.2 (d), 159.1 (s), 160.4 (s), 163.6 (s). 
2-(Cyclohexylamino)-10-benzyl-5,6,7,10-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d] 
pyrimidine-9-carboxamide (29e). This compound was obtained from reaction of 26e. Yield: 85%, 
white solid; mp: 226.6 – 227.2 °C; Rf: (EtOAc) 0.61; IR: 3396 (NH), 3209 - 3122 (NH2), 1696 
(CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.10 – 1.25 (4H, m, CH2 x 2), 1.61 – 1.75 (4H, m, CH2 x 2), 
1.89 – 2.12 (4H, m, CH2 x 2), 2.32 (2H, t, J = 6.8 Hz, CH2), 2.50 (2H, t, J = 6.8 Hz, CH2), 3.62 – 
3.79 (1H, m, CH), 4.91 (1H, d, J = 7.8 Hz, NH), 5.53 (2H, bs, NH2), 6.20 (2H, s, CH2), 6.55 (1H, s, 
H-8), 6.89 (2H, d, J = 7.0 Hz, H-2’ and H-6’), 7.14 – 7.26 (3H, m, H-3’, H-4’ and H-5’), 8.08 (1H, 
s, H-4); 
13
C NMR (CDCl3) (ppm): 23.5 (t), 24.8 (t x 2), 25.7 (t), 27.3 (t), 32.1 (t), 33.4 (t x 2), 48.5 
(t), 49.5 (d), 113.7 (d), 121.9 (s), 126.2 (d x 2), 126.5 (s), 126.6 (d), 126.9 (s), 128.2 (d x 2), 133.0 
(s), 139.9 (s), 158.4 (d), 159.2 (s), 160.4 (s), 163.2 (s).   
2-(Cyclohexylamino)-10-(4-methoxybenzyl)-5,6,7,10-tetrahydropyrrolo[3',2':6,7] 
cyclohepta[1,2-d]pyrimidine-9-carboxamide (29h). This compound was obtained from reaction 
of 26h. Yield: 93%, pale yellow solid; mp: 162.9 °C; Rf: (DCM : EtOAc 7:3) 0.30; IR: 3403 (NH), 
3270 - 3160 (NH2), 1663 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.20 – 1.38 (4H, m, CH2 x 2), 1.57 – 
1.73 (4H, m, CH2 x 2), 1.94 – 2.11 (4H, m, CH2 x 2), 2.31 (2H, t, J = 7.0 Hz, CH2), 2.48 (2H, t, J = 
7.0 Hz, CH2), 3.71 (3H, s, CH3), 3.72 – 3.77 (1H, m, CH), 4.93 (1H, d, J = 8.4 Hz, NH), 5.53 (2H, 
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bs, NH2), 6.12 (2H, s, CH2), 6.53 (1H, s, H-8), 6.70 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.87 (2H, d, 
J = 8.7 Hz, H-2’ and H-6’), 8.09 (1H, s, H-4); 13C NMR (CDCl3) (ppm): 23.5 (t), 24.8 (t x 2), 25.7 
(t), 27.3 (t), 32.1 (t), 33.4 (t x 2), 47.8 (t), 49.6 (d), 55.1 (q), 113.6 (d x 2), 113.7 (d), 121.9 (s), 
126.3 (s), 126.9 (s), 127.7 (d x 2), 132.1 (s), 132.8 (s), 158.3 (s), 158.4 (d), 159.4 (s), 160.5 (s), 
163.3 (s). 
 
9.9.1 Preparation of Pyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine (32) 
To a suspension of CuBr2 (5.4 mmol) in dry ethyl acetate (12 mL) the appropriate ketone 9 (3 
mmol) was added and the reaction mixture was heated to reflux for 2 hours. After cooling the 
reaction mixture was filtered under vacuum to remove the CuBr formed. The solvent was 
evaporated and the residue dissolved in dry DMF (12 mL). K2CO3 (6 mmol) and thiourea (6 mmol) 
were added and the new mixture was stirred at room temperature for one night (16 h). The reaction 
was poured into brine (30 mL) and in the case of formation of a precipitate, the solid was filtered. In 
the absence of precipitate, the aqueous solution was extracted with dichloromethane (3 x 40 mL). 
The organic phase was dried over Na2SO4 and the solvent evaporated at reduced pressure. The 
crude product was then purified by chromatography column (dichloromethane ethyl acetate 8:2). 
Ethyl 2-amino-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazole-8-carboxylate 
(32a) This compound was obtained from reaction of 9a Yield: 52%, white solid; mp: 190 – 191°C; 
IR: 3370 (NH), 3202 - 3156 (NH2) 1692 (CO) cm
-1
; 
1
H NMR (DMSO-d6) (ppm): 1.27 (3H, t, J = 
7.1 Hz, CH3), 1.85 – 1.99 (2H, m, CH2), 2.75 – 2.85 (4H, m, CH2 x 2), 4.22 (2H, q, J = 7.1 Hz, 
CH2), 6.63 (1H, s, H-7), 6.88 (2H, s, NH2), 9.64 (1H, s, NH); 
13
C NMR (DMSO-d6) (ppm): 14.3 
(q), 23.9 (t), 27.0 (t), 27.6 (t), 59.5 (t), 116.4 (d), 118.9 (s), 119.3 (s), 121.6 (s), 129.8 (s), 137.8 (s), 
159.9 (s), 165.5 (s).  
9-(Phenylsulfonyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine 
(32b) This compound was obtained from reaction of 9b Yield: 44 %, yellow solid; mp: 173 - 174 
°C; IR: 3252 - 3143 (NH2) cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.01 – 2.11 (2H, m, CH2), 2.41 (2H, t, J 
= 6.7 Hz, CH2), 2.45 (2H, t, J = 6.7 Hz, CH2), 4.68 (2H, s, NH2), 6.17 (1H, d, J = 3.0 Hz, H-7), 7.35 
(1H, d, J = 3.0 Hz, H-8), 7.40 – 7.55 (3H, m, H-3’, H-4’ and H-5’), 7.86 (2H, d, J = 7.0 Hz, H-2’ 
and H-6’); 13C NMR (CDCl3) (ppm): 24.0 (t), 25.0 (t), 31.8 (t), 113.5 (d), 123.2 (d), 125.3 (s), 126.7 
(s), 127.2 (d x 2), 128.4 (d x 2), 130.5 (s), 133.0 (d), 138.3 (s), 140.1 (s), 162.7 (s). 
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4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-amine (32c) This compound 
was obtained from reaction of 31c Yield: 64 %, brown solid; mp: 66.4 – 67.2 °C; IR: 3455 – 3416 
(NH2), 3287 (NH) cm
-1
; 
1
H NMR (CDCl3) (ppm): 2.02 – 2.09 (2H, m, CH2), 2.87 – 2.94 (4H, m, 
CH2 x 2), 4.97 (2H, bs, NH2), 5.99 (1H, d, J = 2.9 Hz, H-7), 6.58 (1H, d, J = 2.9 Hz, H-8), 9.27 (1H, 
bs, NH); 
13
C NMR (CDCl3) (ppm): 24.3 (t), 27.6 (t), 28.5 (t), 110.3 (d), 116.2 (d), 117.0 (s), 120.5 
(s), 124.8 (s), 139.2 (s), 144.6 (s).  
Ethyl 2-amino-9-methyl-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazole-8-
carboxylate (32d) This compound was obtained from reaction of 9d Yield: 50 %, yellow solid; mp: 
113 - 114 °C; IR: 3255 - 3188 (NH2), 1690 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.34 (3H, t, J = 7.1 
Hz, CH3), 2.05 – 2.09 (2H, m, CH2), 2.61 (2H, t, J = 6.4 Hz, CH2), 2.76 (2H, t, J = 6.4 Hz, CH2), 
4.16 (3H, s, CH3), 4.27 (2H, q, J = 7.1 Hz, CH2), 4.86 (2H, s, NH2), 6.79 (1H, s, H-7); 
13
C NMR 
(CDCl3) (ppm): 14.5 (q), 25.7 (t), 25.8 (t), 29.9 (t), 35.2 (q), 59.6 (t), 117.3 (d), 121.8 (s), 124.2 (s), 
126.2 (s), 132.7 (s), 139.0 (s), 161.5 (s), 163.3 (s) 
Ethyl 2-amino-9-(4-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d][1,3]thiazole-8-carboxylate (32h) This compound was obtained from reaction of 9h Yield: 59 %, 
yellow solid; mp: 59°C; IR: 3253 - 3175 (NH2), 1715 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.27 
(3H, t, J = 7.1 Hz, CH3), 2.05 – 2.12 (2H, m, CH2), 2.63 (2H, t, J = 6.5 Hz, CH2), 2.73 (2H, t, J = 
6.5 Hz, CH2), 3.73 (3H, s, CH3), 4.17 (2H, q, J = 7.1 Hz, CH2), 4.73 (2H, s, NH2), 6.09 (2H, s, 
CH2), 6.73 (2H, d, J = 8.6 Hz, H-3’ and H-5’), 6.86 (1H, s, H-7) 6.89 (2H, d, J = 8.6 Hz, H-2’ and 
H-6’); 13C NMR (CDCl3) (ppm): 14.4 (q), 25.5 (t), 25.7 (t), 30.2 (t), 48.6 (t), 55.1 (q), 59.6 (t), 
113.5 (d x 2), 118.6 (d), 121.4 (s), 124.7 (s), 126.3 (s), 127.5 (d x 2), 132.5 (s), 132.6 (s), 139.1 (s), 
158.1 (s), 161.1 (s), 163.4 (s). 
Ethyl 2-amino-9-(3,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d][1,3]thiazole-8-carboxylate (32j) This compound was obtained from reaction of 9j Yield: 38 %, 
brown solid; mp: 140.6 – 141.0 °C; IR: 3377 – 3253 (NH2), 1696 (CO) cm
-1
; 
1
H NMR (CDCl3) 
(ppm): 1.27 (3H, t, J = 7.1 Hz, CH3), 2.03 – 2.13 (2H, m, CH2), 2.63 (2H, t, J = 6.6 Hz, CH2), 2.73 
(2H, t, J = 6.6 Hz, CH2), 3.66 (6H, s, CH3 x 2), 4.19 (2H, q, J = 7.1 Hz, CH2), 4.77 (2H, s, NH2), 
6.08 (2H, s, CH2), 6.14 (2H, s, H-2’ and H-6’), 6.23 (1H, s, H-4’), 6.87 (1H, s, H-7); 
13
C NMR 
(CDCl3) (ppm): 14.4 (q), 25.6 (t), 25.7 (t), 30.2 (t), 49.1 (t), 55.1 (q), 59.6 (t), 98.6 (d), 104.1 (d x 
2), 118.6 (d), 121.7 (s), 124.7 (s), 126.1 (s), 132.7 (s), 139.1 (s), 142.9 (s), 160.5 (s x 2), 161.1 (s), 
163.5 (s).  
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Ethyl 2-amino-9-(2-bromo-3,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo 
[3',2':6,7]cyclohepta[1,2-d][1,3]thiazole-8-carboxylate (32u) This compound was obtained from 
reaction of 9j Yield: 23 %, brown solid; mp: 189.3 – 189.9 °C; IR: 3334 – 3227 (NH2), 1695 (CO) 
cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.25 (3H, t, J = 7.1 Hz, CH3), 2.00 – 2.09 (2H, m, CH2), 2.69 – 2.84 
(4H, m, CH2 x 2), 3.56 (3H, s, CH3), 3.84 (3H, s, CH3), 4.18 (2H, q, J = 7.1 Hz, CH2), 4.62 (2H, s, 
NH2), 5.43 (1H, s, H-4’), 6.21 (2H, s, CH2), 6.28 (1H, s, H-6’), 6.91 (1H, s, H-7); 
13
C NMR 
(CDCl3) (ppm): 14.3 (q), 26.6 (t), 26.7 (t), 28.4 (t), 51.1 (t), 55.1 (q), 56.2 (q), 59.7 (t), 97.2 (d), 
101.3 (s), 103.2 (d), 118.7 (d), 121.9 (s), 124.6 (s), 126.0 (s), 132.4 (s), 138.3 (s), 142.4 (s), 156.1 
(s), 159.7 (s), 160.9 (s), 162.9 (s).  
Ethyl 2-amino-9-(3,4,5-trimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d][1,3]thiazole-8-carboxylate (32k) This compound was obtained from reaction of 9k Yield: 92 %, 
yellow solid; mp: 149.5 – 150.3 °C; IR: 3408 – 3357 (NH2), 1701 (CO) cm
-1
; 
1
H NMR (CDCl3) 
(ppm): 1.30 (3H, t, J = 7.1 Hz, CH3), 2.03 – 2.11 (2H, m, CH2), 2.63 (2H, t, J = 6.4 Hz, CH2), 2.73 
(2H, t, J = 6.4 Hz, CH2), 3.70 (6H, s, CH3 x 2), 3.76 (3H, s, CH3), 4.22 (2H, q, J = 7.1 Hz, CH2), 
4.78 (2H, s, NH2), 6.14 (2H, s, CH2), 6.23 (2H, s, H-2’ and H-6’), 6.86 (1H, s, H-7); 
13
C NMR 
(CDCl3) (ppm): 14.4 (q), 25.5 (t), 25.6 (t), 30.4 (t), 48.8 (t), 55.7 (q x 2), 59.7 (t), 60.7 (q), 103.6 (d 
x 2), 118.7 (d), 121.6 (s), 124.9 (s), 126.1 (s), 132.6 (s), 135.9 (s), 136.3 (s), 139.3 (s), 152.8 (s x 2), 
161.2 (s), 163.6 (s). 
 
9.9.2 General Procedure of 2-(acetylamino)-Pyrrolo[3',2':6,7]cyclohepta[1,2-
d][1,3]thiazole (33) 
To a solution of appropriate 2-amine-thiazole 31 (0.5 mmol) in dry dichloromethane (5 mL), at 0°C 
were added DIPEA (0.6 mmol) and acetyl chloride (0.55 mmol), and the reaction mixture was 
added for one night at room temperature (24 h). Water (3 mL) was added and the organic phase was 
separated. The acqueous phase was extracted with further dichloromethane (2 x 5 mL), and the 
organic phase, collect dried on Na2SO4 and evaporated at reduced pressure. The residue was 
purified by chromatography column (dichloromethane ethyl acetate 95:5). 
N-[9-(phenylsulfonyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-d][1,3]thiazol-2-
yl]acetamide (33b) This compound was obtained from reaction of 32b Yield: 73 %, white solid; 
mp: 222.6 – 223.4 °C; IR: 3408 (NH), 1713 (CO) cm-1; 1H NMR (CDCl3) (ppm): 1.83 (3H, s, CH3), 
2.04 – 2.10 (4H, m, CH2 x 2), 2.32 – 2.36 (2H, m, CH2), 6.27 (1H, s, H-7), 7.30 – 7.36 (3H, m, H-
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3’, H-4’ and H-5’), 7.44 (1H, s, H-8), 7.71 (2H, d, J = 6.4 Hz, H-2’ and H-6’), 11.95 (1H, s, NH); 
13
C NMR (CDCl3) (ppm): 21.8 (q), 22.4 (t), 23.6 (t), 34.1 (t), 113.2 (d), 123.1 (d), 125.5 (s), 127.4 
(d x 2), 128.7 (d x 2), 130.1 (s), 131.1 (s), 133.6 (d), 136.6 (s), 137.9 (s), 155.8 (s), 168.8 (s).  
Ethyl 2-(acetylamino)-9-methyl-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d][1,3]thiazole-8-carboxylate (33d) This compound was obtained from reaction of 32d Yield: 51 
%, pale yellow solid; mp: 193.8 – 194.2 °C; IR: 3399 (NH), 1701 (CO), 1597 (CO) cm-1; 1H NMR 
(CDCl3) (ppm): 1.35 (3H, t, J = 7.1 Hz, CH3), 1.88 (3H, s, CH3), 2.06 – 2.14 (2H, m, CH2), 2.61 
(2H, t, J = 6.3 Hz, CH2), 2.87 (2H, t, J = 6.3 Hz, CH2), 4.12 (3H, s, CH3), 4.28 (2H, q, J = 7.1 Hz, 
CH2), 6.83 (1H, s, H-7), 10.5 (1H, s, NH); 
13
C NMR (CDCl3) (ppm): 14.4 (q), 22.1 (q), 25.1 (t), 
25.5 (t), 30.0 (t), 34.9 (q), 59.8 (t), 117.5 (d), 122.4 (s), 124.5 (s), 130.1 (s), 132.0 (s), 137.4 (s), 
155.3 (s), 161.4 (s), 167.8 (s).  
Ethyl 2-(acetylamino)-9-(4-methoxybenzyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta[1,2-
d][1,3]thiazole-8-carboxylate (33h) This compound was obtained from reaction of 32h Yield: 65 
%, yellow solid; mp: 87.6 – 88.4 °C; IR: 3403 (NH), 1696 (CO), 1557 (CO) cm-1; 1H NMR (CDCl3) 
(ppm): 1.28 (3H, t, J = 7.0 Hz, CH3), 1.92 (3H, s, CH3), 2.11 – 2.19 (2H, m, CH2), 2.61 (2H, t, J = 
6.3 Hz, CH2), 2.82 (2H, t, J = 6.3 Hz, CH2), 3.69 (3H, s, CH3), 4.20 (2H, q, J = 7.0 Hz, CH2), 6.00 
(2H, s, CH2), 6.63 (2H, d, J = 8.3 Hz, H-3’ and H-5’), 6.77 (2H, d, J = 8.3 Hz, H-2’ and H-6’), 6.91 
(1H, s, H-7), 10.11 (1H, s, NH); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 22.5 (q), 24.7 (t), 25.2 (t), 30.8 
(t), 48.5 (t), 55.1 (q), 59.8 (t), 113.5 (d x 2), 118.6 (d), 122.0 (s), 125.0 (s), 127.2 (d x 2), 130.2 (s), 
131.7 (s), 132.0 (s), 137.6 (s), 155.2 (s), 158.2 (s), 161.0 (s), 167.8 (s). 
Ethyl 2-(acetylamino)-9-(3,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7]cyclohepta 
[1,2-d][1,3]thiazole-8-carboxylate (33j) This compound was obtained from reaction of 32j Yield: 
72 %, brown solid; mp: 70.2 – 71.0 °C; IR: 3264 (NH), 1695 (CO), 1597 (CO) cm-1; 1H NMR 
(CDCl3) (ppm): 1.27 (3H, t, J = 7.1 Hz, CH3), 1.94 (3H, s, CH3), 2.10 – 2.25 (2H, m, CH2), 2.62 
(2H, t, J = 6.3 Hz, CH2), 2.83 (2H, t, J = 6.3 Hz, CH2), 3.57 (6H, s, CH3 x 2), 4.18 (2H, q, J = 7.1 
Hz, CH2), 5.98 (2H, s, CH2), 6.04 (2H, s, H-2’ and H-6’), 6.17 (1H, s, H-4’), 6.93 (1H, s, H-7), 9.96 
(1H, s, NH); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 22.6 (q), 24.8 (t), 25.3 (t), 30.7 (t), 49.1 (t), 55.0 
(q), 59.8 (t), 98.1 (d), 103.9 (d x 2), 118.8 (d), 122.2 (s), 124.9 (s), 130.1 (s), 132.0 (s), 137.8 (s), 
142.4 (s), 154.9 (s), 160.6 (s x 2), 161.0 (s), 167.6 (s).  
Ethyl 2-(acetylamino)-9-(2-bromo-3,5-dimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7] 
cyclohepta [1,2-d][1,3]thiazole-8-carboxylate (33u) This compound was obtained from reaction 
of 32u Yield: xx %, white solid; mp: 192.0 – 192.8 °C; IR: 3413 (NH), 1704 (CO), 1593 (CO) cm-1; 
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1
H NMR (CDCl3) (ppm): 1.29 (3H, t, J = 7.0 Hz, CH3), 1.94 – 2.12 (5H, m, CH3, CH2), 2.73 – 2.77 
(2H, m, CH2), 2.89 – 2.92 (2H, m, CH2), 3.56 (3H, s, CH3), 3.82 (3H, s, CH3), 4.18 (2H, q, J = 7.0 
Hz, CH2), 5.44 (1H, s, H-4’), 6.14 (1H, s, CH2), 6.25 (1H, s, H-6’), 6.95 (1H, s, H-7), 9.16 (1H, s, 
NH); 
13
C NMR (CDCl3) (ppm): 14.3 (q), 23.1 (q), 26.2 (t), 26.7 (t), 28.2 (t), 51.0 (t), 55.1 (q), 56.2 
(q), 59.8 (t), 97.1 (d), 101.1 (s), 103.4 (d), 118.9 (d), 122.3 (s), 124.8 (s), 129.8 (s), 131.8 (s), 137.2 
(s), 142.1 (s), 153.5 (s), 156.1 (s), 159.8 (s), 160.9 (s), 167.5 (s). 
Ethyl 2-(acetylamino)-9-(3,4,5-trimethoxybenzyl)-4,5,6,9-tetrahydropyrrolo[3',2':6,7] 
cyclohepta [1,2-d][1,3]thiazole-8-carboxylate (33k) This compound was obtained from reaction 
of 32k Yield: 39 %, pale brown solid; mp: 73.1 – 73.8 °C; IR: 3405 (NH), 1703 (CO), 1597 (CO) 
cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.30 (3H, t, J = 7.1 Hz, CH3), 2.00 (3H, s, CH3), 2.13 – 2.17 (2H, m, 
CH2), 2.61 – 2.65 (2H, m, CH2), 2.80 – 2.85 (2H, m, CH2), 3.61 (6H, s, CH3 x 2), 3.73 (3H, s, CH3), 
4.23 (2H, q, J = 7.1 Hz, CH2), 6.08 (2H, s, CH2), 6.13 (2H, s, H-2’ and H-6’), 6.91 (1H, s, H-7), 
10.41 (1H, s, NH); 
13
C NMR (CDCl3) (ppm): 14.4 (q), 22.4 (q), 24.9 (t), 25.3 (t), 30.6 (t), 48.8 (t), 
55.7 (q x 2), 59.9 (t), 60.7 (q), 103.2 (d x 2), 118.9 (d), 122.0 (s), 125.2 (s), 130.1 (s), 132.1 (s), 
135.3 (s), 136.4 (s), 137.8 (s), 152.9 (s x 2), 155.3 (s), 161.2 (s), 168.0 (s). 
  
9.9.3 Preparation of 7-bromo-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one 
(31c). 
1-(Phenylcarbonyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (9w). To a solution of 9c 
(6 mmol) in dry DMF (12 mL), NaH (6.6 mmol) was added at 0 °C and the reaction was stirred for 
one hour and half at room temperature. Benzoyl Chloride (9 mmol) was added at  0 °C, and the 
reaction mixture was stirred at room temperature for 3 h. Then the reaction was poured into ice and 
brine (40 mL), and, the aqueous solution was extracted with dichloromethane (3 x 40 mL). The 
organic phase was dried over Na2SO4 and the solvent evaporated at reduced pressure. The crude 
product was purified by chromatography column (dichloromethane). Yield: 82 %, colourless oil; 
IR: 1699 (CO) 1645 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.83 – 2.01 (4H, m, CH2 x 2), 2.59 (2H, t, 
J = 6.1 Hz, CH2), 2.81 – 2.90 (2H, m, CH2), 6.13 (1H, d, J = 2.4 Hz, H-3), 7.17 (1H, d, J = 2.4 Hz, 
H-2), 7.40 – 7.73 (5H, m, Ar); 13C NMR (CDCl3) (ppm): 22.4 (t), 26.0 (t), 27.6 (t), 42.1 (t), 112.4 
(d), 128.2 (d), 128.5 (d x 2), 129.6 (d x 2), 130.1 (s), 133.2 (d), 133.8 (s), 137.2 (s), 169.0 (s), 192.1 
(s).   
7-Bromo-1-(phenylcarbonyl)-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (31w). To a 
solution of 9w (5 mmol) in dry THF (10 mL), pyridine hydrobromide perbromide (5 mmol) 
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dissolved in dry THF (5 mL), was added and the reaction mixture was stirred at room temperature 
for 6 hours. The solid formed was filtered and eliminated, and the organic phases was concentrated 
under reduced pressure. The residue was dissolved in dichloromethane (10 mL), washed with a 
solution at 5% of NaHCO3 (10 mL), dried on Na2SO4 and evaporated at reduced pressure. The 
residue was purified by chromatoghraphy column (dichloromethane). Yield: 60 %, yellow oil; IR: 
1711 (CO) 1636 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.93 – 2.02 (2H, m, CH2), 2.33 – 2.42 (2H, 
m, CH2), 2.82 – 3.09 (2H, m, CH2), 4.63 – 4.70 (1H, m, CH), 6.12 (1H, d, J = 2.6 Hz, H-3), 7.24 
(1H, d, J = 2.6 Hz, H-2), 7.41 – 7.76 (5H, m, Ar); 13C NMR (CDCl3) (ppm): 22.8 (t), 28.5 (t), 32.3 
(t), 55.3 (d), 112.5 (d), 128.6 (d), 129.8 (d x 2), 129.9 (d x 2), 130.1 (s), 133.0 (s), 133.4 (d), 136.3 
(s), 168.6 (s), 184.6 (s).  
7-bromo-4,5,6,7-tetrahydrocyclohepta[b]pyrrol-8(1H)-one (31c). To a solution of 31w (5 mmol) 
in ethanol (15 mL), sodium hydroxide (10 mmol) was added and the reaction mixture was stirred at 
room temperature for 4 hours. The solution was concentrated, cooled at 0°C and acidified using 
HCl 6 M. The acqueous phase was extracted with dichloromethane (3 x 50 mL) and the organic 
phase was collect, dried on Na2SO4 and evaporated at reduced pressure. The residue was purified by 
chromatoghraphy column (dichloromethane). Yield: 72 %, pale brown solid, mp: 99.9 – 100.5 ; IR: 
3425 (NH), 1622 (CO) cm
-1
; 
1
H NMR (CDCl3) (ppm): 1.94 – 2.03 (2H, m, CH2), 2.33 – 2.39 (2H, 
m, CH2), 2.85 – 3.08 (2H, m, CH2), 4.83 – 4.90 (1H, m, CH), 6.10 (1H, d, J = 2.4 Hz, H-3), 7.03 
(1H, d, J = 2.4 Hz, H-2), 9.45 (1H, bs, NH); 
13
C NMR (CDCl3) (ppm): 23.3 (t), 28.5 (t), 32.8 (t), 
55.0 (d), 112.2 (d), 126.3 (d), 127.0 (s), 133.0 (s), 185.2 (s).  
 
 
9.10  Total synthesis of Toxyloxanthone B and toward the synthesis of 
Rubraxanthone 
All the IR spectra were determined in chloroform. 
1
H and 
13
C NMR were registered at 400 MHz 
and 100 MHz using a Bruker spectrometer (TMS as internal standard). 
 
9.10.1 First Approach Fragment A 
2,5-dimethoxyphenol (35) 
   
To a solution of 2,5-dimethoxybenzaldehyde (34) (6 g, 36.1 mmol) in dichloromethane (250 mL), 
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was added at 0°C in small portions mCPBA (10.6 g, 61.4 mmol), and the reaction mixture was 
stirred at room temperature for 18 h. The organic solution was washed with aqueous satured sodium 
bicarbonate solution (200 mL x 2), and then with aqueous satured sodium thiosulfate solution (200 
mL). The organic layer was dried on MgSO4, filtered and concentrated in vacuo to give a dark oil 
that was dissolved in methanol (90 mL), and stirred with aqueous NaOH (4M, 18 mL), for 3h. The 
reaction mixture was acidified with HCl and extracted with ethyl acetate (100 mL x 3). The organic 
layer was dried on MgSO4, filtered and concentrated in vacuo to give an oil that was purified by 
flash chromatography column (6:4 dichlorometane, light petroleum). Yield 77%, clear oil; (Found: 
[M + H
+
], 155.0699. C8H11O3
+
 requires 155.0703); vmax (CHCl3)/cm
-1
: 3538, 3008, 2958, 2938, 
2908, 2838, 2062, 1627, 1599, 1504, 1466, 1336, 1284; δH (400 MHz, CDCl3): 6.79 (1 H, d, J 8.8, 
H-3), 6.59 (1 H, d, J 2.8, H-6), 6.40 (1 H dd, J 8.8, 2.8, H-4), 5.65 (1 H, s, OH), 3.87 (3 H, s, 
OCH3), 3.77 (3 H, s, OCH3);
 δC (100 MHz, CDCl3): 154.5 (C), 146.4 (C), 140.9 (C), 111.4 (CH), 
104.2 (CH), 101.7 (CH), 56.6 (Me),  55.6 (Me). 
2-(benzyloxy)-1,4-dimethoxybenzene (36) 
 
Potassium carbonate (5.4 g, 39 mmol) and Benzyl bromide (3.1 mL, 26 mmol), were added to a 
stirred solution of starting material 35 (4 g, 26 mmol) in acetonitrile (120 mL), and the mixture was 
refluxed for 1hour and 30 minutes. After cooling and filtration of the potassium carbonate, the 
solvent was removed in vacuo and the residue was dissolved in dichloromethane (50 mL), so 
washed with water (50 mL x 2), dried on MgSO4, concentrated in vacuo and purified by flash 
chromatography column (9:1 light petroleum, ethyl acetate). Yield 99%, white solid, mp 38 °C; 
(Found: [M + Na
+
], 267.0990. C15H16NaO3
+
 requires 267.0992); vmax (CHCl3)/cm
-1
: 3010, 2937, 
2910, 2836, 1597, 1511, 1465, 1429, 1381, 1259, 1239, 1183, 1160, 1136; δH (400 MHz, CDCl3): 
7.46 – 7.29 (5 H, m, C6H5), 6.83 (1 H, d, J 8.8, H-3), 6.56 (1 H, d, J 2.8, H-5), 6.43 (1 H, dd, J 8.8, 
2.8, H-4), 5.16 (2 H, s, CH2), 3.87 (3 H, s, OCH3), 3.75 (3 H, s, OCH3); δC (100 MHz, CDCl3): 
154.2 (C), 149.1 (C), 144.1 (C), 137.0 (C), 128.6 (CH x 2), 127.9 (CH), 127.3 (CH x 2), 112.8 
(CH), 103.9 (CH), 102.7 (CH), 71.0 (CH2), 56.8 (Me), 55.6 (Me). 
1-(benzyloxy)-4-bromo-2,5-dimethoxybenzene (37) 
 
NBS (882 mg, 4.95 mmol), was added to a  stirred  solution  of  starting  material  36  (1.10  g,  4.50  
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mmol) in dichloromethane (60 mL), and the solution was stirred at room temperature for 18 hours. 
The reaction was quenched by the addition of satured aqueous sodium bicarbonate solution (30 
mL), and diluted with water (150 mL). The product was extracted with dichlorometane (80 mL x 2), 
the organic extracts were combined, dried on MgSO4, and the solvent removed in vacuo to give the 
crude product as a brown solid that was purified by flash column chromatography (9:1 light 
petroleum, ethyl acetate). Yield 84%, beige solid, mp 88 °C; (Found: [M + Na
+
], 345.0091. 
C15H15
79
BrNaO3
+
 requires 345.0097); vmax (CHCl3)/cm
-1
: 3011, 2937, 1781, 1754, 1722, 1585, 
1505, 1464, 1443, 1388, 1362, 1344, 1192, 1160; δH (400 MHz, CDCl3): 7.46 - 7.34 (5 H, m, 
C6H5), 7.09 (1 H, s, CH), 6.58 (1 H, s, CH), 5.17 (2 H, s, CH2), 3.86 (3 H, s, OCH3), 3.77 (3 H, s, 
OCH3); δC (100 MHz, CDCl3): 150.1 (C), 148.1 (C), 144.6 (C),  136.7 (C), 128.6 (CH x 2), 128.1 
(CH), 127.4 (CH x 2), 117.2 (CH), 107.2 (C), 101.9 (CH), 71.8 (CH2), 57.0 (Me), 56.9 (Me).  
4-(benzyloxy)-2,5-dimethoxybenzaldehyde (38) 
 
Phosphorus oxychloride (1 mL, 11,3 mmol) was added dropwise over 10 minutes, to a stirred 
solution of starting material 36 (2.5 g, 10.2 mmol) in DMF (10 mL), at 0°C. The solution was left to 
warm to room temperature and stirred overnight. When complete, aqueous NaOH (1M, 41 ml) was 
added to the mixture and a solid was formed. The sospension was filtered and the solid washed with 
water, and than purified by flash cromatography column (8:2 light etroleum, ethyl acetate). Yield 
84%, yellow solid, mp 133 °C, (Found: [M + Na
+
], 295.0938. C16H16NaO4
+
 requires 295.0941); 
vmax (CHCl3)/cm
-1
: 3008, 2939, 2870, 2836, 1667, 1606, 1511, 1468, 1453, 1414, 1349, 1278, 1177, 
1125; δH (400 MHz, CDCl3): 10.31 (1 H, s, CHO), 7.48 – 7.40 (5 H, m, C6H5), 7.37 (1 H, s, H-2), 
6.53 (1 H, s, H-3), 5.27 (2 H, s, CH2), 3.91 (3 H, s, OCH3), 3.82 (3 H, s, OCH3); δC (100 MHz, 
CDCl3): 188.0 (CHO), 158.3 (C), 154.8 (C), 144.0 (C), 135.9 (C), 128.8 (CH x 2), 128.3 (CH), 
127.2 (CH x 2), 117.6 (C), 109.5 (CH), 98.3 (CH), 71.1(CH2), 56.3 (Me), 56.1 (Me).  
4-(benzyloxy)-2,5-dimethoxybenzoic acid (39) 
 
To a solution of starting material 38 (2 g, 7.3 mmol) in a mixture of acetone (79 mL) and DMSO 
(32 mL), was added an aqueous solution (24 mL) of sulfamic acid (1.2 g, 12.5 mmol). The solution 
was cooled at 0°C and an aqueous solution (55 mL) of sodium chlorite (1.3 g, 14.7 mmol) was 
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added slowly. The reaction was stirred at 0°C for 30 minutes and then at room temperature for one 
night. Water (150 mL) was added and the solution was extracted with ethyl acetate (200 mL x 3). 
The organic layer was dried on MgSO4, filtered and concentrated in vacuo, to give an oil that was 
purified by flash cromatography column (8:2 dichloromethane, ethyl acetate). Yield 98 %, 
colourless solid, mp 135 °C; (Found: [M + H
+
], 289.1065. C16H17O5
+
 requires 289.1071); vmax 
(CHCl3)/cm
-1
: 3297, 3011, 2943, 2840, 1726, 1611, 1513, 1467, 1452, 1418, 1378, 1313, 1279, 
1239, 1177, 1167; δH (400 MHz, CDCl3): 12.4 (1 H, s, OH), 7.67 (1 H, s, H-6), 7.47 – 7.40 (5 H, m, 
C6H5), 6.59 (1 H, s, H-3), 5.27 (2 H, s, CH2), 3.95 (3 H, s, OCH3), 3.93 (3 H, s, OCH3); δC (100 
MHz, CDCl3): 165.2 (C), 153.3 (C), 153.2 (C), 144.6 (C), 135.8 (C), 128.8 (CH x 2), 128.4 (CH), 
127.2 (CH x 2), 114.9 (CH), 109.3 (C), 98.7 (CH), 71.4 (CH2), 57.2 (Me), 56.4 (Me).  
4-(benzyloxy)-N,N-diethyl-2,5-dimethoxybenzamide (40) 
 
To 7 mL of thionyl chloride at 0°C was added starting material 39 (2 g, 7 mmol) and the resulting 
solution was stirred at reflux for 1 hour. Excess of thionyl chloride was removed by distillation 
(using several toluene co-evaporations to ensure the complete removal off all thionyl chloride) to 
give a white solid which was taken up immediately onto next step. 
Diethylamine (1.45 mL, 13.9 mmol) was added to a solution of the above product in toluene (50 
mL) at 0°C, and the reaction was stirred for one night at room temperature. Upon complete the 
reaction was washed with diluite HCl (25 mL) and brine, than dried on MgSO4, and concentrated in 
vacuo to give a brown oil that was purified by flash cromatography column (9:1 light petroleum, 
ethyl acetate). Yield 76 %, colourless solid, mp 86 °C; (Found: [M + H
+
], 344.1856. C20H26NO4
+
 
requires 344.1856); vmax (CHCl3)/cm
-1
: 3004, 2937, 1612, 1510,1478, 1463, 1437, 1395, 1381, 
1364, 1314, 1280, 1192, 1147; δH (400 MHz, DMSO): 7.49 – 7.35 (5 H, m, C6H5), 6.84 (1 H, s, 
CH), 6.73 (1 H, s, CH), 5.14 (2 H, s, CH2), 3.73 (3 H, s, OCH3), 3.71 (3 H, s, OCH3), 3.46 – 3.38 
(2H, m, CH2), 3.09 (2 H, q, J 6.8, CH2), 1.12 (3 H, t, J 7.2, CH3), 0.98 (3 H, t, J 6.8, CH3); δC (100 
MHz, DMSO): 1675 (C), 149.5 (C), 149.1 (C), 143.4 (C), 137.4 (C), 128.9 (CH x 2), 128.5 (CH), 
128.4 (CH x 2), 118.7 (C), 112.2 (CH), 100.3 (CH), 70.7 (CH2), 56.8 (Me), 56.7 (Me), 42.7 (CH2),  
38.7 (CH2), 14.4 (Me), 13.4 (Me).  
 
 
122 
 
N,N-diethyl-2,4,5-trimethoxybenzamide (43) 
  
To 4 mL of thionyl chloride at 0°C was added 2,4,5-trimethoxybenzoic-acid (42) (1 g, 4.7 mmol) 
and the risultantig solution was stirred at reflux for 1 hour. Excess of thionyl chloride was removed 
by distillation (using several toluene co-evaporations to ensure the complete removal off all thionyl 
chloride) to give a white solid which was taken up immediately onto next step. 
Diethylamine (0.98 mL, 9.4 mmol) was added to a solution of the above product in toluene (50 mL) 
at 0°C, and the reaction was stirred for one night at room temperature. Upon complete the reaction 
was washed with diluted HCl (25 mL) and brine, than dried on MgSO4, and concentrated in vacuo 
to give a brown oil that was purified by flash cromatography column (8:2 light petroleum, ethyl 
acetate). Yield 74 %, colourless solid, mp 82 °C, (Found: [M + H
+
], 268.1535. C14H22NO4
+
 requires 
268.1543); vmax (CHCl3)/cm
-1
: 3003, 2938, 2847, 1612, 1513, 1479, 1463, 1437, 1390, 1364, 1337, 
1281, 1150, 1084; δH (400 MHz, DMSO): 6.72 (1 H, s, CH), 6.71 (1 H, s, CH), 3.82 (3 H, s, 
OCH3), 3.76 (3 H, s, OCH3), 3.70 (3 H, s, OCH3), 3.41 (2 H, broad, CH2), 3.09 (2 H, q, J 7.2, CH2), 
1.12 (3 H, t, J 7.2, CH3), 0.98 (3H, t, J 7.2, CH3); δC (100 MHz, DMSO): 167.6 (C), 150.2 (C), 
149.6 (C), 143.1 (C), 118.2 (C), 112.0 (CH), 98.7 (CH), 56.8 (Me), 56.7 (Me), 56.2 (Me), 42.7 
(CH2), 38.7 (CH2), 14.4 (Me), 13.3 (Me).  
(E)-2-(3,7-dimethylocta-2,6-dienyl)-N,N-diethyl-3,4,6-trimethoxybenzamide (44).
 
To a solution of starting material 43 (500 mg, 1.87 mmol) in dry THF (15 mL) at -78°C, was added 
TMEDA (0.42 mL, 2.80 mmol), secBuLi (1M in THF, 2.80 mL), Copper(I)iodide (533 mg, 2.80 
mmol) and geranyl bromide (0.55 mL, 2.80 mmol),  and the resultant mixture was left to warm to 
room temperature and stirred overnight (16h). The reaction was quenched by the addition of 
saturated aqueous ammonium chloride solution (15 mL), and ethyl acetate (15 mL). The aqueous 
layer was extracted always with ethyl acetate (2 x 30 mL), and then the organic layer was collect, 
dried and concentrated in vacuo, to give the crude product as a brown oil, that was purified by flash 
column chromatography (9:1 light petroleum, ethyl acetate). Yellow oil, Yield 72%, (Found: [M + 
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H
+
], 404.2796. C24H37NO4
+
 requires 404.2723); vmax (CHCl3)/cm
-1
: 2999, 2937, 2360, 1613, 1461, 
1430, 1380, 1364, 1333, 1281, 1241, 1144, 1090; δH (400 MHz, CDCl3): 6.40 (1 H, s, CH), 5.19 (1 
H, t, J 6.4, CH), 5.08 (1 H, t, J 6.9, CH), 3.90 (3 H, s, OCH3), 3.80 (3 H, s, OCH3), 3.76 (3 H, s, 
OCH3), 3.74 (1 H, dq, J 14.0, 7.2, CH2 Et), 3.46 (1 H, dq, J 14.6, 7.0, CH2 Et), 3.40 (1 H, dd, J 
12.8, 6.9, CH2), 3.23 (1 H, dd, J 12.8, 6.9, CH2), 3.18 (1 H, dq, J 14.6, 7.0, CH2 Et), 3.06 (1 H, dq, J 
14.0, 7.2, CH2 Et), 2.05 (2 H, q, J 8.4, CH2), 1.97 (2 H, t, J 8.4, CH2), 1.72 (3 H, s, CH3), 1.67 (3 H, 
s, CH3), 1.59 (3 H, s, CH3), 1.24 (3 H, t, J 7.2, CH3), 1.05 (3 H, t, J 7.2, CH3); δC (100 MHz, 
CDCl3): 167.8 (C), 153.3 (C), 151.7 (C), 141.5 (C), 135.0 (C), 133.4 (C), 131.3 (C), 124.4 (CH), 
122.7 (CH), 119.0 (C), 95.1 (CH), 60.6 (Me), 55.9 (Me x 2), 42.9 (CH2), 39.8 (CH2), 38.5 (CH2), 
26.7 (CH2), 26.6 (CH2), 25.6 (Me), 17.6 (Me), 16.2 (Me), 13.6 (Me), 12.7 (Me).  
N,N-diethyl-4-hydroxy-2,5-dimethoxybenzamide (45) 
 
Starting material (40) (3 g, 8.7 mmol) and Palladium on carbon (10% w/w 300 mg), were 
suspended in a mixture of ethyl acetate (50 mL) and ethanol (50 mL). An H2 atmosphere was 
created and the reaction was left to stirred for 15 hours at room temperature. Upon complete the 
suspension was filtered on a septum of celite than concentrated in vacuo to give the right product 
that didn’t need further purification. Yield 97% clear oil; (Found: [M + H+], 254.1380. C13H20NO4
+
 
requires 254.1387); vmax (CHCl3)/cm
-1
: 3535, 3000, 2939, 2844, 2455, 1726, 1608, 1513, 1479, 
1435, 1350, 1303, 1192, 1170; δH (400 MHz, DMSO): 9.26 (1 H, s, OH), 6.68 (1 H, s, CH), 6.52 (1 
H, s, CH), 3.72 (3 H, s, OCH3), 3.67 (3 H, s, OCH3), 3.43 – 3.36 (2 H, m, CH2), 3.09 (2 H, q, J 7.2, 
CH2), 1.12 (3 H, t, J 7.2, CH3), 0.98 (3 H, t, J 7.2, CH3); δC (100 MHz, DMSO): 167.8 (C) 149.8 
(C), 148.2 (C), 141.8 (C), 117.1 (C), 112.65 (CH), 101.0 (CH), 57.0 (Me), 56.2 (Me), 42.8 (CH2), 
38.7 (CH2), 14.5 (Me),14.4 (Me). 
N,N-diethyl-2,5-dimethoxy-4-(propan-2-yloxy)benzamide (48) 
 
2-Bromopropane  (0.65 mL, 6.91 mmol) was added to a stirred solution of starting material 45 (500 
mg, 1.97 mmol) and potassium carbonate (545 mg, 3.95 mmol) in DMF (8 mL), cooled at 0°C, and 
the resulting mixture was stirred at room temperature for 48 h. Upon complete the reaction was 
diluted with diethyl ether (15 mL) and washed with dilute HCl (20 mL), than extracted with ethyl 
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acetate (3 x 20 mL), dried on MgSO4, and concentrated in vacuo to give a brown oil that was 
purified by flash cromatography column (9:1 light petrol, ethyl acetate). Yield 60%, brown oil; 
(Found: [M + H
+
], 296.1851. C16H26NO4
+
 requires 296.1856); vmax (CHCl3)/cm
-1
: 2981, 2936, 2851, 
1612, 1509, 1477, 1464, 1439, 1393, 1317, 1280, 1192, 1173, 1150, 1110; δH (400 MHz, CDCl3): 
6.74 (1 H, s, CH), 6.52 (1 H, s, CH), 4.52 (1 H, septuplet, J 6.0, CH), 3.79 (3 H, s, OCH3), 3.75 (3 
H, s, OCH3), 3.54 (2 H, broad, CH2), 3.17 (2 H, q, J 7.2, CH2), 1.35 (6 H, d, J 6.0, CH3 x 2), 1.22 
(3H, t, J 7.2, CH3), 1.03 (3H, t, J 7.2, CH3); δC (100 MHz, CDCl3): 168.5 (C), 149.5 (C), 148.4 (C), 
144.8 (C), 119.1 (C), 112.2 (CH), 102.3 (CH), 72.1 (CH), 56.6 (Me), 56.5 (Me), 42.9 (CH2), 38.9 
(CH2), 22.1 (Me x 2), 14.0 (Me), 12.9 (Me). 
N,N-diethyl-2,5-dimethoxy-4-(triisopropylsilyloxy)benzamide (46) 
 
Chlorotriisopropylsilane (1.27 mL, 5.93 mmol) was added to a stirred solution of starting material 
(45) (1.5 g, 5.93 mmol) and imidazole (815 mg, 11.8 mmol) in DMF (15 mL), and the resulting 
mixture was stirred at room temperature for 15 hours. The reaction was diluted with diethyl ether 
(20 mL), washed with water and brine (20 mL x 3), and then dried on MgSO4, and concentrated in 
vacuo to give the crude product as clear oil, that didn’t need further purification. Yield 96%, Clear 
oil; (Found: [M + H
+
], 410.2728. C22H40NO4Si
+
 requires 410.2721); vmax (CHCl3)/cm
-1
: 2945, 2868, 
1610, 1512, 1464, 1446, 1394, 1365, 1332, 1279, 1251, 1174, 1154; δH (400 MHz, DMSO): 6.75 (1 
H, s, CH), 6.52 (1 H, s, CH), 3.71 (3 H, s, OCH3), 3.68 (3 H, s, OCH3), 3.41 (2 H, broad, CH2), 3.08 
(2 H, q, J 7.2, CH2), 1.30 – 1.20 (3 H, m, CH x 3), 1.12 (3 H, t, J 7.2, CH3), 1.07 (18 H, d, J 7.2, 
CH3 x 6), 0.97 (3 H, t, J 7.2, CH3); δC (100 MHz, DMSO): 167.5 (C), 149.3 (C), 145.9 (C), 144.8 
(C), 119.7 (C), 112.2 (CH), 105.4 (CH), 56.5 (Me), 56.4 (Me), 42.7 (CH2), 38.8 (CH2), 18.2 (Me x 
6), 14.4 (Me), 13.4 (Me), 12.5 (CH x 3).  
(E)-2-(3,7-dimethylocta-2,6-dienyl)-N,N-diethyl-3,6-dimethoxy-4-
(triisopropylsilyloxy)benzamide (47). 
 
To a  solution  of  starting  material  (46)  (1g, 2.45 mmol)  in  THF  (30 mL)  at  -78°C,  was  added  
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TMEDA (0.55 mL, 3.67 mmol), secBuLi (1M in THF, 3.67 mL), Copper(I)iodide (697 mg, 3.67 
mmol) and geranyl bromide (0.73 mL, 3.67 mmol),  and the resultanting mixture was left to warm 
to room temperature and stirred overnight (16h). The reaction was quenched by the addition of 
saturated aqueous ammonium chloride solution (30 mL), and ethyl acetate (30 mL). The aqueous 
layer was extracted always with ethyl acetate (2 x 50 mL), and then the organic layer was collect, 
dried and concentrated in vacuo, to give the crude product as a brown oil, that was purified by flash 
column chromatography (9:1 light petroleum, ethyl acetate). Yellow oil, Yield 58% (Found: [M + 
H
+
], 546.3980. C32H56NO4Si
+
 requires 546.3973); vmax (CHCl3)/cm
-1
: 2944, 2868, 2461, 1613, 
1463, 1444, 1405, 1381, 1346, 1313, 1284, 1241, 1148; δH (400 MHz, DMSO): 6.36 (1 H, s, CH), 
5.04 (1 H, t, J 6.8, CH), 5.02 (1 H, t, J 7.5, CH), 3.66 (3 H, s, OCH3), 3.65 (3 H, s, OCH3), 3.53 (1 
H, dq, J 13.6, 7.0, CH2 Et), 3.26 (1 H, dq, J 13.6, 7.0, CH2 Et), 3.23 (1 H, dd, J 14.4, 7.5, CH2), 3.04 
(1 H, dd, J 14.4, 7.5, CH2), 3.00 (2 H, q, J 7.2, CH2), 1.99 (2 H, q, J 6.8, CH2), 1.90 (2 H, t, J 6.8, 
CH2), 1.62 (3 H, s, CH3), 1.60 (3 H, s, CH3), 1.53 (3 H, s, CH3), 1.30 (3 H, septuplet, J 7.5, SiCH x 
3), 1.10 – 1.06 (21 H, m, CH3 x 6, CH3(Et)), 0.94 (3 H, t, J 7.2, CH3); δC (100 MHz, DMSO): 166.7 
(C), 151.4 (C), 149.3 (C), 143.2 (C), 134.6 (C), 133.2 (C), 131.1 (C), 124.5 (CH), 123.0 (CH), 
120.0 (C), 102.5 (CH), 60.6 (Me), 55.9 (Me), 42.7 (CH2), 39.6 (CH2), 38.5 (CH2), 26.7 (CH2), 26.4 
(CH2), 25.9 (Me), 18.3 (Me x 6), 17.9 (Me), 16.4 (Me), 13.9 (Me), 13.0 (Me), 12.7 (CH x 3). 
(E)-2-(3,7-dimethylocta-2,6-dienyl)-N,N-diethyl-3,6-dimethoxy-4-hydroxybenzamide (52).   
 
To a solution of starting material (47) (910 mg, 1.7 mmol) in THF (20 mL), was added TBAF (1M 
in THF, 2.5 mL), and the solution was stirred at room temperature for one night (15h). The resulting 
solution was diluted with ether (100 mL), washed with water and brine (100 mL x 2), dried and 
concentrated in vacuo to give the crude product as a brown oil, that was purified by flash column 
cromatography (8 : 2 light petroleum; ethyl acetate).  Clear oil, Yield 95% (Found: [M + H
+
], 
390.2640. C23H36NO4
+
 requires 390.2639); vmax (CHCl3)/cm
-1
: 3011, 1602, 1521, 1473, 1430, 1282, 
1241, 1164, 1051; δH (400 MHz, CDCl3):  6.44 (1 H, s, CH), 5.88 (1 H, broad, OH), 5.20 (1 H, t, J 
6.0, CH), 5.08 (1 H, t, J 6.4, CH), 3.76 (3 H, s, OCH3), 3.74 – 3.70 (4 H, m, OCH3, CH2 Et), 3.45 (1 
H, dq, J 14.6, 7.0, CH2 Et), 3.41 (1 H, dd, J 12.8, 6.9, CH2), 3.26 (1 H, dd, J 12.8, 6.9, CH2), 3.20 (1 
H, dq, J 14.6, 7.0, CH2 Et), 3.07 (1 H, dq, J 14.0, 7.2, CH2 Et), 2.06 (2 H, t, J 7.6, CH2), 1.99 (2 H, 
t, J 7.6, CH2), 1.72 (3 H, s, CH3), 1.67 (3 H, s, CH3), 1.59 (3 H, s, CH3), 1.23 (3 H, t, J 7.2, CH3), 
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1.06 (3 H, t, J 7.2, CH3); δC (100 MHz, CDCl3): 167.7 (C), 152.4 (C), 149.7 (C), 139.3 (C), 135.5 
(C), 132.7 (C), 131.4 (C), 124.4 (CH), 122.4 (CH), 118.8 (C), 97.3 (CH), 61.4 (Me), 55.6 (Me), 
42.9 (CH2), 39.7 (CH2), 38.4 (CH2), 26.6 (CH2), 26.5 (CH2), 25.7 (Me), 17.6 (Me), 16.2 (Me), 13.6 
(Me), 12.7 (Me). 
(E)-2-(3,7-dimethylocta-2,6-dienyl)-N,N-diethyl-3,6-dimethoxy-4-benzyloxybenzamide (41). 
 
Benzyl bromide (0.23 mL, 1.98 mmol), was added to a stirred solution of starting material (52) (700 
mg, 1.8 mmol) and Cesium carbonate (1.18 g, 3.6 mmol) in acetonitrile (30 mL), and the 
resultanting mixture was stirred at room temperature for two hours. The reaction was diluted with 
ether (150 mL), and washed with water and brine (120 mL). The organic phase was dried on 
MgSO4, and removed in vacuo, to give the crude benzyl-ether product which was purified by flash 
column cromatography (9 : 1 light petroleum; ethyl acetate). Clear oil, Yield 89% (Found: [M + 
H
+
], 480.3115. C30H42NO4
+
 requires 480.3108); vmax (CHCl3)/cm
-1
: 3091, 2995, 2936, 1614, 1463, 
1444, 1431, 1409, 1381, 1332, 1281, 1241, 1144, 1089; δH (400 MHz, CDCl3): 7.50 – 7.35 (5 H, m, 
Ar), 6.45 (1 H, s, CH), 5.20 (1 H, t, J 6.2, CH), 5.15 (2 H, d, J 4.9, CH2), 5.09 (1 H, t, J 7.0, CH), 
3.81 (3 H, s, OCH3), 3.73 - 3.70 (4H, m, OCH3, CH2 Et), 3.45 (1 H, dq, J 14.2, 7.2, CH2 Et), 3.42 (1 
H, dd, J 14.9, 7.0, CH2), 3.26 (1 H, dd, J 14.9, 7.0, CH2), 3.18 (1 H, dq, J 14.2, 7.2, CH2 Et), 3.08 (1 
H, dq, J 14.2, 6.3, CH2 Et), 2.06 (2 H, t, J 8.0, CH2), 1.98 (2 H, t, J 8.0, CH2), 1.74 (3 H, s, CH3), 
1.67 (3 H, s, CH3), 1.60 (3 H, s, CH3), 1.24 (3 H, t, J 7.2, CH3), 1.05 (3H, t, J 7.2, CH3); δC (100 
MHz, CDCl3): 167.7 (C), 152.2 (C), 151.5 (C), 142.1 (C), 136.9 (C), 135.0 (C), 133.5 (C), 131.3 
(C), 128.6 (CH x 2), 128.0 (CH), 127.3 (CH x 2), 124.4 (CH), 122.7 (CH), 119.6 (C), 97.2 (CH), 
71.0 (CH2), 60.7 (Me), 55.8 (Me), 42.9 (CH2), 39.8 (CH2), 38.5 (CH2), 26.9 (CH2), 26.7 (CH2), 25.7 
(Me), 17.6 (Me), 16.2 (Me), 13.6 (Me), 12.7 (Me). 
N,N-diethyl-2-hydroxy-4-((Triisopropylsilyl)oxy)-5-methoxybenzamide (55). 
 
To a solution of starting material 46 (350 mg, 0.85 mmol) in dichloromethane (15 mL), was added  
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at 0°C boron trichloride (1M solution in hexane, 1.71 mL) and the reaction was left to stirrer at 
room temperature for 1h. Ice was added, and the reaction was extracted with dichlorometane (2 x 20 
mL). The organic phase was dried on MgSO4, and removed in vacuo, to give the crude unprotected 
phenol that didn’t need further purification. Yield 94%, beige solid, mp 92 °C; (Found: [M + H+], 
396.2559. C21H38NO4Si
+
 requires 396.2565); vmax (CHCl3)/cm
-1
: 3216, 2946, 2868, 1628, 1587, 
1508, 1478, 1464, 1438, 1384, 1350, 1329, 1263, 1242, 1159, 1099; δH (400 MHz, CDCl3): 6.80 (1 
H, s, CH), 6.55 (1 H, s, CH), 3.77 (3 H, s, OCH3), 3.53 (4 H, q, J 7.2, CH2 x 2), 1.33 – 1.28 (9 H, m, 
CH3 x 2, CH x 3), 1.12 (18 H, d, J 7.2, CH3 x 6);
 
 δC (100 MHz, CDCl3): 171.9 (C), 155.0 (C), 
150.0 (C), 143.3 (C), 112.0 (CH), 109.7 (CH), 109.3 (C), 56.7 (Me), 42.2 (CH2 x 2), 17.8 (Me x 6), 
13.4 (Me x 2), 12.8 (CH x 3).   
 
9.10.2 Second Approach Fragment A 
methyl 2,4-dihydroxybenzoate (58). 
 
To a solution of 2-3-dihydroxybenzoic acid 57 (4g, 26 mmol) in DMF (39 mL), potassium 
hydrogen carbonate (3.12g, 31.2 mmol) was added and the solution stirred for several minutes at 
room temperature. Then, methyl iodide (2.45 mL, 39 mmol) was added, and the reaction mixture 
was warmed to 40°C and stirred for 2 hours. Water (130 mL) was added and the resulting mixture 
was extracted with ethyl acetate (4 x 120 mL). The organic layer was subsequently washed with 5 
% sodium bicarbonate solution and 5 % brine, and dried over MgSO4, filtered and concentrated 
under reduced pressure to give the crude product that was purified by flash column chromatography 
(8 : 2 light petroleum; ethyl acetate). Yield 97%, colourless solid, mp 119 °C; (Found: [M + H
+
], 
169.0496. C15H14NaO4
+
 requires 169.0495); vmax (CHCl3)/cm
-1
: 3585, 3011, 2956, 1671, 1625, 
1600, 1511, 1442, 1346, 1272, 1186, 1143, 1096; δH (400 MHz, DMSO): 10.72 (1 H, s, OH), 10.46 
(1 H, s, OH), 7.65 (1 H, d, J 8.8, CH), 6.39 (1 H, dd, J 8.8, 2.3, CH), 6.31 (1 H, d, J 2.3, CH), 3.85 
(3 H, s, OCH3); δC (100 MHz, DMSO): 170.0 (C), 164.7 (C), 163.1 (C), 132.0 (CH), 108.8 (CH), 
104.4 (C), 102.9 (CH), 52.5 (Me).  
methyl 4-(benzyloxy)-2-hydroxybenzoate (59). 
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A mixture of 58 (4g, 23.8 mmol) and anhydrous potassium carbonate (4.9g 35.7 mmol) in acetone 
(22 mL), was stirred at room temperature for 5 minutes. Benzyl bromide (2.83 mL, 23.8 mmol), 
was added dropwise into the reaction flask and the mixture was stirred at 10-15°C for 3 hours. 
Water (30 mL) and ethyl acetate (30 mL) were added and two phases were separated. The aqueous 
phase was extracted with further ethyl acetate (3 x 40 mL). The combined organic layers were 
washed with brine (40 mL), dried over MgSO4, filtered and concentrated under reduced pressure to 
give the crude product, which was purified by flash column chromatography (9 : 1 light petroleum; 
ethyl acetate). Yield 82% colourless solid, mp 104 °C, (Found: [M + Na
+
], 281.0781. C15H14NaO4
+
 
requires 281.0784); vmax (CHCl3)/cm
-1
: 3008, 2956, 1668, 1623, 1583, 1505, 1441, 1382, 1349, 
1255, 1183, 1142, 1099, 1014; δH (400 MHz, DMSO): 10.78 (1 H, s, OH); 7.74 (1 H, d, J 7.2, CH), 
7.47 – 7.36 (5 H, m, Ar), 6.64 – 6.61 (2 H, m, CH x 2), 5.18 (2 H, s, CH2), 3.88 (3 H, s, OCH3); δC 
(100 MHz, DMSO): 169.8 (C), 164.7 (C), 163.0 (C), 136.8 (C), 131.8 (CH), 128.9 (CH x 2), 128.5 
(CH), 128.2 (CH x 2), 108.5 (CH), 105.9 (C), 102.4 (CH), 70.1 (CH2), 52.7 (Me).  
methyl 4-(benzyloxy)-2,5-dihydroxybenzoate (60). 
 
To a stirred mixture of starting material 59 (3.5g 13.5 mmol) in aqueous solution of NaOH (1M 135 
mL), was added over 30 minutes, a solution of potassium persulfate (7.7g 28.5 mmol) in water (135 
mL), at 0°C. After stirring for 20 hours at room temperature, the reaction mixture was acidified to 
pH 4 with HCl conc. The mixture was filtered to remove the starting material unreacted (2.25g), 
and to the aqueous phase was added further HCl conc. (30 mL), and heated to 80 °C for 2 hours. 
After cooling at room temperature, ethyl acetate (150 mL) was added, and then the aqueous layer 
was extracted with further ethyl acetate (3 x 200 mL). The organic phases, were collect, dried on 
MgSO4 and evaporated to give a dark oil that was purified by column cromatography (9 : 1 light 
petroleum; ethyl acetate). The product obtained was furthermore crystallized with methanol and 
then filtered to give a colourless solid. Yield 15%, mp 165.8 °C, (Found: [M + Na
+
], 297.0716. 
C15H14NaO5
+
 requires 297.0733); vmax (CHCl3)/cm
-1
: 3684, 3555, 3011, 2956, 2414, 1669, 1635, 
1509, 1440, 1399, 1374, 1276, 1239, 1168, 1082, 1000; δH (400 MHz, DMSO): 10.33 (1 H, s, OH), 
8.94 (1 H, s, OH), 7.50 – 7.35 (5 H, m, Ar), 7.18 (1 H, s, CH), 6.63 (1 H, s, CH), 5.18 (2 H, s, CH2), 
3.86 (3 H, s, OCH3); δC (100 MHz, DMSO): 170.0 (C), 156.1 (C), 154.2 (C), 140.1 (C), 136.9 (C), 
128.9 (CH x 2), 128.4 (CH), 128.2 (CH x 2), 114.4 (CH), 103.7 (C), 102.1 (CH), 70.2 (CH2), 52.6 
(Me). 
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methyl 4-(benzyloxy)-2-hydroxy-5-(methoxymethoxy)benzoate (61). 
 
To a solution of 60 (450 mg, 1.64 mmol) in dichloromethane (18 mL), were added at 0°C, DIPEA 
(0.51 mL, 2.95 mmol), and after few minutes, MOMCl (0.14 mL, 1.8 mmol). The mixture was 
stirred for 2 hours at room temperature. Water (15 mL) was then added and the mixture was 
extracted with ethyl acetate (3 x 15 mL). The organic layer was dried over MgSO4, and evaporated. 
The residue was purified by flash column cromatography (9:1 light petroleum, ethyl acetate) to give 
the title compound like a colourless solid Yield 78%, mp 104.3 °C, (Found: [M + Na
+
], 341.0994. 
C17H18NaO6
+
 requires 341.0996); vmax (CHCl3)/cm
-1
: 3011, 2955, 1668, 1620, 1511, 1497, 1441, 
1355, 1259, 1192, 1162, 1097, 1070, 988; δH (400 MHz, DMSO): 10.58 (1 H, s, OH), 7.48 – 7.37 
(6 H, m, Ar, CH), 6.73 (1 H, s, CH), 5.20 (2 H, s, CH2), 5.09 (2 H, s, CH2), 3.88 (3 H, s, OCH3), 
3.39 (3 H, s, OCH3); δC (100 MHz, DMSO): 169.7 (C), 158.4 (C), 156.3 (C), 139.5 (C), 136.6 (C), 
129.0 (CH x 2), 128.6 (CH), 128.3 (CH x 2), 117.8 (CH), 103.9 (C), 102.4 (CH), 96.2 (CH2), 70.5 
(CH2), 56.2 (Me), 52.7 (Me).  
 
9.10.3 Fragment B 
5-((Triisopropylsilyl)oxy)benzene-1,3-diol (65). 
 
Chlorotriisopropylsilane (1.7 mL, 7.93 mmol) was added to a stirred solution of phloroglucinol 64 
(3g, 23.8 mmol) and imidazole (540 mg, 7.93 mmol) in DMF (70 mL), and the resulting mixture 
was stirred at room temperature for one night. The reaction was diluted with diethyl ether (100 mL), 
washed with water and brine (100 mL x 3), and then dried on MgSO4, and concentrated in vacuo to 
give the crude product as a yellow oil, that was purified by flash column chromatography (light 
petroleum, ethyl acetate 9:1) to give the title compound as a clear oil. Yield 61%; (Found: [M + H
+
], 
283.1720. C15H27O3Si1
+
 requires 283.1724); vmax (CHCl3)/cm
-1
: 3324, 3010, 2946, 2868, 1670, 
1603, 1498, 1463, 1387, 1145; δH (270 MHz, CDCl3): 6.14 (2 H, broad, OH), 6.00 (2 H, d, J 2.1, H-
2, H-6), 5.96 (1 H, t, J 2.1, H-4), 1.27 – 1.14 (3 H, m, CH  x 3), 1.04 (18 H, d, J 6.8, CH3 x 6); δC 
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(68 MHz, CDCl3): 158.1 (C), 157.1 (C x 2), 100.5 (CH x 2), 96.4 (CH), 17.9 (Me x 6), 12.7 (CH x 
3). 
3,5-bis(Benzyloxy)phenol (66). 
 
Benzyl bromide (1.77 mL, 14.9 mmol), was added to a stirred solution of starting material 65 (2g, 
7.1 mmol) and cesium carbonate (5.1g, 15.6 mmol) in acetonitrile (50 mL), and the resultanting 
mixture was stirred at room temperature for two hour. The reaction was diluted with diethyl ether 
(250 mL), and washed with water and brine (200 mL). The organic phase was dried on MgSO4, and 
removed in vacuo, to give the crude benzyl protected product which was taken up immediately onto 
next step. 
TBAF (1M in THF, 10.6 mL) was added to a stirred solution of the above product in THF (50 mL), 
and the reaction was stirred at room temperature for one night. The resulting solution was diluted 
with ether (250 mL), washed with water and brine (150 mL x 2), dried and concentrated in vacuo to 
give the crude product as a brown oil, that was purified by flash column chromatography (light 
petroleum, ethyl acetate 9:1) to give the title compound as a white solid. Yield on two step 41%; 
colourless solid, mp 89 °C; (Found: [M + H
+
], 307.1319. C20H19O3
+
 requires 307.1329); vmax 
(CHCl3)/cm
-1
: 3409, 3068, 3010, 2933, 2876, 1601, 1494, 1454, 1375, 1275, 1153; δH (400 MHz, 
CDCl3): 7.44 – 7.35 (10 H, m, Ar), 6.27 (1 H, t, J 2.0, H-4), 6.13 (2 H, d, J 2.0, H-2, H-6), 5.02 (4 
H, s, CH2 x 2), 4.78 (1 H, s, OH); δC (100 MHz, CDCl3): 160.8 (C x 2), 157.2 (C), 136.8 (C x 2), 
128.6 (CH x 4), 128.0 (CH x 2), 127.5 (CH x 4), 95.3 (CH x 2), 94.9 (CH), 70.1 (CH2 x 2).   
3,5-bis(Benzyloxy)-2-bromophenol (67) 
 
To a solution of 66 (1g, 3.27 mmol) in dichloromethane (50 mL) at -78°C, was added slowly NBS 
(0.58 g, 3.27 mmol). After three hours the reaction was complete and was quenched with an 
aqueous solution of potassium carbonate at 10% (25 mL), than warmed at room temperature. The 
mixture was diluted with water (200 mL), and extracted with dichloromethane (150 mL x 2), than 
the organic phase was collected, dried on MgSO4, and concentrated in vacuo and purified by flash 
column chromatography (9:1 light petroleum, ethyl acetate). Yield 88%, beige solid, mp 81 °C; 
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(Found: [M + H
+
], 385.0441. C20H18BrO3
+
 requires 385.0434); vmax (CHCl3)/cm
-1
: 3068, 3011, 
2878, 1596, 1498, 1483, 1446, 1375, 1307, 1190, 1159; δH (400 MHz, CDCl3): 7.48 – 7.33 (10 H, 
m, Ar x 2), 6.38 (1 H, d, J 2.4, H-4), 6.27 (1 H, d, J 2.8, H-2), 5.68 (1 H, s, OH), 5.11 (2 H, s, CH2), 
5.02 (2 H, s, CH2); δC (100 MHz, CDCl3): 159.7 (C), 155.9 (C), 153.9 (C), 136.4 (C), 136.3 (C), 
128.7 (CH x 2), 128.6 (CH), 128.2 (CH), 128.0 (CH x 2), 127.6 (CH x 2), 127.0 (CH x 2), 94.7 
(CH), 94.6 (CH), 92.0 (C), 70.8 (CH2), 70.4 (CH2).  
3,5-bis(benzyloxy)-2-(trimethylsilyl)phenyl-trifluoromethanesulfonate (62) 
  
To a solution of bromophenol 67 (250 mg, 0.65 mmol) in THF (2.5 mL), was added HMDS (300 
μL, 1.43 mmol), and the solution was heated to 70°C and maintained for 5 h. The reaction was 
cooled to room temperature and concentrated under vacuum, and the resulting oil was immediately 
taken on to the next step. 
The crude was taken up in THF (9 mL) and cooled to -100°C. n-Butyllithium (2.5 M in hexanes, 
310 μL, 0.78 mmol) was added slowly and the reaction was allowed to warm to -82°C. The reaction 
was cooled again to -100°C and maintained between -100°C and -82°C for 30 minutes. 
After this period, triflic anhydride (142 μL, 0.84 mmol) was added at -100°C. The reaction was 
warmed to -80°C, quenched by the addition of saturated aqueous sodium bicarbonate solution (5 
mL), and subsequently warmed to room temperature. The reaction was diluted with diethyl ether 
(20 mL) and washed with brine (15 mL). The organic layer was dried with MgSO4, concentrated 
under vacuum, and purified by flash column chromatography (98:2 light petroleum, ethyl acetate). 
Yield 70 %, clear oil, (Found: [M + H
+
], 511.1226. C24H26F3O5SSi
+
 requires 511.1217); vmax 
(CHCl3)/cm
-1
: 3156, 3011, 2902, 2253, 1794, 1603, 1562, 1466, 1381, 1300, 1140, 1092, 1040; δH 
(400 MHz, CDCl3): 7.43 – 7.39 (10 H, m, Ar x 2), 6.60 (1 H, d, J 2.0, H-3), 6.55 (1 H, d, J 2.0, H-
5), 5.05 (2 H, s, CH2), 5.04 (2 H, s, CH2), 0.33 (9 H, s, CH3 x 3); δF (376.5 MHz, CDCl3): -72.62 (3 
F, s, CF3); δC (100 MHz, CDCl3): 165.2 (C), 161.5 (C), 155.3 (C), 136.0 (C), 135.9 (C), 128.8 (CH 
x 2), 128.6 (CH x 2), 128.4 (CH), 128.2 (CH), 127.8 (CH x 2), 127.6 (CH x 2), 118.6 (Me, JC-F = 
321 Hz), 112.6 (C),  99.3 (CH), 99.1 (CH), 70.9 (CH2), 70.5 (CH2), 1.0 (Me x 3).  
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9.10.4 Toward the synthesis of Toxyloxanthone and Rubraxanthone 
 
1,3,6-tri(benzyloxy)-7-(methoxymethoxy)-9H-xanthen-9-one (63). 
 
To a solution of fragment A 61 (409 mg, 1.28 mmol) in dry THF (15 mL), was added sodium 
hydride (1.29 mmol) and the mixture was left to stirrer for 45 minutes. The mixture was heated to 
65°C and was added Caesium fluoride first, and then was added a solution of fragment B 62 (720 
mg, 1.41 mmol) in dry THF (10 mL), over 30 minutes. The mixture was stirred for 24 h always at 
65°C, then was cooled, and was diluted with ether (100 mL), and washed with brine (100 mL). The 
aqueous layer was extracted with ethyl acetate (2 x 60 mL), then dried over MgSO4, filtered and 
evaporated to give a residue that was purified by flash column chromatography (8:2 light 
petroleum, ethyl acetate) Light brown solid yield 40% mp 149 °C, (Found: [M + H
+
], 575.2062. 
C36H31O7
+
 requires 575.2064); vmax (CHCl3)/cm
-1
: 3691, 3068, 3010, 2931, 1715, 1644, 1624, 1606, 
1499, 1453, 1438, 1376, 1268, 1182, 1156, 1122, 1076; δH (400 MHz, CDCl3):  8.00 (1 H, s, CH), 
7.67 (2 H, d, J 7.15, Ar), 7.51 – 7.34 (13 H, m, Ar), 6.87 (1 H, s, CH), 6.55 (1 H, d, J 2.3, CH), 6.50 
(1 H, d, J 2.3, CH), 5.31 (2 H, s, CH2), 5.27 (2 H, s, CH2), 5.25 (2 H, s, CH2), 5.14 (2 H, s, CH2), 
3.56 (3 H, s, OCH3); δC (100 MHz, CDCl3): 174.3 (C), 163.3 (C), 160.7 (C), 159.7 (C), 154.6 (C), 
151.6 (C), 143.9 (C), 136.4 (C), 135.9 (C), 135.8 (C), 128.8 (CH x 4), 128.6 (CH x 2), 128.4 (CH), 
128.3 (CH), 127.7 (CH), 127.6 (CH x 2), 127.2 (CH x 2), 126.8 (CH x 2), 116.6 (C), 113.2 (CH), 
107.5 (C), 101.0 (CH), 97.2 (CH), 96.1 (CH2), 94.0 (CH), 71.0 (CH2), 70.8 (CH2), 70.5 (CH2), 56.4 
(Me). 
7-(hydroxy)-1,3,6-tri(benzyloxy)-9H-xanthen-9-one (69). 
 
To a solution of starting material 63 (380 mg, 0.66 mmol) in anhydrous dichloromethane (24 mL), 
was added trifluoroacetic acid (4 mL) at 0 °C, and the reaction mixture was stirred for 30 minutes at 
room temperature. Saturated sodium hydrogen carbonate (30 mL) was added slowly and the 
mixtyre extracted with ethyl acetate (3 x 30 mL). The combined organics fractions were washed 
with saturated brine solution (10 mL), dried over MgSO4, filtered and concentrated in vacuo to give 
an oil that was purified by flash column chromatography (7:3 light petrol, ethyl acetate). Yield 94%, 
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colourless solid, mp 174 °C, (Found: [M + H
+
], 531.1814. C34H27O6
+
 requires 531.1802); vmax 
(CHCl3)/cm
-1
: 3687, 3603, 3011, 2437, 1630, 1602, 1500, 1438, 1272, 1239, 1174, 1118, 1017; δH 
(400 MHz, CDCl3): 7.82 (1 H, s, CH), 7.62 (2 H, d, J 7.3, Ar), 7.48 – 7.35 (13 H, m, Ar), 6.91 (1 H, 
s, CH), 6.54 (1 H, s, CH), 6.48 (1 H, s, CH), 5.27 (2 H, s, CH2), 5.24 (2 H, s, CH2), 5.13 (2 H, s, 
CH2); δC (100 MHz, CDCl3): 175.0 (C), 163.5 (C), 160.7 (C), 159.8 (C), 151.2 (C), 150.2 (C), 
143.0 (C), 136.3 (C), 135.7 (C), 135.0 (C), 129.0 (CH x 2), 128.9 (CH), 128.8 (CH x 2), 128.7 (CH 
x 2), 128.4 (CH), 127.9 (CH x 2), 127.8 (CH), 127.6 (CH x 2), 126.8 (CH x 2), 117.0 (C), 109.9 
(CH), 107.3 (C), 99.6 (CH), 97.1 (CH), 94.0 (CH), 71.6 (CH2), 70.8 (CH2), 70.5 (CH2).  
7-(2,2-dimethylbut-3-yn-1-yl)-1,3,6-tri(benzyloxy)-9H-xanthen-9-one (70). 
 
Potassium carbonate (82 mg, 0.594 mmol) and potassium iodide (82 mg) were added to a solution 
of starting material 69 (150 mg, 0.283 mmol) in acetone (15 mL). Commercially 3-chloro-3-methyl-
1-butyne (80 μL, 0.707 mmol) was added in a single portion and the reaction mixture was heated to 
reflux and stirred for 48 hours. After cooling ether (60 mL) was added, and the ethereal solution 
was washed with 1N NaOH (3 x 10 mL). The organic layer was dried over MgSO4, and 
concentrated in vacuo to give a solid that was purified by flash column chromatography (8:2 light 
petroleum, ethyl acetate). Yield 75% colourless solid, mp 162 °C, (Found: [M + H
+
], 597.2287. 
C39H33O6
+
 requires 597.2272); vmax (CHCl3)/cm
-1
: 3689, 3305, 3011, 1645, 1623, 1605, 1498, 1443, 
1379, 1270, 1182, 1119, 1048, 1028; δH (400 MHz, CDCl3): 8.28 (1H, s, CH), 7.65 (2H, d, J = 7.3 
Hz, Ar), 7.52 (2H, d, J = 7.3 Hz, Ar), 7.46 – 7.34 (11H, m, Ar), 6.89 (1H, s, CH), 6.55 (1H, d, J = 
1.8 Hz, CH), 6.49 (1H, d, J = 1.8 Hz, CH), 5.28 (2H, s, CH2), 5.20 (2H, s, CH2), 5.13 (2H, s, CH2), 
2.57 (1H, s, CH), 1.72 (6H, s, CH3 x 2); δC (100 MHz, CDCl3): 174.5 (C), 163.2 (C), 160.7 (C), 
159.7 (C), 157.4 (C), 152.5 (C), 142.2 (C), 136.4 (C), 136.0 (C), 135.7 (C), 128.8 (CH x 2), 128.7 
(CH x 2), 128.6 (CH x 2), 128.4 (CH), 128.1 (CH), 127.7 (CH), 127.6 (CH x 2), 127.2 (CH x 2), 
126.8 (CH x 2), 119.9 (CH), 116.4 (C), 107.6 (C), 100.7 (CH), 97.2 (CH), 94.1 (CH), 85.5 (C), 74.9 
(C), 74.3 (CH), 70.9 (CH2), 70.8 (CH2), 70.5 (CH2), 29.6 (Me x 2). 
5,9,11-tri(benzyloxy)-3,3-dimethylpyrano[3,2-a]xanthen-12(3H)-one (71). 
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A solution of starting material 70 (60 mg) in toluene (14 mL) was heated under reflux for 2 hours 
and half. The solvent was evaporated and the residue purified by flash column chromatography (8:2 
light petroleum, ethyl acetate). Colourless solid, yield 97% mp 182 °C; (Found: [M + H
+
], 
597.2283. C39H33O6
+
 requires 597.2272); vmax (CHCl3)/cm
-1
: 3689, 3606, 3011, 2928, 1701, 1615, 
1438, 1378, 1274, 1192, 1166, 1125, 1059, 1016; δH (400 MHz, CDCl3): 8.14 (1 H, d, J 9.8, CH), 
7.62 (2H, d, J 7.3, Ar), 7.49 – 7.35 (13 H, m, Ar), 6.74 (1 H, s, CH), 6.48 (1 H, d, J 2.1, CH), 6.43 
(1 H, d, J 2.1, CH), 5.85 (1 H, d, J 9.8, CH), 5.30 (4 H, s, CH2 x 2), 5.09 (2 H, s, CH2), 1.53 (6 H, s, 
CH3 x 2); δC (100 MHz, CDCl3): 176.9 (C), 162.9 (C), 160.5 (C), 158.8 (C), 152.3 (C), 151.3 (C), 
139.8 (C), 136.6 (C), 136.4 (C), 131.8 (CH), 128.8 (CH x 2), 128.7 (CH x 2), 128.6 (CH x 2), 128.4 
(CH), 128.0 (CH), 127.6 (CH x 3), 126.9 (CH x 2), 126.7 (CH x 2), 121.6 (CH), 120.9 (C), 111.8 
(C), 108.5 (C), 101.1 (CH), 97.3 (CH), 93.5 (CH), 75.3 (C), 70.8 (CH2), 70.7 (CH2), 70.4 (CH2), 
27.1 (Me x 2).  
5,9,11-trihydroxy-3,3-dimethylpyrano[3,2-a]xanthen-12(3H)-one (Toxyloxanthone B) (72). 
 
To a stirred solution of starting material 71 (20 mg, 0.033 mmol), and pentamethylbenzene (45 mg, 
0.3 mmol) in dry dichloromethane (1 mL), was added BCl3 (0.2 mL, solution 1 M in hexane,) 
dropwise over 10 min at -78 °C. After 45 min, the reaction mixture was quenched with a mixture 
chloroform-methanol (10:1, 4mL) at -78 °C and warmed to room temperature. The excess of 
solvents were removed under reduced pressure. The residue was purified by preparative TLC (8:2:1 
cyclohexane, ethyl acetate, methanol). Yield 65% pale yellow solid, mp 240 °C, (Found: [M + 
Na+], 281.0781. C15H14NaO4
+
 requires 281.0784); λmax (MeOH)/nm 243 (log ε 4.21), 262 (4.19), 
331 (4.05), 322sh (4.02), 384 (3.67); vmax (CHCl3)/cm
-1
: 3689, 3605, 3011, 2925, 1601, 1433, 1239, 
1117, 930, 826; δH (500 MHz, (CD3)2CO): 14.08 (1 H, s, 11-OH), 8.07 (1 H, d, J 10.1, H-1), 6.39 (1 
H, s, H-6), 6.23 (1 H, s, H-8), 6.08 (1 H, s, H-10), 5.70 (1 H, d, J 10.1, H-2), 1.44 (6 H, s, CH3 x 2); 
δC (125 MHz, (CD3)2CO): 180.5 (C-12), 165.3 (C-5), 165.2 (C-9), 163.3 (C-11), 156.9 (C-7a), 
155.6 (C-6a), 141.3 (C-4a), 129.6 (C-2), 122.2 (C-1), 118.0 (C-12b), 103.1 (C-6), 101.9 (C-11a), 
101.6 (C-12a), 97.6 (C-10), 92.9 (C-8), 74.9 (C-3), 26.2 (Me x 2). 
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